Medication Adherence Outcomes in Elderly Patients with Hypertension and Chronic Kidney Disease: a Geographical Approach by Han, Yun
 
 
Medication Adherence Outcomes in Elderly Patients with Hypertension and 









A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
(Social and Administrative Sciences) 















Associate Professor Steven R. Erickson, Co-Chair 
Professor Rajesh Balkrishnan, Co-Chair, University of Virginia 
Professor Richard A. Hirth 

















© Yun Han 2017 












I dedicate this dissertation to my husband Lu Wang, for all his love and support. 
  












This dissertation work would not have been possible without help, support, and 
encouragement from many great individuals. First and foremost, I owe my deepest gratitude 
to my advisor, Professor Rajesh Balkrishnan, for his guidance, persistent help and 
encouragement. His enthusiasm, creative thinking, efficiency in work deeply influence me. I 
am so fortunate to be able to have his guidance throughout my graduate studies. I appreciate 
that he always makes himself available, genuinely cares about his students, and trust his 
students. More importantly, he is always positive, and smiling to me. I appreciate all the work 
that he has done to help me grow and move to the next stage of my career. I would like to 
sincerely thank my committee members: Professor Steven Erickson, Professor Richard Hirth 
and Professor Rajiv Saran. They have always given me constructive comments and 
suggestions from clinical, policy and statistical perspectives. Their guidance and knowledge 
are the most valuable resource I have on campus. They have always been patient and willing 
to assist me with any of my questions. I could not accomplish my degree without their help 
every step of the way. 
 
I also want to thank my colleagues at the University of Michigan Kidney Epidemiology and 
Cost Center. I am particularly grateful for the assistance given by Diane Steffick for her 
thoughtful suggestions and endless patience. I would like to thank April Wyncott, Vivian 
  iv 
 
Kurtz and Janet Kavanagh for their firm support, warm encouragement and quick response. I 
would thank Zhi He and Yanming Li for their insightful comments on my dissertation work. 
Also, I am indebted to Miao Wang, Anca Tilea, Lan Tong and Haoyu Gu for their substantial 
help. They are excellent statisticians, data analysts and database experts.  
 
I am truly blessed to have many fantastic friends and loving family members in my life. I feel 
so lucky that I can share my thoughts, worries and happiness with my dearest friends. They 
always stand by me in my difficult times. Also, I would like to express the deepest 
appreciation to my parents, Xiufeng Han and Ye Zhang. I thank my patients for their endless 
love, support and trust. I would not accomplish my degree without their support and 
encouragement. Also, I thank my parents for bearing the physical distance between us over 
the years. I cherish every moment I spend with them. 
 
Finally, and most importantly, I thank my husband Lu Wang. Thank you for being with me 
for seven years, listening to me, inspiring me, taking care of me and sharing your life with 
me. Having you by my side is the best thing in my life. Your love makes my life so special 
and beautiful.  
  






TABLE OF CONTENTS 
DEDICATION ........................................................................................................................................ ii 
ACKNOWLEDGMENTS ..................................................................................................................... iii 
LIST OF FIGURES ............................................................................................................................. viii 
LIST OF TABLES ................................................................................................................................. ix 
LIST of ABBREVIATIONS AND ACRONYMS ............................................................................... xii 
ABSTRACT .......................................................................................................................................... xv 
Chapter 1INTRODUCTION ................................................................................................................... 1 
1.1 Statement of the problem .............................................................................................................. 1 
1.2 Nature of the Study ....................................................................................................................... 2 
1.3 Study Aims .................................................................................................................................... 2 
1.4 Significance of the Study .............................................................................................................. 4 
1.5 Innovation of the Study ................................................................................................................. 5 
Chapter 2 LITERATURE REVIEW ....................................................................................................... 6 
2.1 Epidemiology and economic burden of CKD ............................................................................... 6 
2.2 Renal function trajectory and CKD care ..................................................................................... 10 
2.2.1 CKD screening, diagnosis, and staging ................................................................................ 14 
2.2.2 Comorbid conditions of CKD .............................................................................................. 16 
2.2.3 CKD complications .............................................................................................................. 17 
2.2.4 CKD progression and mortality ........................................................................................... 19 
2.3 CKD treatment and management ................................................................................................ 20 
2.4 Medicare prescription drug plans ................................................................................................ 24 
2.5 Neighborhood and population health .......................................................................................... 26 
2.6 Cardiovascular medication use among patients with hypertensive CKD ................................... 30 
2.6.1 Patterns of cardiovascular medication use ........................................................................... 30 
2.6.2 Outcome associated with cardiovascular medication use..................................................... 32 
2.6.3 Adherence to cardiovascular medications in CKD patients ................................................. 35 
2.7 Conceptual Model ....................................................................................................................... 41 
Chapter 3 METHODOLOGY ............................................................................................................... 44 
  vi 
 
3.1 Study design ................................................................................................................................ 44 
3.1.1 Data sources and linkage ...................................................................................................... 48 
3.1.2 Study population................................................................................................................... 49 
3.2 Measurement of study variables .................................................................................................. 53 
3.2.1 Individual-level characteristics ............................................................................................. 53 
3.2.2 Contextual characteristics ..................................................................................................... 54 
3.2.3 Healthcare outcomes ............................................................................................................ 55 
3.2.4 Medication utilization ........................................................................................................... 56 
3.3 Study Aim1: Compare the effects of different pharmacologic therapies on CKD outcomes for 
hypertensive CKD in Medicare Part D enrollees .............................................................................. 56 
3.4 Study Aim2: Examine how patients’ adherence to ACEIs and ARBs influence their CKD 
progression, renal failure and mortality by incorporating time varying effect.................................. 59 
3.5 Study Aim3: Model ACEIs/ARBs adherence as a function of individual and contextual factors 
among aged hypertensive patients with CKD in the United States. .................................................. 61 
Chapter 4 DISSERTATION MANUSCRIPT ONE: Comparison of effects of different pharmacologic 
therapies on chronic kidney disease (CKD) outcomes in Medicare Part D enrollees with hypertensive 
CKD ...................................................................................................................................................... 66 
4.1 Abstract ....................................................................................................................................... 66 
4.2 Introduction ................................................................................................................................. 68 
4.3 Methods ....................................................................................................................................... 70 
4.4 Results ......................................................................................................................................... 74 
4.5 Discussion ................................................................................................................................... 78 
4.6 Conclusion .................................................................................................................................. 82 
Chapter 5 DISSERTATION MANUSCRIPT TWO: Effects of adherence to angiotensin-converting 
enzyme inhibitors (ACEIs) and angiotensin-receptor blockers inhibitors (ARBs) on the progression of 
chronic kidney disease (CKD) in Medicare Part D enrollees ............................................................... 92 
5.1 Abstract ....................................................................................................................................... 92 
5.2 Introduction ................................................................................................................................. 94 
5.3 Methods ....................................................................................................................................... 96 
5.4 Results ......................................................................................................................................... 99 
5.5 Discussion ................................................................................................................................. 101 
5.6 Conclusion ................................................................................................................................ 104 
Chapter 6 DISSERTATION MANUSCRIPT THREE: Environmental and individual predictors of 
medication adherence among elderly patients with hypertension and chronic kidney disease (CKD): a 
geospatial approach ............................................................................................................................. 112 
6.1 Abstract ..................................................................................................................................... 112 
6.3 Methods ..................................................................................................................................... 116 
  vii 
 
6.4 Results ....................................................................................................................................... 121 
6.5 Discussion ................................................................................................................................. 123 
6.6 Conclusion ................................................................................................................................ 127 
Chapter 7 OVERALL CONCLUSION ............................................................................................... 137 
7.1 Major findings ........................................................................................................................... 138 
7.2 Study implications and future research ..................................................................................... 140 
7.3 Study limitations ....................................................................................................................... 141 
7.4 Overall conclusion .................................................................................................................... 142 
APPENDICES .................................................................................................................................... 143 
REFERENCES ................................................................................................................................... 145 










LIST OF FIGURES 
 
Figure 2-1 Trends in prevalence of recognized CKD, overall and by CKD stage, among 
Medicare patients aged 65+, 2000-2014 .................................................................................... 7 
Figure 2-2 Kidney function trajectory and corresponding care ............................................... 13 
Figure 2-3 Conceptual Model .................................................................................................. 43 
Figure 3-1 Overall Study design and study cohort selection criteria ....................................... 47 
Figure 6-1 Distribution of 1 year ACEIs/ARBs adherence ................................................... 132 
Figure 6-2 Townsend deprivation score (distribution, β & p-value) ..................................... 133 
Figure 6-3 Proportion of population residing in MUAs (distribution, β & p-value) ............. 134 
Figure 6-4 Proportion of Medicare beneficiaries (distribution, β & p-value) ....................... 135 
Figure 6-5 Number of general physicians/10,000 population (distribution, β, and p value) . 136 
 
  










LIST OF TABLES 
 
Table 2-1Definition and description of CKD stage ................................................................. 15 
Table 4-1 Descriptive statistics of individual demographic characteristics among elderly 
patients with hypertension and incident chronic kidney disease (CKD) by status of 
ACEIs/ARBs use (n=66,315) .................................................................................................. 83 
Table 4-2 Descriptive statistics of individual cardiovascular-related characteristics among 
elderly patients with hypertension and incident chronic kidney disease (CKD) by status of 
ACEIs/ARBs use (n=66,315) .................................................................................................. 84 
Table 4-3 Descriptive statistics of individual medication-related characteristics among elderly 
patients with hypertension and incident Chronic Kidney Disease (CKD) by status of 
ACEIs/ARBs use (n=66,315) .................................................................................................. 85 
Table 4-4 The association between different pharmacologic therapies and developing 
end-stage renal disease (ESRD) among elderly patients with hypertension and incident 
chronic kidney disease (CKD) , using Cox proportional hazards (PH) model (n=66,315) ..... 86 
Table 4-5 The association between different pharmacologic therapies and all-cause mortality 
among elderly patients with hypertension and incident chronic kidney disease (CKD), using 
Cox proportional hazards (PH) model (n=66,315) .................................................................. 88 
Table 4-6 Predictors of ACEIs/ARBs use among elderly patients with hypertension and 
incident chronic kidney disease (CKD): multivariate logistic regression (n=66,315) ............. 90 
  x 
 
Table 4-7 Sensitivity analysis: the association between different pharmacologic therapies and 
developing end-stage renal disease (ESRD) among elderly patients with hypertension and 
incident chronic kidney disease (CKD) , using Cox proportional hazards (PH) model 
(n=66,315) ................................................................................................................................ 91 
Table 4-8 Sensitivity analysis: the association between different pharmacologic therapies and 
all-cause mortality among elderly patients with hypertension and incident chronic kidney 
disease (CKD) , using Cox proportional hazards (PH) model (n=66,315) .............................. 91 
Table 5-1 Descriptive statistics of individual demographic characteristics among elderly 
patients with hypertension and chronic kidney disease (CKD) (n=65,574) .......................... 105 
Table 5-2 Descriptive statistics of individual cardiovascular-related characteristics among 
elderly patients with hypertension and chronic kidney disease (CKD) (n=65,574) .............. 106 
Table 5-3 Descriptive statistics of individual medication-related characteristics among elderly 
patients with hypertension and chronic kidney disease (CKD) (n=65,574) .......................... 107 
Table 5-4 The association between medication adherence and developing end-stage renal 
disease (ESRD) among elderly patients with hypertension and chronic kidney disease (CKD) 
, using time-dependent Cox proportional hazards (PH) model (n=65,574) ........................... 108 
Table 5-5 The association between medication adherence and all-cause mortality among 
elderly patients with hypertension and chronic kidney disease (CKD), using time-dependent 
Cox proportional hazards (PH) model (n==65,574) .............................................................. 110 
Table 6-1 Descriptive Statistics of individual demographic characteristics among elderly 
patients with hypertension and chronic kidney disease (CKD) by status of ACEIs/ARRs 
adherence (n=70,201) ............................................................................................................ 128 
Table 6-2 Descriptive Statistics of cardiovascular-related characteristics among elderly 
patients with hypertension and chronic kidney disease (CKD) by status of ACEIs/ARRs 
adherence (n=70,201) ............................................................................................................ 129 
  xi 
 
Table 6-3 Descriptive Statistics of environmental characteristics in county level (n=2981) 130 
Table 6-4 The association between environmental characteristics and average ACEIs/ARBs 
adherence at county level using Geographically Weighted Regression (n=1522) ................ 130 
Table 6-5 The association between individual, environmental characteristics and 
ACEIs/ARBs adherence at individual level using Mixed model (n=70,201) ........................ 131 
 
  










LIST of ABBREVIATIONS AND ACRONYMS 
 
AASK – African American Study of Kidney Disease  
ACEIs – angiotensin-converting enzyme inhibitors  
ACP – American College of Physicians 
ACR – albumin-creatinine ratio  
ACS – American community Survey 
AFIB – atrial fibrillation;  
AIC –Akaike Information Criterion  
AIDS – acquired immunodeficiency syndrome 
AMI – acute myocardial infarction;  
ARBs – angiotensin-receptor blockers  
ASHD – atherosclerotic heart disease 
AT1R – angiotensin type 1 receptor  
AT2R – angiotensin type 2 receptor  
BIC – Bayesian Information Criterion  
BUN – blood urea nitrogen 
CABG – coronary artery bypass grafting;  
CCI – Charlson comorbidity index  
CHF – congestive heart failure 
CHF – congestive heart failure  
  xiii 
 
CIBIS-II – cardiac insufficiency bisoprolol study II  
CKD – chronic kidney disease  
CKD-MBD – chronic kidney disease–mineral bone disorder 
CMS – Centers for Medicare & Medicaid Services  
CRT-D –cardiac resynchronization therapy with defibrillator devices. 
CVA/TIA – cerebrovascular accident/transient ischemic attack  
CVD – cardiovascular disease  
DALYs – Disability Adjusted Life Years  
ESRD – end-stage renal disease 
FIPS – Federal Information Processing Standard 
GFR – glomerular filtration rate 
GWR – geographically weighted regression 
HCPCS – Healthcare Common Procedure Coding System  
HMO – Health Maintenance Organization 
HRSA – Health Resources and Services Administration 
HTN – hypertension 
ICD – implantable cardioverter defibrillators 
ICD-9-CM – International Classification of Diseases, Ninth Revision, Clinical Modification  
IDNT – Irbesartan Diabetic Nephropathy Trial 
IRB – Institutional Review Board. 
K/DOQI – Kidney Disease Outcomes Quality Initiative  
LIS – Low-income Subsidy  
MA-PD – Medicare Advantage prescription drug  
MDRD – modification of diet in renal disease study 
MERIT-HF – Metoprolol Controlled-Release Randomized Intervention Trial in Heart Failure  
  xiv 
 
MSP – Medicare Saving Programs 
MUAs – medically underserved areas  
NDC – national drug code  
NHANES – National Health and Nutrition Examination Survey   
PAD – peripheral arterial disease 
PCI – percutaneous coronary interventions  
PCSA – Primary Care Service Area  
PDC – proportion of days covered 
PDP – Prescription Drug Plans  
RAAS – renin-angiotensin-aldosterone system 
RAS – renin-angiotensin-system  
RCT – randomized controlled trial 
REGARDS – Reasons for Geographic and Racial Differences in Stroke study  
RRI-CKD – Renal Research Institute Chronic Kidney Disease study 
SAFs – Standard Analytical Files 
SCA/VA – sudden cardiac arrest and ventricular arrhythmias;  
SENIORS – Seniors with Heart Failure trial 
SSA – Social Security Administration  
SSI – Supplemental Security Income  
USRDS – United States Renal Data System 
USRDS ADR – United States Renal Data System Annual Data Report 
VIF – variance inflation factor 
  












OBJECTIVES: Chronic kidney disease (CKD) patients with uncontrolled blood pressure are 
at high risk of cardiovascular events, hospitalization, and mortality. There is limited research 
evaluating utilization patterns of anti-hypertensives in hypertensive CKD patients. This study 
aims to assess anti-hypertensives use, particularly, angiotensin-converting enzyme inhibitors 
(ACEIs) and angiotensin-receptor blockers (ARBs) in the United States, and explore 
contextual and individual risk factors of treatment compliance. 
METHODS: Hypertensive CKD patients were selected using Medicare 5% sample claims 
data from the United States Renal Data System (USRDS) databases (2006-2013). We 
included patients who diagnosed with hypertension and CKD, and followed them from Jan 1, 
2008 to Dec 31, 2013. We first investigated medication treatment patterns among incident 
CKD patients. We then performed time-dependent survival analyses to evaluate long-term 
benefits of being adherence to ACEIs/ARBs. Medication adherence in this study was 
measured by proportion days covered (PDC). Lastly, we used geographically weighted 
regression model (GWR) to explore risk factors of medication adherence. 
RESULTS: Approximately 50% of incident hypertensive CKD patients received 
guideline-recommended ACEIs/ARBs after their first diagnosis of CKD. Anti-hypertensive 
regimens including ACEIs/ARBs and statins yielded better CKD outcomes than regimens 
without these drugs. Additionally, continuously being adherent to ACEIs and ARBs was 
associated a significant decline in risk of end-stage renal disease (ESRD) and mortality in 
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long run. However, only 61% of hypertensive CKD who used ACEIs/ARBs had good 
medication compliance (PDC ≥80%). Patients residing in the Northeast region and the 
Midwest region demonstrated better adherence than those residing in the Southern United 
States. Availability of primary resources, neighborhood deprivation status, and coverage of 
Part D Low-income Subsidy (LIS) were factors related with medication adherence. 
Geographically varied association between contextual characteristics and adherence were 
displayed by maps. 
CONCLUSIONS: Utilization of guideline-recommended ACEIs/ARBs is suboptimal in 
elderly patients with hypertension and CKD in the United States, although they had 
significant long-term benefits on CKD outcomes. Adherence to ACEIs/ARBs is 
geographically differentiated across the United States. Contextual and individuals risk factors 
identified in this study are helpful to design population-based strategies in a local area to 
promote medication compliance, from a population perspective.









1.1 Statement of the problem  
Approximately 15% of adults in the United States may have CKD with varied seriousness 
levels 
1
. Aging adults are particularly at high risk of CKD, as over one-third of elderly adults 
have CKD, either spots estimates of Glomerular Filtration Rate (GFR) less than 60 
ml/min/1.73m
2
 or albumin-creatinine ratio (ACR) ≥ 30 mg/g 
1
. Medicare spending for elderly 
adults with CKD represents 20% of total Medicare spending 
1
.   
 
Pharmacological therapies and lifestyle changes can slow down CKD progression to ESRD, 
when kidney failure occurs and dialysis or kidney transplant is required
2
. Hypertension is a 
previously established risk factor for CKD progression. Although about 74 percent of CKD 
patients have hypertension, only 28 percent of them achieve blood pressure under-controll
1
. 
ACEIs and ARBs are guideline-recommended blood pressure lowering agents for patients 
with hypertensive CKD. They have substantial effects on the renin-angiotensin-aldosterone 
(RAA) hormonal system. Previous studies showed low adherence to ACEIs/ARBs related 




A major knowledge gap exists in understanding the relationship between access to health care 
and use of ACEIs/ARBs in elderly patients with hypertensive CKD. No study has 
systematically modeled how individual and contextual factors affect ACEIs/ARBs adherence 
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by incorporating geographical variation across continuous space. Meanwhile, limited 
research has compared the effect of different pharmacological treatment strategies in 
hypertensive CKD. Additionally, there is lack of a model that can more accurately assess the 
effect of ACEIs/ARBs on the progression of CKD and mortality by accounting for the time 
varying medication consumption. This knowledge is critical to develop effective 
interventions for elderly patients with hypertension and CKD. It is our hypothesis that 
patients’ adherence to ACEIs/ARBs is critical to CKD progression and mortality, and it is 
influenced by the barriers of accessibility to health care and availability of health care, such 
as residing in Medically Underserved Areas (MUAs) and numbers of physicians per 
population.  
 
1.2 Nature of the Study 
This retrospective cohort study aimed to explore the predictors of medication use behaviors, 
and examine the association between medication use behaviors and health care outcomes for 
elderly hypertensive patients with CKD in the United States. We applied a theoretical 
framework modified from health services behavioral research models to address our research 
questions.  
 
1.3 Study Aims  
The purpose of this study is to provide pharmacological treatment strategies to delay the 
progression to ESRD for elderly patients with hypertensive CKD in the United States, and 
develop and use of methodology to measure and model geographically varied predictors of 
medications adherence. We refined the spatial methodologies for use in future medication 
use/renal disease studies in the United States. Additionally, the time-dependent medication 
use behavior model we developed in this study can be used in other chronic diseases. Our 
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central hypothesis was that elderly patients with hypertensive CKD who had better access to 
healthcare and healthcare availability were more likely to be adherent to their prescribed 
ACEIs/ARBs, and further demonstrated better CKD treatment outcomes. The rationale for 
the proposed study was to identify contextual and individual factors that related with poor 
adherence to ACEIs/ARBs, and accurately model how ACEIs/ARBs consumption were 
associated with CKD progression and mortality. The results of our study will provide 
important information on physicians’ prescribing strategies aimed at improving the 
effectiveness of treatment and delaying CKD progression to ESRD in elderly hypertensive 
patients. Our main data was the Medicare 5% sample claims from the USRDS databases 
(2006-2013). In this study, we tested our central hypothesis with the following three aims: 
 
Aim 1 Compare the effects of different pharmacologic therapies on CKD outcomes for 
hypertensive CKD in Medicare Part D enrollees.  
Aim 2 Examine the effects of ACEIs/ARBs adherence on CKD progression and mortality.  
Aim 2 Model ACEIs/ARBs adherence as a function of individual and contextual factors 
among aged hypertensive patients with CKD in the United States. 
 
These aims yielded the following outcomes: In aim 1, we described the anti-hypertensive 
therapies hypertension patients received when they first diagnosed with CKD, and compare 
effects of these different regimens. In aim 2, we explored how ACEIs/ARBs adherence 
delays progression to ESRD and mortality, and provided evidence to encourage increased use 
of ACEIs/ARBs in hypertensive patients with CKD. In aim 3, we examined geographic 
variation in medication adherence to ACEIs/ARBs among aged hypertensive patients with 
CKD in the United States, and explored the relationship between individual characteristics, 
contextual characteristics and medication adherence.  
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1.4 Significance of the Study 
The National Kidney Foundation Clinical Practice Guidelines recommend the target blood 
pressure for hypertensive patients with CKD should be <130/80mm Hg. There are two main 
treatment goals of antihypertensive therapy in CKD: (1) lower blood pressure and (2) block 
the RAA hormonal system using ACEIs or ARBs
5
. ACEIs and ARBs are recommended as 
the preferred agents for blood pressure control in all diabetic CKD patients and nondiabetic 
patients with urine ACR ≥200 mg/g, as well as hypertensive patients with mild to moderate 
kidney dysfunction. Despite the effects of ACEIs/ARBs, that have objectively demonstrated 
protective effects on the progression of renal insufficiency in several randomized control trial 
studies
6–8
, there is evidence that ACEIs/ARBs are underutilized in hypertensive CKD 
patients. Less than half of CKD patients used ACEIs/ARBs to control their blood pressure, 
and the highest ACEIs/ARBs utilization rate was observed in moderate CKD patients
9,10
. 
Little research has compared different pharmacological treatment strategies for hypertensive 
CKD patients; evaluated the long-term effects of ACEIs/ARBs on CKD progression to ESRD 
and mortality; as well as explored risk factors of ACEIs/ARBs adherence. 
 
This contribution is significant because the first step of our research is expected to provide 
evidence for clinicians when they select pharmacological treatments for elderly patients with 
hypertension and CKD. Additionally, this study contributes to understanding of how much 
improvement in healthcare outcomes can be obtained by continuously being adherent to 
ACEIs/ARBs. Lastly, the major crucial step of our research is expected to find predictors of 
ACEIs/ARBs adherence and provide helpful information for designing effective 
interventions. For instance, the contextual factors identified in this study may be helpful for 
healthcare providers to target on CKD patients at high risk of poor medication compliance. 
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1.5 Innovation of the Study 
To the best of our knowledge, this is the first study that explored geographic varied predictors 
of ACEIs/ARBs adherence among aged hypertensive CKD patients. We conducted a 
theoretically grounded analysis to identify contextual risk factors. Unlike global regression 
model that ignores the connections between geographic areas, the spatial model we used in 
our study is able to incorporate the spatial autocorrelation when model medication adherence 
as a function of potential predictors
11,12
. The strength of our study is we are able to provide 
visualized information, such as maps that reflect geographic differences in the relationship 
between predictors and medication adherence. Results of our study support the long-term 
benefits of ACEIs/ARBs, and encourage increased use of ACEIs/ARBs among elderly 
hypertensive patients with CKD. In addition, we believe our study could help healthcare 
providers understand the geographic variation of the relationship between predictors and 
medication adherence. This information is valuable for researchers to design local 
interventions aiming at improving ACEIs/ARBs use among elderly CKD patients, and 
support health care policy makers to allocate medical resources within small administrative 
areas. Furthermore, the proposed research is innovative, as we developed a multivariate Cox 
regression model with ACEIs and ARBs use as time-varying covariates to assess the 
long-term benefits of ACEIs and ARBs.  
  






Chapter 2  
LITERATURE REVIEW 
 
2.1 Epidemiology and economic burden of CKD 
CKS is becoming a greater priority for global public health and healthcare
13,14
. The 
prevalence of CKD in the general population varied widely across regions, from 5.8% in 
Poland to 13.1% in the United State
13
. Findings from the Global Burden of Disease study 
2010 showed numbers of deaths from chronic kidney disease in 2010 was 735.6 million, 
82.3% more than in 1990. This caused the CKD increased from the 27
th
 cause of death to the 
18
th
 cause of death in the world over the two decades
15
. In term of the overall disease burden, 
in 2010, CKD accounted for a total of 21.51 million disability-adjusted life years 




Old adults have a markedly higher risk of developing CKD worldwide
17
. For example, by 
analyzing data from the National Health and Nutrition Examination Survey (NHANES), 
2011-2014, researchers found one-third of NHANES participants aged 60 and older had 
CKD, compared with 7% of those aged 20-39 and 11% of those aged 40–59
1
. Figure 2-1 
shows the trend of prevalence of recognized CKD in Medicare beneficiaries by CKD stage. 
Overall, the CKD prevalence had gradually increased over the past decade, from 2.7% in 
2000 to 11% in 2014
1
. Meanwhile, total Medicare spending on elderly patients with CKD 
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was increased steadily from 7.4 billion in 2000 to 52.8 billion in 2014. The fastest growing 
occurred in 2006-2007, the period that Part D program launched. This increased spending 
may because of the growing prevalence of CKD, earlier detection of CKD, increased access 
to prescription drugs, as well as improved identification and reporting using claims data. 
 
 
Figure 2-1 Trends in prevalence of recognized CKD, overall and by CKD stage, among 





CKD is generally a progressive and irreversible disease, which has been categorized into five 




































Adopted from USRDS  annul data report 2016. Distribution of the overal CKD prevalence, 
visualized by a blue curve (the points drawn to the scale of the vertical axis on the left), 
and four curve of the CKD prevalence by stage (the points blue drawn to the scale of the 
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known as kidney failure, need the initiation of kidney replacement therapy, either dialysis or 
a kidney transplant, to stay alive. Global variations in ESRD incidence and prevalence were 
observed in international comparison studies
14
. Taiwan, the Jalisco region of Mexico, and the 
United States had the highest incidence of treated ESRD, at 455, 421, and 370 per million 
people
1
. In terms of the prevalence of treated ESRD, Taiwan ranked the first, followed by 
Japan and the United States.  
 
The time scale of CKD progression is varied across populations. The rate of decline in renal 
function is influenced by several factors including the cause of CKD, CKD stage at the time 
of diagnosis, and type of intervention received
18–21
. A longitudinal cohort study found that 
1.1% of patients with stage 2 CKD developed ESRD within a 5-year observation period, 
compared to 1.3% in stage 3 CKD and 19.9% in stage 4 CKD
22
. Meanwhile, the mortality 
rate was 19.5%, 24.3% and 45.7% for patients with stage 2, 3, and 4 CKD respectively. 
Death from cardiovascular diseases and diabetes is competing risk of progression to kidney 
failure.  
 
Globally, CKD and its consequent ESRD are associated with substantial adverse impacts on 
individual utility and social welfare, including medication expenditures and loss of working 
time due to disability and absenteeism. According to the United States Renal Data System 
Annual Data Report 2016 (USRDS ADR), total Medicare expenditures for CKD rose to 
$52.8 billion in 2014. Even though only 11% of elderly Medicare population had been 
diagnosed with CKD, they accounted for 21% of total Medicare expenditures in 2014
1
. With 
regard to ESRD, total Medicare expenditures for ESRD reached 32.8 billion in 2014, 3.3% 
higher than 2013. In term of indirect cost, CKD and its complications caused a significant 
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economic burden for employers due to productivity loss
23,24
. For instance, after receiving 
epoetin alfa treatment, absenteeism in patients with CKD-related anemia had been reduced by 
52.3 days, a 91.5% increase in productivity
25
.    
 
The healthcare costs for CKD patients increase with disease progression and the presence of 
their comorbidities
1,26
. Findings from the USRDS ADR 2016 illustrated that Medicare 
expenditure for CKD increased with CKD progression. Elderly patients with stage 4-5 had 
the highest per person per year Medicare spending in 2014, at $28,541, compared to $21,176 
and $19,075 for patients with stage 3 and patients with stage 1-2. In addition, among patients 
with ESRD, per person per year Medicare spending reached $75,214, 3.3 times greater than 
overall CKD patients ($22,745)
1
. Thus, slowing the progression of CKD has substantial 
benefits on reducing financial burdens on the healthcare system. When considering the onset 
of comorbidities, the average expenditure per year at risk was highest in patients with all 
three chronic conditions of CKD, diabetes, and congestive heart failure ($38,561), followed 
by patients with comorbid CKD and congestive heart failure ($30,395), patients with 
comorbid CKD and diabetes ($18,610) and patients with only CKD ($15,673).  
 
Given the larger number of comorbid conditions in CKD patients and the high cost of 
CKD-related treatments, substantial disparities in accessibility, utilization of CKD care and 
treatment outcome were observed across socioeconomic and racial groups
27,28
. On the one 
hand, health insurance plays an important role in increasing affordability of CKD care, 
improving CKD care quality and further improving treatment outcome. Among the CKD 
patients younger than 65 years in the United States, patients covered by private insurance 
were least likely to reach ESRD and die, compared to patients with public insurance and 




. There were more barriers to treatment among patients in developing nations than 
those in developed nations, because of the more expensive treatment and lack of insurance 
coverage
30
. On the other hand, population-based differences in treatment outcome may also 
be affected by patient’s characteristics and healthcare quality. For example, the United States 
had a significantly higher incidence of ESRD than Europe counties, although comparable 
prevalence of CKD was observed
31
. An international comparison study by Hallan et al using 
nationally representative data illustrated CKD patients in the United States had a higher risk 
of progression from advanced CKD to ESRD than those in Norway. And this higher risk of 
progression in the United States might be attributable to late nephrologist referral and high 
rates of obesity and diabetes.  
 
2.2 Renal function trajectory and CKD care  
Humans are born with two kidneys, bean-shaped organs located in the upper abdominal area. 
Kidneys serve several essential roles in regulate the balance of body chemicals. The main 
functions of kidney include removing waste products of metabolism and regulating fluid 
balance through the urine system. By these actions that kidneys serve as the main pathway for 
drug excretion. The kidneys also produce a variety of important hormones, such as 
erythropoietin, calcitriol (1,25- dihydroxycholecalciferol) and renin . Erythropoietin plays a 
key role in regulating red blood cells production. Calcitriol, an active form of Vitamin D, can 
stimulate the small intestine for improving absorption of Ca2+ and phosphates, which are 
essential elements for bone growth and bone health. As a critical part of the renin – 
angiotensin–aldosterone system (RAAS), renin is able to regulate blood pressure. 
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Renal function declines with age, even among healthy adults. Loss of kidney function is 
varies substantially between population, and the decline rate usually follows a non-linear 
pattern
32
. Figure 2-2 illustrated an overview of the renal function trajectory and the 
corresponding healthcare services patients received
20,33
. In general, elderly adults who have 
diabetes, hypertension, cardiovascular disease or any family history of CKD are under higher 
risk of developing CKD. Patients with these diseases are more likely to be given screening 
tests for CKD, which include urine test for albuminuria and blood test for creatinine. 
Meanwhile, patients with diabetes or hypertension are recommended to control their blood 
pressure and glycemia to prevent kidney disease. When patients are diagnosed with CKD and 
the stage is confirmed, treatments are given to delay CKD progression and reduce CKD 
complications. If patients are diagnosed with early-stage CKD (stage 1-3), they will receive 
treatments for their comorbid conditions, which may include hypertension, diabetes and lipid 
control. On the other hand, if patients have advanced kidney damage and experience a steep 
decrease in GFR, they are likely to need kidney replacement in the near future. In that case, 
physicians will estimate progression, provide care for CKD complications, and prepare for 
kidney transplant. When kidney failure happens, patients need regular dialysis to remain alive 
until a new kidney is available for transplantation.  
 
The decline in renal function may follow distinctly different patterns from patient to patient. 
Modifying treatment strategies based on the latest tests results and onset of comorbid 
conditions are preferred. Given these facts, CKD patients are recommended to monitor their 
kidney function by having physician order urine and blood tests at least once per year. More 
frequent monitoring is recommended by Kidney Disease Outcomes Quality Initiative 
(K/DOQI) for patients with advanced CKD
20
. Delaying the progression of CKD is a critical 
goal in CKD management, and it is also where oral medications can come into play. 
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Pharmacological therapies for CKD are the focus of our research, but before describing our 
study we will briefly introduce some important component of CKD care, as well as the 
comorbidities and complications of CKD.
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Figure 2-2 Kidney function trajectory and corresponding care 
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Adapted from KDOQI guidelines 
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2.2.1 CKD screening, diagnosis, and staging  
Early detection of CKD allows clinicians to provide medical interventions at an early stage, 
nevertheless, the awareness of CKD is extremely low as only 3%, 5%, 8% and 44% of CKD 
patients in stage 1,2,3, and 4 were aware of their kidney disease
1
. Therefore, implementing 
CKD screening programs is warranted. These programs can bring significant benefits to CKD 
patients in delaying the onset of ESRD, preventing the development of CKD complications, 
as well as reducing the risk of death from cardiovascular diseases
34
. Although approximately 
13% of Americans are living with CKD, it is not uncontroversial to screen the general 
population without any selection. The consequences of “false positive” of laboratory tests 
induce unnecessary referrals, costs, and anxiety
35
. K/DOQI recommends screening people 
who have higher risk of developing CKD: elderly adults who have been diagnosed with 
diabetes, hypertension, cardiovascular disease, or having any family history of hypertension, 
diabetes or CKD. A study of NHANES participants aged 20-59 found the prevalence of CKD 
in adults with diabetes was 4 times greater than those without diabetes (33.8% vs. 8.2%). 
Meanwhile, CKD prevalence in adults with hypertension was 2.6 times greater than those 
without (18.9% vs. 7.4%)
36
. A study by Vassalotti et al. evaluated the Early Evaluation 
Program (KEEP) and found more CKD patients has been detected at early stage by targeting 




Procedures of CKD screening and diagnosis include several laboratory tests such as 
creatinine blood test, creatinine clearance test, blood urea nitrogen (BUN) test, and albumin 
urine test. GFR is an ideal indicator of kidney function, however, measuring GFR directly 
involves high cost and time-consuming. Instead, the 24-hour creatinine clearance and serum 
creatinine concentration have been measured to assess GFR. Considering the fact that kidney 
function varies across age, gender and race, several prediction equations have been developed 
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to calculate estimated GFR. The modification of diet in renal disease (MDRD) Study and 
Cockcroft-Gault equations have been widely used in adults, while the Schwartz and 
Counahan-Barratt equations have been applied in children.  
 
In 2002, K/DOQI introduced the definition of CKD and classified its stages using laboratory 
measurements, regardless of underlying cause
20
. CKD had been categorized into five 
categories based on the estimated GFR and the presence of kidney damage. Table 2.1 lists 
these categories and their corresponding laboratory criteria. However, it is worth to note that 
using the threshold values from the K/DOQI guidelines alone to diagnose and classify CKD 
is dangerous. Physicians need to take age, race and gender specific reference values of 





Table 2-1Definition and description of CKD stage 
 
Stage GFR Description ICD-9-CM 
code 
I ≥ 90 mL/min/1.73 m
2
 Kidney damage with normal or increased GFR 585.1 




Kidney damage with mild decreased GFR 585.2 
III 30–59mL/min/1.73m
2












 Kidney failure regardless of kidney damage, or 
kidney failure treated by dialysis or        




Adapted from the National Kidney Foundation’s K/DOQI guidelines 
20
 
  16 
 
2.2.2 Comorbid conditions of CKD  
Hypertension  
The study using national representative data indicated approximately 74% of CKD patients in 
the United States have hypertension as comorbidity
1
. Hypertension and CKD are related in 
two ways. On the one hand, hypertension is a major cause of CKD that uncontrolled high 
blood pressure damages blood vessels and consequently reduces the blood supply to kidney. 
The tiny filtering units in kidneys are also damaged by high blood pressure. On the other 
hand, hypertension is a common complication of CKD that reduced kidney function may lose 
their ability to remove extra fluid and regulate blood pressure. Thus, the rate of loss in kidney 
function is more likely to be accelerated by hypertension. A report of national health statistics 





Hypertension is generally an asymptomatic condition. A recent national representative study 
found 29% of American adults had hypertension in 2011-2012, while 17% of them were 
unware of their high blood pressure
40
. Additionally, only 76% of hypertension patients took 
anti-hypertensive agents during the study period, and approximately half of them control their 
blood pressure under controlled. Given the facts that CKD patients with comorbid 
hypertension have relatively high medication burden and poor treatment outcome, our study 
will specifically focus on this vulnerable population, and examine their medication use 
patterns, as well as medication adherence outcomes.  
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Diabetes 
Diabetes is the leading cause of kidney disease, which can harm kidneys in several ways: 
narrowing the blood vessels inside kidneys; damaging nerves in the bladder which may cause 
patients unaware of a full bladder, and further lead to an increased pressure of bladder; 
increasing risk of urinary tract infection caused by bacteria that reproduce rapidly in urine 
with a high sugar level
41
. Approximately 39% of American adults with CKD had diabetes as 
well
1
. Making blood pressure and blood glucose under controlled is recommended for 
patients with both diabetes and CKD. ACEIs and ARBs are recommended as first line 




2.2.3 CKD complications  
Decline in renal function is associated with several serious complications, including anemia, 
mineral and bone disorders, and cardiovascular disease
43
. CKD complications are more likely 
to occur in patients with moderate or severe loss of renal function.  
 
Anemia  
As we discussed in the previous section, kidneys play an important role in a number of 
essential hormones to keep body healthy. Erythropoietin, the hormone produced by kidney, is 
an essential component of red blood cell production. Anemia happens when the human body 
is short of red blood cells, which provide energy for daily activities. Fatigue, feeling short of 
breath and sleep disorders are common symptoms of anemia
44
. Therapies including 
erythropoiesis stimulating agents and iron are recommended to improve energy and physical 
function for anemia patients with kidney dysfunction
45
. A recent nationally representative 
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study found 14% of American adults with CKD had anemia in 2007-2010, meanwhile the 
prevalence of anemia increased with the decline of kidney function
46
. The same study also 
found approximately only 23% of CKD patients with anemia received treatment, though 
anemia patients with moderate and severe kidney damage were more likely to receive 
treatment compared to those with mild kidney damage.   
 
Mineral and bone disorders  
Chronic kidney disease–mineral bone disorder (CKD-MBD) may present when kidney 
dysfunction causes an imbalance of calcium and phosphorus in blood
47
. Damaged kidneys 
cannot remove extra phosphorus from the body and convert Vitamin D to the activated form, 
calcitriol. A lower calcitriol concentration inhibits calcium absorption from food, and further 
reduces the level of blood calcium. Moreover, declined blood calcium stimulates the release 
of parathyroid, a hormone regulating calcium balance. Ultimately, a lower level of blood 
calcium, along with a higher level of blood phosphorus and parathyroid hormone cause 
calcium to be removed from bone to blood. Besides bone damages, high blood calcium and 
phosphorus levels will damage blood vessels and increase risk of cardiovascular disease as 
well. Common symptoms of mineral and bone disorders include bone pain, weak bones, and 
itchy skin. Lower phosphorus diet and therapies including phosphate binders, vitamin D and 
calcimimetics are recommended to patients with CKD-MBD
48
. Previous studies of Vitamin D 
deficiency in CKD patients found the prevalence rate of CKD-MBD varied from 55% to 83% 
from study to study, depending on different definition of conditions and study population 
characteristics
49–51
.   
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Cardiovascular disease 
Cardiovascular disease (CVD) ranked in the first place of mortality in both the general 
population and patients with kidney failure. Cardiac function interacts closely with renal 
function. First, common risk factors such as hypertension and diabetes could cause both 
cardiovascular disease and CKD. According to the most recent USRDS ADR, 5.3% of 
elderly Medicare beneficiaries had presence of both diabetes and CKD, and the prevalence of 
having diabetes and CVD was 13% in 2014
1
. Second, CVD may occur when kidney 
dysfunction leads to onset of anemia, metabolic bone disease, inflammation, or 
dyslipidemia
43
. Research evidence indicated that CKD was an independent risk factor of 
developing CVD
52
. Third, cardiovascular diseases may worsen kidney function through 
multiple mechanisms, like haemodynamic abnormalities, neurohormonal activation, 
inflammatory activation and potential adverse effects of diuretics
53
. A high prevalence of 





2.2.4 CKD progression and mortality 
According to the clinical practice guideline by K/DOQI, the progression of CKD is defined 
as a decline in estimated GFR of >5 ml/min/1.73 m
2
 within one year, or >10 ml/min/1.73 m
2
 
within 5 years, or present of Microalbuminuria/ Macroalbuminuria. The decline of kidney 
function follows non-linear patterns
55
. As we discussed in the previous section, CKD 
comorbidities and complications can accelerate the progression to kidney failure. For 
example, a study of CKD progression demonstrated that the progression rate is higher in 
patients with diabetes than non-diabetes, after controlling estimated GFR and albuminuria 




. Moreover, a numbers of CKD patients die from cardiovascular disease before 




CKD patients are at high risk of hospitalization and all-cause mortality, and the risk increased 
with disease severity. For example, in 2013, the all-cause hospitalization rate of Medicare 
beneficiaries with CKD was 2.5 times higher than their age-gender-race matched counterparts 
without CKD, at 627 hospitalizations versus 248 hospitalizations per 1,000 patient years at 
risk. Similarly, the all-cause mortality rates were 118 deaths and 48 deaths per 1,000 person 
years at risk among patients with CKD and without CKD. Also worthy of mention, a 
gradually decline was observed in both all-cause hospitalization rate and mortality rate 
among Medicare beneficiaries with CKD in the past decade
1
.   
 
2.3 CKD treatment and management  
Treatment strategies for CKD are varied based on the underlying cause of kidney disease, 
onset of CKD comorbidities and complications. Oral medication therapy serves as a critical 
part of CKD therapy to control CKD complications and delay CKD progression. The purpose 
of our study is to assess the association between ACEI/ARB use and CKD outcomes in 
hypertensive CKD patients. Moreover, this study investigates not only ACEIs/ARBs, but also 
some other commonly used cardiovascular agents. A total of six types of cardiovascular 
agents are investigated: renin-angiotensin-system inhibitors (ACEIs and ARBs), other 
antihypertension agents (diuretics, calcium channel blockers, beta-blockers and calcium 
channel blockers) and lipid lowering agents (statins). The mechanisms of these 
cardiovascular agents are distinctly different. We will briefly introduce each of these drug 
classes in this section.  
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Renin-angiotensin-system (RAS) Inhibitors 
ACEIs and ARBs are the two main drug classes under RAS inhibitors, which demonstrate 
renoprotective effects on kidney function in two ways: reducing blood pressure and reducing 
proteinuria
42
. RAS inhibitors play an essential role in regulating blood pressure
57
. Rein, 
released by kidney can convert angiotensinogen to angiotensin I. Angiotensin I can be further 
transformed to angiotensin II by enzymes including angiotensin-converting enzyme (ACE), 
chymase and other enzymes. Ultimately, angiotensin II controls blood pressure by 
stimulating angiotensin type 1 receptor (AT1R) for vasoconstriction, and stimulating 
angiotensin type 2 receptor (AT2R) for vasodilation and sodium excretion
58,59
. ACEIs and 
ARBs reduce blood pressure by blocking the pathway of RAS at difference places. ARBs 
directly blocked the stimulation of AT1R, while ACEIs inhibit the activity of 
angiotensin-converting enzyme (ACE) and consequently reduce the level of angiotensin II. 
Besides the effect of lowering blood pressure, ACEIs and ARBs have substantial effect on 
reducing proteinuria. Proteinuria, when present, may be a consequence of impairments of 
glomerular permeability which is caused by increased glomerular capillary pressure. ACIEs 
and ARBs reduce proteinuria by maintaining the glomerular filtration barrier to proteins and 
reducing filtered protein-dependent inflammatory signals. 
 
Common ACEIs agents include benazepril, lisinopril, ramipril, captopril, enalapril. Side 
effect of ACEIs include, but are not limited to, cough, low blood pressure, dizziness, 
headache, and increased uric acid levels. It is worth noting here the existence of serious but 
rare side effects of ACEIs, like kidney failure, liver failure, and allergic reactions. Common 
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ARBs agents include candesartan, eprosartan, irbesartan, losartan, olmesartan, and valsartan. 
Side effects of ARBs are similar with ACEI, but patients are more likely to tolerate ARBs.   
 
Diuretics 
Diuretics are used to control extracellular fluid volume expansion, which is established to be 
associated with hypertension. Thus, diuretics reduce blood pressure by excreting extra 
sodium and water out of the body. There are three types of diuretics, and each works by 
diverse means. Loop diuretics inhibit reabsorption of sodium in the thick ascending loop of 
Henle in the kidneys. Thiazide diuretics inhibit reabsorption of sodium in the distal 
convoluted tubule in the kidneys. Potassium-sparing diuretics can inhibit potassium-sparing 
exchangers in the distal convoluted tubule in the kidneys, aldosterone action, or epithelial 
sodium channels. Diuretics are commonly prescribed together with other antihypertension 
agents due to its mechanism of lowering blood pressure
42
. For example, the combination 
therapy of diuretics and ACEIs/ARBs performs better than monotherapy of ACEIs/ ARBs. 
This may because impair sodium reabsorption due to kidney dysfunctions stimulate release of 
renin from kidney, and further increase the level of angiotensin I. Moreover, adding diuretics 
to other anti-hypertension agents with side effect of sodium and water retention can help 
patients to get their blood pressure better controlled. Common loop diuretics include, but are 
not limited to, furosemide, bumetanide, and ethacrynic acid. Bendroflumethiazide and 
hydrochlorothiazide are examples of thiazide diuretics. Potassium-sparing diuretics include 
triamterene, spironolactone, amiloride, and so on.. Common side effects of diuretics include 
hyponatremia, dizziness and headaches.  
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Beta-blockers  
Beta-blockers decrease the blood pressure by blocking adrenergic receptors, primarily beta-1 
receptors in the heart, and further dropping heart rate. Meanwhile, beta-blockers are able to 
work on beta-2 receptors located in blood vessels, which dilate blood vessels and 
consequently reduce blood pressure. Beta-blockers that are available for use include atenolol, 
metoprolol, propranolol, bisoprolol, and timolol. Beta-blocker may cause diarrhea, stomach 
cramps, nausea, and vomiting. Additional cautions are needed for patients with heart disease, 
because beta-blockers may cause heart failure in these populations.  
 
Calcium channel blockers 
Calcium channel blockers reduce blood pressure by dilating the arteries, and further reducing 
the pressure in arteries. There are two types of calcium channel blockers: dihydropyridine 
(DHP) calcium channel blockers (e.g. felodipine, isradipine, and nifedipine) and 
non-dihydropyridine (e.g. diltiazem and erapamil). The side effects of calcium channel 
blockers include headache, constipation, rapid/slow heart rate, and so on.  
Statins 
Statins are one of main types of lipid lowering agents, which can reduce the levels of 
cholesterol in blood by blocking the pathway of producing cholesterol in the liver. Although 
statins are not blood pressure lowing agents, but they play an important role in keeping 
vascular health, and preventing presence of cardiovascular diseases. Statins that approved for 
use include atorvastatin, cerivastatin, fluvastatin, lovastatin and so on. Side effects of statins 
include, but are not limited to, headache, difficulty sleeping, muscle aches. 
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2.4 Medicare prescription drug plans  
Numerous studies have investigated the positive impact of health insurance on access to 
medication and medication adherence
60–62
. The subjects of our study are elderly Medicare 
beneficiaries with prescription drug coverage. In this section, we will briefly introduce the 
Medicare program, particularly focusing on the Medicare prescription drug plans.  
 
Medicare is a national social insurance program, which aims to provide health insurance for 
Americans aged 65 or older beginning in 1966. Medicare has expended its coverage to 
younger adults with disabilities and people with ESRD since 1972
63
. There are four 
components under Medicare. Part A is hospital insurance which covers hospital care, skilled 
nursing facility care, nursing home care, hospice and home health service. Part B is medical 
insurance which covers outpatient services or supplies that are not covered in Part A. 
Services like preventive care, ambulance services, and durable medical equipment are 
covered in Part B. Part C plans are also called Medicare Advantage Plans (MA), which are 
alternative choices of Part A and Part B, launched in 1997. Different with original 
“fee-for-service” Part A and Part B, Part C plans are capitated-fee health plans. Moreover, 
Part C plans generally provide additional benefits to their beneficiaries including dental and 
prescription drug coverage. Over the past decade, the enrollment rate of Part C increased 
from 16% to 31% (2006-2015)
64
. Part D was introduced in 2006 to provide prescription drug 
benefits. Medicare beneficiaries who enrolled both Part A and Part B are eligible for Part D. 
Enrolling in Part D plans is optional, but a late enrollment penalty will be charged to people 
who do not enroll Part D when fist eligible for Medicare. Part D enrollment rate has increased 
over time since its implementation. 
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Overall, Medicare beneficiaries can get prescription drug coverage from either a stand-alone 
Prescription Drug Plans (PDP) or a Medicare Advantage plan included prescription drug 
coverage (MA-PD). In 2015, approximately 45% of Medicare beneficiaries receive 
prescription benefits from standalone PDP, while 24% of them receive the coverage from 
MA-PD. Part D plan designs are required to meet the feature of ”standard benefit plan” 
defined by the Centers for Medicare & Medicaid Services (CMS) annually. The list of 
covered drugs, also called formulary, varies between Part D plans, and so do cost-sharing and 
utilization requirements. Prescription drugs for common chronic conditions like 
anti-hypertension agents, anti-diabetes agents and antihyperlipidemic agents are covered. 
Besides the monthly premiums, beneficiaries need to pay 100% of their prescription costs 
until the initial deductible is met ($360 in 2016). Then beneficiaries pay 25% of drugs costs 
before the total costs reaching the initial coverage limit ($3310 in 2016). After that, 
beneficiaries fall into a coverage gap, also called donut hole, which is designed to control 
overuse and inappropriate use of medication. During this time period, beneficiaries have to 
pay 100% of their drug costs up to the out-of-pocket threshold ($4,850 in 2016), although 
they may receive certain discounts on the brand-name drugs and generic drugs (55% and 42% 
in 2016). The Affordable Care Act (ACA) is gradually closing this coverage gap and will 
eliminate it by 2020. Once beneficiaries getting out of donut hole, they are eligible to receive 
catastrophic coverage benefit, where only a fixed amount or 5% of the retail price will be 
charged.    
 
There is an extra Help program, also known as the Low-Income Subsidy (LIS) under 
Medicare Part D
65
. The LIS provides subsidies for the monthly premiums, deductibles and 
copayments to help low income beneficiaries pay their prescription drugs. Some Part D 
enrollees are automatically qualify for the LIS (“deemed LIS beneficiaries), those includes 
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beneficiaries who are dually eligible for both Medicare and Medicaid, who are Supplemental 
Security Income (SSI) recipients, and who are enrolled in the Medicare Saving Programs 
(MSP). The rest Part D beneficiaries need to apply for the LIS (“non-deemed LIS 
beneficiaries) and their eligibilities are determined by the State Medicaid office or the Social 
Security Administration (SSA).  
 
According to the 2016 USRDS ADR, comparable Part D enrollment rate was observed in 
Medicare beneficiaries with and without CKD (71% vs 66%). However, elderly adults with 
CKD carried a higher overall drug burden compared with those without, as total prescription 
spending for Part D enrollees with CKD was 50% higher than general Part D enrollees 
($4,198 vs. $2,806 per person per year). Additionally, LIS program improves access and 
affordability of needed medications in the most vulnerable population. The 2016 USRDS 
ADR reported total prescription spending for CKD patients with LIS was more than 2 times 
greater than those without LIS, at $7,352 compared to $3,262. Moreover, out-of-pocket cost 
accounted for only 1% of total prescription spending in LIS population while accounted for 
29% in non-LIS population. 
 
2.5 Neighborhood and population health 
Geographic variation exists in health risks, utilization of healthcare services and health 
outcomes. Characteristics of residential neighborhood, like neighborhood social support, 
social economic positions, primary care resources and health care quality may account for 
these geographical differences in health behaviors, disparities in healthcare utilization and 
outcomes. People living in the same area are more likely than those from different areas to 
have similar lifestyle, health-related beliefs, health behaviors and healthcare system. Thus, by 
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targeting contextual characteristics, population-based strategies can yield greater public 
health impact on health promotion, from a population perspective. Here we discuss some 
important neighborhood characteristics related with health improvement.  
Neighborhood support and participation  
Social support and social participation at neighborhood level are showed to have positive 
effects on population health. A study of neighborhood support and infant’s birth weight in 
Chicago revealed that the difference in birth weight between African-American and White 
was reduced from 297g to 154g by adjusting for individual factors, and was further reduced 
to 124g by adding adjustment of neighborhood social support
66
. Another study investigated 
the effect of neighborhood on medication use in women aged above 45 found residents with 
low social participation were less likely to use hormone replacement therapy compared to 
their counterparts with active social participation
67
. Residents might benefit from 
neighborhood support and participation from sharing health promotion information, adopting 




Neighborhood socioeconomic status  
Research evidence indicates the effect of residing in a deprived neighborhood on risk 
behaviors, presence of diseases and poor treatment outcomes persists, even after adjusting for 
individual socioeconomic status. For example, a multilevel study on the relationship between 
neighborhood and drug use revealed living in poverty neighborhoods increased the risk of 
using heroin and cocaine, after adjusting individual factors
72
. Previous studies also found 
people living in deprived areas were more likely to have hypertension, obesity, and 
developing cardiovascular disease
73
. Also, treatment outcome is relatively poor in deprived 
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areas. Shacham et al examined the relationship between neighborhood characteristics and 
HIV managements in outpatient settings in the St Louis metropolitan area
74
. Researchers 
found people from deprived areas were less likely to receive antiretroviral prescription and 
demonstrated a lower CD4 count. A cohort study in patients after discharge for acute 
myocardial infarction (AMI) conducted by Tonne et al demonstrated that people living in 
affluent census tracts had a significant higher survival rate compared with those living in poor 
census tracts, with adjustments for individual, clinical and socioeconomic factors
75
.    
 
Health care resources  
Variation in health resources across regions also accounts for disparities in utilization of 
health care and population health. Research evidence from ecological studies illustrated that 
better access to primary care, measured by number of primary care physicians per capita, was 
associated with less hospitalizations and a lower mortality rate
76–78
. Findings from these 
studies indicated that improving access to primary care might reduce disparities in mortality 
between socioeconomic and racial/ethnic groups. Furthermore, previous study found a 
positive relationship between physician-population-ratio and adherence to practice guidelines 
in the fibromyalgia setting
79
. Patients in the area with higher physician density were less 
likely to have chronic opioid use, a treatment with insufficient evidence for therapeutic 
efficacy, compared with those in the medically underserved area. The increased adherence to 
the practice guidelines might be attributable to more information dissemination between 
physicians, increased awareness of the guideline and familiarity with the guideline as results 
of less work burden.   
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Treatment strategies and healthcare quality  
Disparities in population health may also be due to distinct treatment strategies and 
healthcare quality between regions. Two studies of medication use in Medicaid enrollees 
showed there were significant differences in both opiates use and antiretroviral agents use 
across the United States
80,81
. This difference might be raised by the distinct design of state 
Medicaid programs and different medical practice between physicians. A recent study by 
Sargen et al assessed diabetic drugs use in Medicare enrollees across hospital referral 
regions
82
. Findings from this study indicated metformin and thiazolidinedione were more 
likely to be prescribed to people in the Western United States and the Central United States 
respectively, while sulfonylureas and insulins were both widely used in the South and 
Midwest. Race and income were associated with prescription patterns as well.  
 
With regards to the quality of healthcare, two studies from England examined how healthcare 
quality varied across regions, and illustrated that the quality of health services, like 
preventive care, was better in regions with higher social economic positions
83,84
. Meanwhile, 
more programs were available for chronic diseases, like diabetes and asthma, in affluent 
regions than deprived regions. When specific to medication use, a study of high risk 
medications use in Part D enrollees found people residing in the Southern United States were 
more likely to receive the pharmacological therapy including high risk medications, 
compared to their counterparts living in the New England area
85
.   
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2.6 Cardiovascular medication use among patients with hypertensive CKD 
2.6.1 Patterns of cardiovascular medication use  
CKD patients are at high risk of uncontrolled blood pressure and cardiovascular conditions. 
Approximately two thirds of American adults with CKD had inadequate blood pressure 
control
86
. For this reason, cardiovascular medications are the most frequently used 
therapeutic groups in people with CKD not requiring dialysis. Combination therapy with two 
or more drugs is necessary when the target blood pressure cannot be achieved by using a 
single drug. Therefore, CKD patients were taken more anti-hypertension agents than their 
hypertensive counterparts
4,87,88
. A cross-sectional study of 13,065 REGARDS (Reasons for 
Geographic and Racial Differences in Stroke) participants showed that the prevalence of 
receiving 4 and more types of antihypertensive agents in CKD participants was 2 times 
greater than those without CKD (10% vs.5%)
88
. Despite a majority of both participants with 
and without CKD receiving two antihypertensive agents (37% and 40%), participants with 
CKD were more likely to receive three different antihypertensive agents (27% vs.17%) and 
less likely to receive a single drug, compared to those without CKD (26% vs. 39%). 
 
Patterns of cardiovascular agents use are individualized based on therapeutic goal, efficacy, 
tolerability, complexity of regimen, and cost. There is little research describing the patterns of 
cardiovascular agents use in CKD patients
89–91
. Bailie et al (2005) used data from the 
RRI-CKD study (the Renal Research Institute Chronic Kidney Disease study) found CKD 
patients were most likely on calcium channel blocker (52%), followed by beta-blocker (46%), 
ACIEs (44%), Statins (16%) and ARBs (13%)
92
. Furthermore, medication use was varied by 
co-existing conditions. For instance, CKD patients with proteinuria and diabetes 
demonstrated the highest utilization rate of calcium channel blocker (64%), while CKD 
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patients with coronary artery disease had the highest utilization rate of beta-blocker (65%) 
and statins (24%). A noticeable higher utilization rate of ACEIs was observed in both 
proteinuric patients with and without diabetes (58% and 52%), while a higher utilization rate 
of ARBs was only showed in proteinuric patients without diabetes (23%). Another study 
examined 420 pre-dialysis CKD patients and found a relatively high utilization rate in all 
cardiovascular agents. Diuretic ranked first in term of utilization rate (80%), followed by 
RAS inhibitors (67.1%), calcium channel blocker (64.8%), beta-blockers (42.4%), and statins 
(36.2%). Different with other studies, this study collected medication use data during the 
period from the first nephrology consultation to initiation of dialysis. Thus, the high 





Factors that associated with cardiovascular agents use in CKD patients are not well studied. 
A recent national representative study of NHANES participants explored factors associated 
anti-hypertensive agents use in CKD patients
91
. In this study, CKD patients who were older, 
aware of hypertension or diabetes, and had advanced kidney damage were more likely to take 
anti-hypertensive agents. Additionally, significant differences in utilization rate by CKD 
stages were only observed in ACEIs and diuretics, but not in ARBs, beta-blockers and 
calcium channel blockers. Another study in New Mexico HMO (health maintenance 
organization) enrollees found diabetic CKD patients showed a higher utilization rate of 
ACEIs than those without diabetes regardless of disease severity
93
. There was no noticeable 
difference in ACEIs use between patients with and without a nephrology referral.  
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2.6.2 Outcome associated with cardiovascular medication use  
This section describes the existing evidence on the efficacy of each cardiovascular agent in 
the CKD population. Although all antihypertensive agents are effective in lowering blood 
pressure, some drug classes might bring additional benefits besides lowering blood pressure 





According to the K/DOQI clinical practice guidelines, regimens including ACEIs and ARBs 
are preferred for diabetic nephropathy and nondiabetic nephropathy with level of proteinuria 
greater than 200 mg/g
42
. The American College of Physicians (ACP) also recommends use of 
ACEIs and ARBs to patients with hypertensive CKD
94
. The Irbesartan Diabetic Nephropathy 
Trial (IDNT) compared the protective effect of ARBs and calcium channel blockers in 
hypertensive patients with kidney disease due to type 2 diabetes
95
. A total of 1,715 patients 
were randomly assigned to treatment with irbesartan, amlodipine or placebo. Compared to the 
other two groups, patients received ARBs demonstrated a significantly slower increase in the 
serum creatinine concentration, a lower risk of doubling the serum creatinine concentration 
and less likely to develop ESRD. However, there was no difference in term of all case 
mortality and cardiovascular related outcomes. Another randomized controlled trial (RCT) 
study of 352 patients with nondiabetic kidney disease found patients receiving regimens 
including the ACEI ramipril showed a slower decline in GRF and a reduced proteinuria, 
compared with patients receiving conventional antihypertensive regimens
96
. Furthermore, the 
protective effect of ACEI treatment was independent of changes in blood pressure. Findings 
from these studies indicate ACEIs and ARBs have renoprotective effects in addition to 
lowering blood pressure.        
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Diuretics 
Diuretics are preferred antihypertensive agents for heart failure with systolic dysfunction, 
reducing risk of recurrent stroke and coronary artery disease
42
. A RCT study of 4,336 elderly 
patients with isolated systolic hypertension and kidney disease showed patients receiving 
therapies including diuretic were less likely to experience adverse cardiovascular events 
within a 5-year observation period
97
. Meanwhile, research evidence indicated that adding 
diuretics to regimens with ACEIs/ARBs may strengthen the efficacy of antihypertensive 
treatments
42
. A pilot RCT study from Weir et al assessed effect of the ARB valsartan on 
blood pressure in hypertensive African Americans who were on low salt diet
98
. A total of 88 
patients on a 100 mEq Na+/day diet received valsartan therapy (160 mg/day) for 4 weeks at 
first, then they received the same valsartan therapy with a supplementation of 100 mEq 
Na+/day for another 4 weeks. After that, patients were randomly assigned three different 
regiments while continuing the high salt diet for additional 6 weeks: doubling the dose of 
valsartan, adding the diuretic hydrochlorothiazide (12.5 mg/day) or the ACEI benazepril (20 
mg/day) to the baseline valsartan therapy. This study found the effect of valsartan on 
lowering blood pressure was not significantly diminished by high salt diet. Moreover, 
combination therapy of an ARB and a diuretic was more effective in lowering blood pressure 
than the therapy either adding an ACEI or doubling the dose of ARB.  
Beta-blockers 
Beta-blockers are of particular benefits in patients with angina, myocardial infarction, and 
congestive heart failure and so on.
42
. The cardiac insufficiency bisoprolol study II (CIBIS-II) 
trial demonstrated that patients with heart failure and kidney dysfunction who received the 
beta-blocker bisoprolol had a lower risk of all-cause mortality and heart failure 
hospitalization than comparison group, and these protective effects were observed in all 
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patients regardless the severity of renal impairment at baseline
99
. Similarity, findings from the 
Seniors with Heart Failure (SENIORS) trial and the Metoprolol Controlled-Release 
Randomised Intervention Trial in Heart Failure (MERIT-HF) trial showed that the benefits of 
beta-blockers in reducing risk of hospitalization and modality were comparable between 




Calcium channel blockers 
Calcium channel blockers are recommended for some specific types of CVD, such as 
congestive heart failure due to diastolic dysfunction and angina pectoris
42
. Besides the effect 
of regulating blood pressure, there is strong evidence that nondihydropyridine calcium 
channel blockers have added benefits of slowing the progression of diabetic kidney disease 
by reducing proteinuria. A RCT study of 34 Africa American patients with hypertension and 
diabetic kidney disease found patients who received the calcium channel blocker verapamil 
had a slower decline of creatinine clearance and a greater reduction in proteinuria compared 
to those received the beta-blocker atenolol, despite comparable blood pressure control
102
. 
Another RCT study of 92 normotensive patients with insulin-dependent diabetes and 
microalbuminuria found treatment group with the calcium channel blocker nifedipine 
demonstrated a marked lower risk of progression to clinical albuminuria and 
macroalbuminuria compared to placebo group over a 3-year study period
103
.     
 
Statins 
Use of statins in hypertensive CKD is recommended in the clinical practice guideline from 
ACP
94
. As reported in the USRDS ADR 2016, statins are the most commonly used oral 
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medication in CKD patients regardless the stage and cause of kidney disease
1
. Previous 
studies have revealed the cardiovascular benefits of statins in CKD patients, nevertheless 
there was lack of RCT evidence for benefits in preserving kidney function
104–106
. A 
meta-analysis study by Navaneethan et al included a total of 26 RCTs and quasi-RCTs and 
found non-dialysis dependent CKD patients who received statins had a significant lower risk 
of cardiovascular mortality and all-cause mortality compared to those received placebo or 
regimens without statins
107
. In term of kidney function, there was no difference in creatinine 
clearance between statins and non-statins groups, but a greater reduction in 24 hour urinary 
protein excretion was observed in statins group.  
 
2.6.3 Adherence to cardiovascular medications in CKD patients 
Medication compliance is the cornerstone in achieving the goals of pharmacological 
treatments
108
. A number of studies revealed that poor adherence to prescribed medication was 
associated with increased hospital admissions and mortality
109–112
. Consequences of poor 
medication-taking behaviors accounted for more than $100 billion in healthcare expenditures 
per year
113,114
. CKD patients are at high risk of poor medication adherence due to presence of 
depression, development of functional and cognitive impairment, complex medicine 
regimens and pill burden
115–119
. Previous studies found hypertensive CKD patients who had 
poor adherence to their prescribed medications were less like to make their blood under 
controlled and consequently more likely to experiencing progression of CKD
4,88,120
. 
However, adherence to medications, especially adherence to cardiovascular agents, has not 
been extensively studies in patients with CKD not yet on dialysis.  
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A broad range of adherence rate ranging from 65% to 83% was observed in studies of 
medication adherence in CKD patients
4,88,120–123
. This variation may attributable to different 
study designs, type of the target medications and heterogeneity in study populations. There is 
no standard method to measure medication adherence, and accordingly definition of 
nonadherence are varied across studies
124
. Medication adherence can be assessed either 
directly or indirectly. Direct methods include testing the concentration of drug in blood or 
urine, measuring biomarkers with the investigated medications, and direct observation of 
taking medication
114
. Though direct methods reflect medication taking behaviors, seldom 
studies use indirect methods because they are costly and labor-intensive. Indirect methods of 
assessing adherence are frequently used in adherence studies, including patient self-reports, 
prescription records from electronic databases, medication monitoring in form of pill counts 
and using electronic monitoring devices.  
 
In general, adherence studies with self-report measures showed better medication compliance 
from 67% to 83%
88,120,121
 than those with objective measures from 65% to 70%
4,122,123
. This 
difference may be attributable to the recall bias and social desirability bias from self-reports. 
It is worthwhile to note that self-reports such as questionnaire and diary methods have 
moderate-to-high concordance with electronic measures, while interview-based self-reports 
have poor concordance
125
. Studies using self-report measures have advantage in obtaining 
subjective reasons for medication nonadherence and early discontinuation, such as health 
belief and perceived treatment effects
126
. Studies using prescription claims data have 
advantage in relatively large sample size, long observation period, timely and inexpensive 
compared to other measures. While worthy to note is that medication records reflects the total 
quantity of doses taken but not daily doses taken and timing of doses. Moreover, the accuracy 
of claims data is questionable when patients can obtain their prescriptions from other outside 
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resources, and when researchers cannot distinguish decisions of discontinuation made by 
physicians because of lack of efficacy and decisions made by patients because of poor 
adherence
127
. Pill counts and electronic monitoring devices are commonly used to monitor 
medication taking behaviors as well. Use of pill counts is simple and economic, but it is not 
accurate as the patients may discard pills before visits
128
. Use of electronic monitoring 
devices is relatively costly and may not be an ideal method for conditions needing multiple 
prescriptions. But this method has an additional advantage in capturing timing of dose taken 




Reasons for nonadherence to prescribed medication vary by conditions, characteristics of the 
target medication and investigated populations. A meta-analysis conducted by DiMatteo 
reviewed a total of 568 adherence studies in all fields from 1948 to 1998, and found 
education, income and socioeconomic status were positively related with adherence to 
medical recommendations. However, the effects of age and gender on adherence were varied 
across studies
130
. Similarly, when examined medication adherence in CKD patients, younger 
age, male, lower levels of income and education were risk factors of poor adherence in some 




Medication adherence in CKD patients is also influenced by patients’ health status. Previous 
studies found CKD patients who were unable to self-administer their medications, had 
presence of depression and had more hospital visits demonstrated a lower adherence rate to 
their medications
4,88,121
. Inconsistent evidence was observed from study to study regarding to 
the association between kidney function and adherence. Schmitt et al using pharmacy claims 
found patients with worse kidney function had a lower medication adherence; while a study 
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of the African American Study of Kidney Disease (AASK) participants using self-reported 
adherence measures found CKD patients with moderate and severe CKD were more likely to 
be adherent to their medications than patients with mild CKD
4,131
. A retrospective cohort 
study by Chang et al found medication adherence was associated with worsening kidney 




Forgetfulness was the most common reason for unintentional nonadherence given by 
patients
88,120,132
. Besides that, research evidence revealed that medication taking behaviors 
were also related with characteristics of regimens, such as complexity of medicine regimens, 
pill burden, the salience of conditions, perceived need of medications, perceived benefits of 
medications, side effects and effective physician-patient communications
121,132–134
. Normally, 
CKD patients have a higher pill burden compared to the general population. A prospective 
cohort study showed CKD patients took an average of 6.7 pills per day
121
. Moreover, CKD 
patients may receive their prescribed medications not only from nephrologists but also from 
other physicians depending on their existing comorbid conditions. This makes the regimens 
more complex for CKD patients. Recent interview-based studies found that CKD patients 
prioritized their prescribed medications and skipped the medications perceived as less 
important
133,134
. For example, statins, medications for an typically asymptomatic disease 
dyslipidaemia, were often underutilized in both elderly population and CKD patients
135,136
. 
This might because lipid lowering agents were perceived as less important in preserving 
kidney function
133,134
. A qualitative study by Tolmie et al found that low adherence to lipid 
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Previous studies have assessed the treatment effect of medication adherence in hypertensive 
CKD patients. Hong et al used data from the AASK trial study and found poor adherence 
increased the visit-to-visit variability of systolic blood pressure. In this study, a total of 988 
AASK participants were followed by one year and medication adherence was measured by 
self-reports and pill counts
131
. Another adherence study of 7,227 CKD patients using two 
year claims data showed patients who had poor adherence to their prescribed 
antihypertension were 23% more likely having uncontrolled blood pressure
4
. However, few 
studies had investigated the effects of medication adherence on the progression of kidney 
disease. Previous studies indicated that medication adherence declined over time. Two 
studies conducted by Magacho et al and Change et al found medication adherence rate in 
patients with kidney dysfunction decreased by 54% in a one-year period and 29% in a 
three-year period
121,123
. Thus, further studies with large sample size and examining long-term 
effects of medication adherence on renal function preservation are warranted.    
 
As pointed out by the report of the World Health Organization, health professionals, not only 
general practitioners but also nurses, pharmacists, and psychologists play an essential role in 
promoting adherence to treatment
108
. Several review papers summarized the effectiveness of 
interventions aiming to improve medication compliance and treatment outcomes, and found 
the effects were inconsistent across studies
138–140
. Multidisciplinary care is also recommended 
in the CKD setting
141
. Research evidence indicated that interventions with either nurse 
coordinated care or pharmacist coordinated care increased use of cardiovascular medications 
and consequently reduced medication-dependent risk factors, like hypertension and 
cholesterol
142–145
. However, there is lack of evidence that these interventions can significantly 
reduce cardiovascular events and mortality. Though substantial studies have evaluated factors 
related with poor adherence in CKD patients, few of them focuse on factors that influence the 
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access to medications from perspective of neighborhood, characteristics of the place that 
patients lived in. Our study will illustrate how contextual factors impact medication 
adherence in CKD patients across different regions. The findings of our study will support 
health professionals in developing locally population-based interventions to improve 
medication taking behaviors and further promote treatment outcomes.  
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2.7 Conceptual Model 
Health behaviors and health outcomes are jointly determined by characteristics of 
environment and population at risk. This forms the basis of Anderson’s Behavioral Model, 
developed by Aday and Andersen, which has been widely used in health services research to 
predict healthcare utilization and outcomes over the past decades
146
. The conceptual 
framework of this study is developed based on Andersen’s Behavioral Model (Figure 2-3). 
Three components of individual determinants of health behaviors and outcomes are proposed 
in Anderson’s model, which are predisposing, enabling, and need. Predisposing refers to the 
properties exist prior to the onset of conditions. Demographic, social structure and health 
beliefs factors are generally viewed as predisposing characteristics. The enabling component 
describes individuals’ potential accessibility to health care. The need component indicates 
disease severity, which can be captured by either patient-perceived severity or that evaluated 
by health professionals. We will conduct this study using health claims data, so we are lack of 
measures for the subjective concepts in Anderson’s Behavioral model, such as individuals’ 
health belief and perceived severity. Demographic factors including age, gender, and race are 
captured in our study. Access to care is measured by prescription drug coverage. Patients’ 
comorbidities are indicators of need for care, which are captured by diagnosis in medical 
claims.  
 
Furthermore, we also define three dimensions of contextual determinants of health behaviors 
and outcomes, including availability, predisposing characteristics and enabling resources. 
Availability describes the characteristics of health system, such as volume and distribution of 
medical resources in an area, as at the county level in this study, which are measured by 
number of general physicians per 10,000 persons and percentage of people residing in 
MUAs. Predisposing characteristics and enabling resources have the same meaning as at the 
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individual level. Therefore, census statistics of external environments will serve as proxies of 
these concepts. Percentage of Medicare beneficiaries indicates the predisposing 
characteristics in each county. Deprivation score is used to assess the enabling resources at 
country level, which is measured by the Townsend index. The Townsend index incorporates 
unemployment rate, percentage of households without car ownership, home ownership and 
overcrowding.  
 
Healthcare utilization of interest in this study is ACEIs/ARBs use among elderly hypertensive 
patients with CKD, and the healthcare outcomes are defined as CKD related treatment 
outcomes. Based on our conceptual model, individual and contextual characteristics will 
directly affect healthcare outcomes or indirectly affect them through healthcare utilization. 
Our conceptual model will be useful to identify mutable variables that explain use of 
ACEIs/ARBs, and further promote equitable access via policies. Generally, variables under 
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Contextual factors (county level)  
  
Medication Utilization  
 Patterns of medication use 
 Utilization rate  





Individual factors  
Predisposing Characteristics 




 Health insurance coverage (Part 







 Number of general physicians per 10,000 
persons 
 % of population residing in MUAs 
 
Enabling Recourses 
 Deprivation score (Townsend Index) 
 Non-car ownership 
 Non-home ownership 
 Household overcrowding 
 Unemployment rate 
 
Predisposing Characteristics 
 % of Medicare beneficiaries  
 






Chapter 3  
METHODOLOGY 
 
This study assessed the relationship between access to cardiovascular medications, 
medication use, and CKD related outcomes among Medicare beneficiaries with hypertension 
and CKD in the United States. This section details the study design, study population, and 
measurements, as well as statistical methods implemented by each of the three study aims.  
 
3.1 Study design 
This was a retrospective cohort study of aged Medicare beneficiaries who had hypertension 
and CKD in the United States. We utilized the 5% sample of Medicare claims (from January 
1, 2006 to December 31, 2013) data from the USRDS databases, Medicare claims data have 
been widely used in health services research for several reasons. First, elderly adults are at 
high risk for chronic kidney disease. Second, the 5% Medicare claims are nationally 
representative for Medicare beneficiaries who are not enrolled in a Medicare Advantage plan. 
The 5% sample of Medicare claims data contains claims from a 5% random sample of 
Medicare beneficiaries, whose CMS Health Insurance Claims number has the last two digits 
of 05, 20, 45, 70 or 95. Claims from hospice, inpatient hospitalizations, skilled nursing 
facility, outpatients, physician/supplier, home health agency, durable medical equipment, and 
prescription drug event are accessible. Third, since 2006, the year Medicare Part 
implemented, researchers are able to obtain medication use information from the Medicare 
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Part D claims data. ACEIs and ARBs, along with other cardiovascular agents are covered by 
all of Part D claims. Thus, as long as the patients filled their prescriptions from the Medicare 
Part D network, these are recorded in this electronic system. Moreover, the sampling design 
of Medicare 5% sample data also supports a longitudinal study design over years, which 
enable researchers to assess the long-term benefits of pharmacological treatment, such as 
CKD progression and mortality in CKD patients. 
 
Figure 3-1 showed the overall study deign and study cohort extraction criteria. Our study 
comprised four main periods: a seven-year selection period (from 01/01/2006 to 12/31/2012) 
to select all hypertensive Medicare beneficiaries who had a diagnosis of CKD; a two-year 
baseline period (from 01/01/2006 to 12/31/2007) to assess medical history; an one-year look 
baseline period (from 01/01/2007 to 12/31/2007) to evaluate medication use history; and a 
six-year follow-up period (from the index date, 01/01/2008 to the end date, 12/31/2013) to 
examine long-term medication use and associated treatment outcomes. The primary outcomes 
in this study included medication use patterns, medication adherence, and progression to 
ESRD, as well as all-cause mortality. Patients were censored at the date of death or the date 
of last recognized CKD related visit when progression to ESRD was the event, while they 
were all censored at the end date of our study when all-cause mortality was the event. 
 
In order to capture complete medication histories, continuously covered by Medicare 
stand-alone Part D plans from the beginning of 2007 to the end of 2013 were required. We 
identified the eligible hypertensive CKD patients starting from a retrospective cohort of 
hypertension patients, beneficiaries with diagnosis of hypertension in the two-year baseline 
period. We then included patients who had been diagnosed with CKD during the selection 
period. To ensure each eligible hypertensive CKD patients having a long enough follow-up 
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time, the selection period was ended one year ahead of the end date of this study. 
Beneficiaries whose first observed CKD claim was before the index date were classified as 
prevalent CKD, while the rest were classified as incident CKD. Subjects who developed 
ESRD or died in the two-year baseline period were excluded from our study. This study was 
approved by University of Michigan’s Institutional Review Board (IRB). 
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Figure 3-1 Overall Study design and study cohort selection criteria 
 
Baseline period 
Two-year for medical history 
One-year period for Rx use 
history 
 
Follow-up Period  
Censor date:  
Date of last CKD related visit (when 
developing ESRD is the event) 
End date of our study period (when 




1 had hypertension diagnoses (at least 1 inpatient/ 2 outpatient claims) in the baseline period. 
2 continuously enrolled in Medicare A&B /CDM managed-care network from 2006/1/1 to the end 
date/date of death. 
3 being alive in the baseline period 
4 aged 67 and older at 2008/1/1 
5 continuously enrolled in Medicare Part D from 2007/1/1 to the end date/date of death. 
6 had diagnoses of CKD during 2006-2013 (at least 1 inpatient / 2 outpatient claims). CKD patients 
with any CKD claims during baseline period were classified as prevalent cases, otherwise were 
classified as incident cases. 
Exclusion Criteria 
1 had ESRD diagnosis before 01/01/2008 
2 date of first CKD claim after 01/01/2013 
3 date of last CKD claim before 01/01/2008 
Start Date: 
2006/1/1  End date 
2013/12/31  
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3.1.1 Data sources and linkage  
The 5% sample of Medicare claims (2006-2013) from the USRDS databases were used in 
this study to obtain individual information on aged beneficiaries who enrolled in Part D. To 
achieve the study aims, these data sets were further linked to the U.S. Census Bureau 
American Community Survey (ACS) 5-Year Estimates data (2009-2013) for characteristics 
of external environmental status, and to the Health Resources and Services Administration 
(HRSA) Primary Care Service Area (PCSA) data (2007) for primary care resources in the 
county level. This unique dataset also contained spatial information of population center, 




The 5% sample of Medicare claims from the USRDS databases consist of data from the CMS 
Medicare 5% Sample Standard Analytical Files (SAFs), ESRD related information extracted 
from the ESRD Medical Evidence form (CMS 2728), and death related information extracted 
from the ESRD Death Notification form (CMS 2746) as well as the Master Beneficiary 
Summary File. The CMS Medicare 5% Sample SAFs contains claims from a 5% random 
sample of Medicare beneficiaries. In the USRDS database, the unique Health Insurance 
Claim Number and Beneficiary Identification Code are used to match ESRD and death 
information to Medicare claims for beneficiaries in the 5% Medicare cohort. In this study, we 
used these linked datasets in the USRDS databases to identify our eligible study cohorts.  
 
The U.S. Census Bureau provides demographic, social-economic, health insurance coverage 
and transportation status in a population level based on the ACS 5-Year Estimates
149
. The 
current information of communities collected by ACS annually helps to determine how 
federal funding is spent on investments and services. About 3.5 million addresses each year 
are randomly selected to participate in the survey. The 5- year estimates use 60 months of 
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collected data which report the most reliable but less current information on communities, 
and support examining smaller geographies, such as counties
149
. The PCSA data contains 
nationwide data on the United States primary health care resources and population in zip code 
level which reflects patient’s healthcare utilization
150
. This ecological information were first 
aggregated to county level by Federal Information Processing Standard (FIPS) county code, 
and then linked with other environmental data. Map of Centers of Population provides the 
longitude and latitude of the center for counties in the United States. This type of information 
is necessary in spatial analysis. In the end, a crosswalk file of FIPS county code and Social 
Security Administration (SSA) state/county code were created to link these etiology data, 
spatial data with the Medicare claims. Completely de-identified data were used for study 
analysis. 
 
3.1.2 Study population 
For Aim 1, we followed these steps to extract the study cohort:  





2) Confirm the hypertension diagnosis by requiring having at least one inpatients or two 
outpatient claims 
 
    
 
 
Select individuals with any HTN claim during the two-year baseline period (2006/1/1-2007/12/31) 
N=1,380,660 
Identity hypertensive patients with at least 1 HTN inpatient claim or 2 HTN 
outpatient claims in 2006-2013 
N=1,233,037 
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4) Exclude non-elderly Medicare beneficiaries and those who died before the beginning 
















Exclude hypertensive patients who did not continuously enroll Medicare A&B from 




Exclude hypertensive patients who did not continuously enrolled in Medicare Part D 
from 2007/1/1 to the end date (2013/12/31, for those were alive) or date of death 
N=269,738 
 
Exclude hypertensive patients who aged below 67 at the index date (2008/1/1) 
N=739,511 
 
Exclude hypertensive patients who died in the baseline period (2006/1/1-2007/12/31) 
N=687,980 
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6) Restrict to subjects based on their ESRD/CKD visits to ensure each of them had at 





















Then we followed additional steps to identify the final study sample for Aim 2 and Aim 3 
1) From the total hypertensive CKD patients, select a subset of subjects who had a 
history of ACEIs/ARBs use 
Exclude patients with ESRD diagnosis before 01/01/2008  
N=266,547  
 
Exclude patients with date of first CKD claim after 01/01/2013  
N=259,786 
 
Exclude patients with date of last CKD claim before 01/01/2008 
N=252,598 
 
Total hypertensive CKD patients: N=109,532  
Incident CKD case: N=66,315       (Aim1) 
Prevalent CKD case: N=43,217 
 










2) From the total hypertensive CKD patients, select a subset of subjects who had used 













Exclude hypertensive CKD patients without any claims of ACEIs/ARBs within 
the one-year baseline period 
N=65,574   (Aim2) 




Exclude hypertensive CKD patients who died within one year period since their 
first ACEIs/ARBs claim after index date. 
N=73,235 
 
Exclude hypertensive CKD patients with date of first ACEIs/ARBs after 
12/31/2012  
N=70,201 (Aim 3) 
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3.2 Measurement of study variables 
3.2.1 Individual-level characteristics 
Predisposing Characteristics 
Demographic: Medicare 5% sample claims from the USRDS database were the primary 
resources for demographic information (age, gender and race). Age was calculated based on 
the birthday and index date (01/01/2008). Race were defined as white, black, Asian, and 
others.  
 
Enabling Resources  
Prescription drug coverage: In this study, all study subjects were enrolled in stand-along Part 
D plans. To distinguish the different premiums and copayments that the subjects may have, 
we were further classified them into three categories based on the receipt of a low income 
subsidy in 2008: Part D with deemed LIS, Part D with non-deemed LIS, as well as Part D 
without LIS. Beneficiaries with deemed LIS are mainly Medicare and Medicaid dual eligible 
beneficiaries. They are automatically enrolled in LIS and typically have lowest premiums and 
copayments compared to the other two groups
151
. For example, beneficiaries with deemed 
LIS receive a 100% premium subsidy for their prescription drug coverage, and their 
copayments of covered drugs are reduced to a fixed amount or even eliminated. Beneficiaries 
who are not Medicare dual eligibles but have incomes below 150% of the Federal Poverty 
Level are eligible to apply LIS, also called non-deemed LIS beneficiaries. They receive a 
premium subsidy varing from 25% to 100% of their monthly premium. Meanwhile, they pay 
up to 15% of expenditures for all Part D covered drugs. It is noteworthy that there is no gap 
in prescription drug coverage, also known as “donut hole”, in beneficiaries with either 
deemed or non-deemed LIS. 
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Need 
Comorbidities: Comorbidities at baseline were identified for each study subjects using a 
two-year observation period (2006-2007) based on the Medicare 5 percent files. We 
determined comorbidities using the same algorithm that implemented with the USRDS ADR: 
having at least one inpatient claim or two outpatient claims with specified diagnosis/ 
procedure codes. The validity and reliability of this method had been examined in previous 
studies
152
. Inpatient claims include claims of inpatient hospitalizations, skilled nursing 
facility, and home health service. Outpatient claims include claims of outpatient hospital 
services and physician/supplier. The International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) code and the Healthcare Common Procedure Coding 
System (HCPCS) code were used to determine onset of conditions.      
 
Charlson comorbidity index (CCI) was implemented as a comorbidity burden measure in this 
study. CCI is a previously validated measure to predict mortality. The index calculation 
involves a total of 22 distinct conditions (heart disease, chronic lung disease, liver disease, 
acquired immunodeficiency syndrome [AIDS], and so on.), and each of them is assigned a 
weight score from 1 to 6 based on their association with mortality
153
. An adapted CCI was 
calculated with exclusion of diabetes, kidney and cardiovascular diseases. Higher CCI 
indicates greater comorbidity burden, which could be either having multiple comorbid 
conditions or having severe conditions. Separate indictors were generated for conditions that 
were closely related with CKD, like diabetes, cardiovascular conditions and cardiovascular 
procedures. 
 
3.2.2 Contextual characteristics 
Predisposing Characteristics 
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The rate of general physicians per 10,000 persons and percentage of population residing in 
MUAs at county level served as proxy of availability. These two numbers were extracted 





Deprivation score was derived from four census variables: percentage of household without 
car ownership and home ownership, percentage of household overcrowding (more than 1 
person per room), and unemployment rate among people aged 16 and over
155
. We first took a 
log transformation of household overcrowding rate and unemployment rate, and then 
standardize all four variables. The sum of these four standardized score was Townsend index. 
A larger positive Townsend index indicates severe deprivation.  
 
3.2.3 Healthcare outcomes  
Due to a lack of laboratory test results in Medicare 5% sample claims we cannot measure the 
course of renal function. Thus, the progression of CKD was defined as being diagnosed with 
ESRD. The primary outcomes in this study were CKD associated clinical outcomes. The 
specified measures include being diagnosed with ESRD and all-cause death. In the USRDS 
database, the date of ESRD is determined by the first service date extracted from the ESRD 
Medical Evidence form (CMS 2728). Date of death is obtained from the ESRD Death 
Notification form (CMS 2746) as well as the Master Beneficiary Summary File. We defined 
a censored date for those who did not experience the specified outcomes within our study 
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period. When diagnosed ESRD was the interested outcome, we had their data censored when 
the last CKD-related visit happened. When mortality was the outcome of interest, the 




3.2.4 Medication utilization 
In this study, we investigated utilization of ACEIs and ARBs among hypertensive CKD 
patients, as well as other four most commonly used cardiovascular agents (statins, 
beta-blockers, diuretics, and calcium channel blockers). Medicare prescription drug event 
files contain comprehensive information about filled prescriptions, such as the generic and 
brand name, the corresponding National Drug Code (NDC), supply days of each fill, and the 
date that the prescription filled. We first found all active ingredients under each of therapeutic 
drug classes from the website of the Anatomical Therapeutic Chemical Classification System. 
We then developed a list of NDC codes for each active ingredient based on the National Drug 
Code Directory from the Food and Drug Administration. Lastly, we identified prescription 
event for each drug class by matching pharmacy claims against the list of NDCs
156
. 
Measurement of medication use was varied across study aim1-3. In the next section, we 
introduced measurement of medication use and statistical analysis for the three study aims. 
 
3.3 Study Aim1: Compare the effects of different pharmacologic therapies on CKD 
outcomes for hypertensive CKD in Medicare Part D enrollees 
Introduction:  
Pharmacologic therapies including ACEIs/ARBs are strongly recommended for hypertensive 
patients with early stage CKD in the clinical guideline developed by the ACP. Meanwhile, 
there is evidence that statin therapy demonstrates a beneficial effect for hypertensive CKD 
patients. By analyzing medication prescription patterns and comparing effects of different 
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therapies on CKD outcomes, our study provided significant information for clinicians when 
they make CKD treatment decisions. 
 
Research cohort:  
We used a subgroup of our hypertensive CKD cohort to assess medication use patterns, that 
was, elderly hypertensive patients who were newly diagnosed with CKD (as shown in section 
3.1.2). 
 
Medication related measures: 
Medication use 
Dummy variables were created to indicate utilization of each drug class. A value of 1 
represented patients having at least 1 pharmacy claim under the specified drug class during 
the first six months after diagnosis of CKD.  
Medication Persistence 
Medication persistence reflects the duration of complying with the prescribed drug, 
calculating as time period from the initiation of the drug to the discontinuation of the drug. 
Medication persistence has been widely used as a measurement of medication adherence in 
observational research studies. The definition of discontinuation can be varied from study to 
study, and it usually determined by the characteristics of conditions and drugs. Generally, the 
supply days of a cardiovascular agent are one-month or three-month. Thus, we defined 
non-persistence as a minimum three-month medication fill gap.   
Pharmacological therapy patterns 
Patients with hypertension and CKD receive either monotherapy or combination therapy to 
treat their conditions. To explore the effects of different treatment strategies, we grouped the 
six types of cardiovascular agents investigated in this study into three categories: RAS 
  58 
 
inhibiting agents (ACEIs and ARBs), statins, and other antihypertension agents (calcium 
channel blocker, beta-blockers and diuretics). Therefore, patients were classified into eight 
different treatment groups according to their medication use status: receiving none of the 
studied cardiovascular agents; receiving monotherapy of RAS inhibiting agents, statins, or 
other antihypertension agents; receiving combination therapy that contained any two of the 
above three categories; as well as receiving combination therapy that included at least one 
RAS inhibiting agent, one other antihypertension agent plus statin. 
 
A more restricted measure of pharmacological therapy patterns was also developed for 
sensitivity analyses, which incorporated the concept of medication persistence. To be 
considered as a qualified user of a specified drug class, patients need to be on the drug for 
more than three months. Similarly, to be considered as receiving combination therapy, the 
overlap days of filling individual components should be above 3 months. By using this 
restricted measure, fewer patients were expected to be classified as receiving combination 
therapies.  
 
Statistical analysis  
Descriptive analyses were conducted by status of ACEIs/ARBs use, presented as mean and 
standard deviation for continuous variables, as well as frequency and percentage for 
categorical variables. To assess the characteristic difference between these two subgroups, 
two-tailed t-tests and chi-square tests will be used for continuous variables and categorical 
variables. Multivariate Cox regressions were conducted to assess the relationship between 
pharmacological treatment patterns, onset of ESRD and all-cause mortality.  
Logistic regression model was implemented to explore the predictors of receiving 
ACEIs/ARBs after the first diagnosis of CKD in hypertensive patients.  
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3.4 Study Aim2: Examine how patients’ adherence to ACEIs and ARBs influence their 
CKD progression, renal failure and mortality by incorporating time varying effect. 
Introduction  
The progression of CKD is associated with increased healthcare cost and mortality. Several 
randomized clinical trials in the field of CKD demonstrated use of ACEIs/ARBs had a 
protective effect on CKD progression and mortality
157,158
. However, few studies have 
systematically assessed the long-term benefits of ACEIs and ARBs in delaying the 
progression of CKD and death using claims data
159,160
. The objectives of study Aim 2 was to 
examine how patients’ adherence to RAS inhibiting agents potentially associated with renal 
failure and mortality among aged patients with hypertension and CKD. 
 
Study population 
Hypertensive CKD patients who had used ACEIs/ARBs in the one-year baseline period were 
selected as eligible study subjects in study Aim2. A history of ACEIs/ARBs use indicated 
that ACEIs/ARBs were applicable to these patients, and they ought to be adherent to the 
prescribed ACEIs/ARBs (illustrated in section 3.1.2). 
 
Medication related measures: 
Medication adherence 
We used the Proportion of Days Covered (PDC) to quantify medication adherence behavior 
in this study. PDC is widely used as a measure of medication adherence for analyses using 
secondary database. PDC is defined as the proportion of number of days covered by the 
prescription fills within a given period. When using PDC as a proxy of medication adherence, 
we assumed that medications were taken by patients during the supplied days.  
  60 
 
 
We defined a refill interval began with the date of first pharmacy claim within each drug 
class and ended with the last date of observed period. For example, we used the last date of 
baseline period to calculate baseline medication adherence, while used the end date of our 
study /date of death to calculate the follow-up medication adherence. The PDC was computed 
as the total days supply for each drug class divided by total days in the refill interval. The 
total days supply for each drug class was calculated by the sum of total days supply for the 
specified drug class subtracting their overlap days. Adherence can be presented using the 




𝑇𝑜𝑡𝑎𝑙  𝑑𝑎𝑦𝑠 𝑠𝑢𝑝𝑝𝑙𝑦 𝑓𝑜𝑟 𝑎𝑙𝑙 𝑝ℎ𝑎𝑟𝑚𝑎𝑐𝑦 𝑐𝑙𝑎𝑖𝑚𝑠 𝑤𝑖𝑡ℎ𝑖𝑛 𝑡ℎ𝑒 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑒𝑑 𝑑𝑟𝑢𝑔 𝑐𝑙𝑎𝑠𝑠 −  𝑂𝑣𝑒𝑟𝑙𝑎𝑝 𝑑𝑎𝑦𝑠
𝐸𝑛𝑑 𝑑𝑎𝑡𝑒 𝑜𝑓 𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑝𝑒𝑟𝑖𝑜𝑑 − 𝐹𝑖𝑟𝑠𝑡 𝑑𝑎𝑡𝑒 𝑜𝑓 𝑑𝑒𝑠𝑝𝑒𝑛𝑠𝑖𝑛𝑔 𝑡ℎ𝑒 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑒𝑑 𝑑𝑟𝑢𝑔 𝑐𝑙𝑎𝑠𝑠
, 
 
Time-varying medication adherence 
To develop a time-varying measurement of medication adherence, PDC was measured 
quarterly from the index date (01/01/2008) to the end date (12/31/2013 or date of death). 
Thus, the denominator of the above equation was fixed to 90 days, except for the last quarter 
in patients who died in our study period. 
 
Statistical analysis  
We defined a censored date for those who do not experience the specified outcomes within 
our study period. Patients were censored at the date of the CKD related visit when ESRD was 
the investigated outcome, while patients were censored at the end of our study (Dec 30
th
 
2013) when assess overall survival time. To calculate the relative risk of developing our 
specified outcomes, we used multivariate Cox regression modeling with delayed entry. Since 
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medication use was a time-varying covariate, the model was presented as the following 
equation: 
 
𝜆𝑖(𝑡, 𝑃𝐷𝐶 𝑜𝑓 𝐴𝐶𝐸𝐼𝑠𝑖(𝑡), 𝑃𝐷𝐶 𝑜𝑓 𝐴𝑅𝐵𝑠𝑖(𝑡), 𝑃𝐷𝐶 𝑜𝑓 𝑂𝑡ℎ𝑒𝑟𝑅𝑥𝑖(𝑡), ) =
𝜆0(𝑡)exp {𝛽1(𝑡)𝑃𝐷𝐶 𝑜𝑓 𝐴𝐶𝐸𝐼𝑠𝑖(𝑡) + 𝛽2(𝑡)𝑃𝐷𝐶 𝑜𝑓 𝐴𝑅𝐵𝑠𝑖(𝑡) + 𝛽3(𝐿𝐼𝑆 𝑠𝑡𝑎𝑡𝑢𝑠) +
𝛽4(𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 𝑎𝑔𝑒) + 𝛽5(𝑔𝑒𝑛𝑑𝑒𝑟) + 𝛽6(𝑟𝑎𝑐𝑒) + 𝛽(𝑡)𝑃𝐷𝐶 𝑜𝑓 𝑂𝑡ℎ𝑒𝑟𝑅𝑋𝑖(𝑡) +
𝛽(𝑜𝑡ℎ𝑒𝑟 𝑐𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒𝑠)}  
 
Where t represented the ESRD free time or overall survival. 𝜆0(𝑡) referred to the common 
baseline hazard for all subjects. 𝑃𝐷𝐶 𝑜𝑓 𝐴𝐶𝐸𝐼𝑠𝑖(𝑡) , 𝑃𝐷𝐶 𝑜𝑓 𝐴𝑅𝐵𝑠𝑖(𝑡) and 
𝑃𝐷𝐶 𝑜𝑓 𝑂𝑡ℎ𝑒𝑟𝑅𝑥𝑖(𝑡) were time-varying covariates representing the characteristics of 
medication use for individual i at time t. exp (𝛽1(𝑡)) and exp (𝛽2(𝑡)) were the 
time-dependent parameters of interest, representing the adjusted hazard ratio of 1 unit change 
in these characteristics at time or duration t. We also controlled subjects’ demographic 
characteristics at baseline, including age, gender and race. Other potential covariates 
included: baseline indicators of enabling resource (health insurance coverage) and baseline 
comorbidity indicators (CCI scores, diabetes, as well as common cardiovascular diseases and 
procedures). We tested the proportional hazard assumption through scaled Schoenfeld 
residuals, and use the model fit statistics for model comparison and selection. The statistical 
significance level is p < 0.05.  
 
3.5 Study Aim3: Model ACEIs/ARBs adherence as a function of individual and 
contextual factors among aged hypertensive patients with CKD in the United States. 
Introduction 
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Despite the benefits of ACEIs/ARBs in CKD progression and renal event, medication 
adherence among CKD patients need to be further improved. An observational study found 
33% of CKD patients had poor medication adherence to antihypertensive agents
4
. In study 
Aim3, we assessed elderly hypertensive CKD patients’ adherence to ACEIs/ARBs across 
different geographic region, and explore preventable and modifiable risk factors for 
medication adherence.  
 
Research cohort  
We extracted a subgroup of our hypertensive CKD cohort to assess one –year medication 
adherence, which was, patients who had at least one pharmacy claims for an ACEI or an 
ARB in the follow-up period. Subjects who died within one year period from their first 
ACEIs/ARBs claim during the follow-up period, and those who initiated their ACEIs/ARBs 
after 12/31/2012 were excluded (illustrated in section 3.2). 
 
Medication related measures: 
One-year ACEIs/ARBs adherence  
According to the clinical practice guideline in CKD, both ACEIs and ARBs should be used at 
moderate to high doses for CKD patients, and they can be used as alternatives to each other 
when the preferred class cannot be used
42
. Thus, in the study Aim3, ACEIs and ARBs were 
combined together when we computed PDC. Adherence to ACEIs/ARBs was calculated in 
the form of PDC with one year fixed refill interval starting from the first date of dispensing 
ACEIs/ARBs. Thus, the equation of PDC was total days covered by ACEIs/ARBs in the 
one-year refill interval divided by 365. By using the fixed refill interval, we were able to 
adjust discontinued therapy. 
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Statistical analysis  
For descriptive analyses, we first stratified patients into two groups: PDC greater than 80%, 
and PDC below 80%, which was the most widely used threshold for medication adherence
161
. 
Descriptive data including means, standard deviation, frequencies, and percentages were 
calculated for each group. Two-tailed t-tests for continuous variable and chi-square tests for 
categorical were used for group comparison.  
 
GWR was conducted to investigate the association between contextual factors and 
medication adherence at county level using GWR4 software. First, we aggregated the PDC of 
ACEIs/ARBs to the county level, and then conducted Moran's I test. A statistically significant 
Moran’s I test indicated the existence of spatial autocorrelation in county-level mediation 
adherence. We then applied a multivariate linear regression model to establish a properly 
specified model for GWR. The model can be described by the following equation: 
 
𝑌(𝑎𝑔𝑔𝑟𝑒𝑔𝑎𝑡𝑒𝑑 𝑎𝑑ℎ𝑒𝑟𝑒𝑛𝑐𝑒%)
= 𝛽0 + 𝛽1(𝑟𝑎𝑡𝑒 𝑜𝑓 𝑔𝑒𝑛𝑒𝑟𝑎𝑙 𝑝ℎ𝑦𝑠𝑖𝑐𝑖𝑎𝑛)
+ 𝛽2(% 𝑜𝑓 𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑟𝑒𝑠𝑖𝑑𝑖𝑛𝑔 𝑖𝑛 𝑀𝑈𝐴𝑠) + 𝛽3(𝐷𝑒𝑝𝑟𝑖𝑣𝑎𝑡𝑖𝑜𝑛 𝑠𝑐𝑜𝑟𝑒)
+ 𝛽4(% 𝑜𝑓 𝑀𝑒𝑑𝑖𝑐𝑎𝑟𝑒 𝑏𝑒𝑛𝑒𝑓𝑖𝑐𝑖𝑎𝑟𝑖𝑒𝑠) 
 
Second, we checked the redundancy among our explanatory variables using Variance 
Inflation Factor (VIF) value. Variable with the largest VIF value were removed one by one 
until all variables’ VIF value below 2. The adjusted R squared value refers how much of the 
variance in medication adherence are explained in our model. Third, we performed a GWR 
model and examine the changes in goodness-of-fit using R
2
 and the Akaike Information 
Criterion (AICc). In addition, we also evaluated the performance of GWR model with 
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ordinary least squares (OLS) model through GWR ANOVA test. A significant F value 
indicates GWR is preferred to the OLS model. 
 
Different from OLS, GWR is able to provide results of local regression model for each 
independent variable and each geographical location. By doing that, researchers first define a 
circle of some radius around a particular patients’ location 𝑝𝑖, called kernel (in our case, 
center of population at county level), and then run a local OLS regression model only on the 
basis of patients located within the circle. Thus, the coefficient 𝛽𝑖𝑗 will be interpreted as an 
estimated association between independent variable j and medication adherence in and 
around location 𝑝𝑖. A weight will be assigned to each patient in the circle by the kernel 





{1 − (𝑑𝑖𝑘 ℎ⁄ )
2}2                       𝐼𝑓 𝑑𝑖𝑘 < 𝑟,
0                                                   𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
  
 
Where 𝑎𝑖𝑘 is the weight assigned to patient k when location of patient i (𝑝𝑖) is the center of 
the kernel; 𝑑𝑖𝑘 is the distance between patient k and i; h refers to the kernel bandwidth; and r 
stands for the radius of the circle. The constant variable r and h control the size of the circle 
and the range of the “circle of influence” of the geographical data. In this study, the Gaussian 
kernel was used to define r: r was smaller where patient distribution was denser, and r was 
larger when patient distribution was sparse. The AICc wass used to determine h. Lastly, we 
conducted geographical variability test for each of our explanation variables. A positive value 
of “DIEF of Criterion” indicate there is not significant spatial variation in the local estimates 
of the investigated explanation variable, and the variable is preferred to treat as global 
variable rather than local variable. In the end, virtualized maps were developed by SAS 
software to display results of GWR analyses. 
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We further conducted a mixed effect model to assess the association between individual 
factors, contextual factors, and medication adherence, controlling random effects of county 
factors. All individual level variables were included in this model based on our conceptual 
model. The statistical significance level is p<0.05. 
  






Chapter 4  
DISSERTATION MANUSCRIPT ONE: Comparison of effects of different 
pharmacologic therapies on chronic kidney disease (CKD) outcomes in Medicare Part D 
enrollees with hypertensive CKD 
 
4.1 Abstract  
OBJECTIVES: Little research has evaluated cardiovascular agents use patterns in CKD 
patients and compared effects of different pharmacologic therapies on CKD outcomes. This 
study aimed to assess medication use patterns in elderly patients with hypertensive CKD in 
the United States. Associations between different anti-hypertensive regimens and CKD 
outcomes were investigated.  
 
METHODS: We used Medicare 5% sample claim data from the USRDS database 
(2006-2013) in this retrospective study. Eligible cases were hypertensive patients who were 
newly diagnosed with CKD and continuously enrolled in Medicare stand-alone Part D plans. 
We investigated six drug classes: ACEIs, ARBs, other anti-hypertensive agents (calcium 
channel blockers/ beta-blockers/ diuretics), and statins. Medication use was defined as having 
at least one pharmacy claim within each drug class during a six-month period after the date of 
first diagnosis of CKD. The multivariate Cox regression model was used to assess effects of 
different pharmacologic therapies on progression to end-stage renal disease (ESRD) and 
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death. Logistic regression was used to explore factors that were associated with using 
guideline-recommend ACEIs/ARBs. 
 
RESULTS: About 32,973 of the 66,315 incident hypertensive CKD patients (50%) were 
using ACEIs/ARBs within six months after the diagnosis of CKD. Approximately 5.2% of 
patients received ACEIs/ARBs monotherapy, while 4.4%, 17.5% and 22.7% of them received 
the following combination therapies: ACEIs/ARBs plus statins, ACEIs/ARBs plus other 
anti-hypertensive agents, and all of the above three therapeutic groups. Compared to 
combination therapy of statins and other anti-hypertensive agents, therapies adding 
ACEIs/ARBs showed a significantly decreased risk of ESRD and death (HR=0.69, p=0.0115; 
HR=0.88, p<0.0001). Additionally, the risk of ESRD and mortality was reduced by 0.53 and 
0.85 when substituting other anti-hypertensive agents plus statins with ACEIs/ARBs plus 
statins (HR=0.53, p=0.0112; HR=0.85, p<0.0001).   
 
CONCLUSIONS: Use of guideline-recommended ACEIs/ARBs were suboptimal in elderly 
patients with hypertension and CKD. Therapies including ACEIs/ARBs were preferred as 
initiation therapy than non-ACEIs/ARBs therapies in hypertensive CKD. Regimens including 
ACEIs/ARBs and statins were associated with reduced risk of ESRD and death. These 
findings may provide evidence for clinicians when they select pharmacological treatments for 
elderly patients with hypertension and CKD. 
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4.2 Introduction 
Chronic kidney diseases (CKD) is becoming a major worldwide public health problem
13,14
. In 
the United States, the prevalence of CKD in the general population is 15%, estimated based 
on participants from NHANES 2011-2014, a large nationally representative sample
1
. Old 
adults are particularly at high risk of CKD, as one-third of NHANES participants aged 60 and 
older have CKD
1
. Decline of renal function is associated with several serious complications, 
like anemia, mineral and bone disorders, and cardiovascular conditions, as well as increased 
risk of mortality
22,43,52,163
. Therefore, CKD and its consequent kidney failure, also known as 
ESRD, pose a significant burden on patients and their families, as well as the healthcare 
system. As reported by the United Sates Renal Data System Annual Data Report (USRDS 
ADR), the overall Medicare expenditures for CKD and ESRD have continuously increased 
over time and reached $52.8 billion and $32.8 billion in 2014, accounted for 21% and 7.2% 




Hypertension is the second leading cause of kidney failure in the United States
39
. 
Approximately 74% of CKD patients in the United States had co-existing hypertension
1
. 
Moreover, previous studies had revealed that uncontrolled blood pressure may accelerate the 
progression of CKD
164,165
. Unfortunately, individuals with CKD were at a higher risk of 
uncontrolled blood pressure compared to those without CKD
86,166,167
. High prevalent of 
uncontrolled blood pressure may attributable to the different underlying cause for 
hypertension and the suboptimal utilization of anti-hypertensive agents. The current research 
revealed that CKD patients had a greater drug burden than the general population
88
. For 
example, two previous CKD studies showed their investigated cohorts took an average of 
eight different medications and 6.7 pills daily respectively
92,121
. In particular, more than half 
of CKD patients received polypharmacy to control their blood pressure, and a certain 
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proportion of CKD patients took three or more different anti-hypertensive agents
4,91
. The 
complexity of regimen and the heavy pill burden were previously established risk factors of 
medication compliance
121,132–134
. Thus, examining medication use pattern of medication and 
comparing the effect of different strategies on CKD outcomes may provide significant 
information for clinicians to reduce the total number of medications and develop personalized 
anti-hypertensive regimens for patients with CKD and hypertension. 
 
Despite the important role of anti-hypertensive agents in CKD treatment, few studies have 
examined the medication use pattern in this population
89,91,92
. A study by Kalyani et al. 
assessed the utilization of common anti-hypertensive agents using NHANES data and found 
anti-hypertensive agents, especially ACEIs and ARBs were under used among CKD 
patients
91
. However, this study did not investigate the combination therapies, and the 
precision of the measurement for medication use pattern might be limited by the inherent 
characteristics of self-report measures. In addition, this cross-sectional study did not compare 
the treatment outcomes between patients receiving different anti-hypertensive regimens.     
 
The purpose of this study is to examine the medication use pattern of cardiovascular agents 
among elderly patients with CKD and hypertension in the United State. Moreover, we also 
investigated the relationship between different anti-hypertensive therapies and long-term 
treatment outcomes. We then explored the factors associated with using 
guideline-recommended ACEIs/ARBs. Besides ACEIs and ARBs, other four different types 
of cardiovascular agents that were most commonly used in individuals with CKD were 
studies: statins, beta-blockers, calcium channel blockers and diuretics. To achieve our study 
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goals, we restricted our study cohort to incident CKD patients and examine their medication 
use within the first six-month after diagnosis of CKD. 
 
4.3 Methods 
4.3.1 Study design and data source 
To achieve the study objectives, we conducted a retrospective cohort study among older 
hypertensive patients with newly diagnosed CKD using data on the 5% Medicare cohort from 
the USRDS databases (2006-2013). The Medicare 5% files from the USRDS databases 
mainly consist of data from the CMS Medicare 5 % SAFs. These files contain comprehensive 
information on demographic characteristics, Medicare enrollment status, diagnoses, 
procedures, and filled prescription for a random 5% sample of Medicare beneficiaries across 
the United States over time. In the USRDS databases, the Medicare claims are further linked 
to data extracted from the ESRD Medical Evidence form (CMS 2728), the ESRD Death 
Notification form (CMS 2746) as well as the Master Beneficiary Summary File to obtain 
information on ESRD and death. 
 
This study design comprised a 2-year baseline period that began from 01/01/2006 to 
12/31/2007 to assess patients’ history of morbidities and procedures. Meanwhile, a 1-year 
baseline period was applied to assess patients’ history of prescription drug use (year of 2007).  
Eligible incident CKD patients were identified in the selection period (01/01/2008 – 
12/31/2012), and were followed from the date of the first CKD diagnosis to the date of death 
or the end of our study (12/31/2013).  
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4.3.2 Study population 
Our study samples were selected based on a series of inclusion and exclusion criteria. Among 
the 1,233,037 Medicare beneficiaries who were diagnosed with hypertension in the 2-year 
baseline period, we included those who continuously enrolled in both Medicare Part A and B, 
and were not enrolled in a Medicare Advantage plan (Part C) from the beginning of 2006 to 
the date of death or the end of this study. To obtain all claims for prescription drugs, 
continuously enrolled in Medicare Part D from the beginning of 2007 to the end of this study 
was also required. In addition, we restricted our cohort to aged Medicare beneficiaries by 
excluding those who aged below 67 by the end of baseline period (12/31/2007), and those 
who died in the baseline period. Then, we selected hypertensive CKD patients by including 
those with at least one CKD inpatient claims or two outpatient claims during the study period. 
To ensure that we followed each study subject for a period of at least one year, we excluded 
patients who developed ESRD in the baseline period, and those with date of the first 
observed CKD claim after 01/01/2013/, and date of the last observed CKD claim before the 
end of the baseline period. Lastly, we extracted a subset group of hypertensive patient with 
incident CKD who had no CKD related claims in the baseline period.  
 
4.3.3 Measures 
Survival outcome measures  
ESRD free time was calculated as the time from the date of first CKD claim to the starting 
date of ESRD. The date of ESRD initiation for our study subjects was determined by the date 
of first ESRD service extracted from the CMS 2728 form. Subjects who did not progress to 
ESRD in our study period were censored at the date of death or the date of the last CKD 
related visits, the date they were last known to be alive and ESRD free. Overall survival 
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referred to the time from the date of first CKD claim to date of death from all cause. Subjects, 
who were alive until 12/31/2013, were censored on that date. 
 
Medication related measures 
The present study investigated six types of cardiovascular agents that were most commonly 
used by Part D enrollees with CKD: ACEIs, ARBs, statins, diuretics, calcium channel 
blockers and beta-blockers. Medication use of each drug class was captured by a binary 
variable, with 1 indicating at least one pharmacy claim within the specified drug class in the 
first 6 months of CKD diagnosis. To further assess different therapeutic strategies of 
cardiovascular agents in hypertensive CKD patients, ACEIs and ARBs were considered 
together as RAS blocking agents, meanwhile diuretics, calcium channel blockers and 
beta-blockers were grouped together named as other anti-hypertensive agents. Therefore, 
patients were classified into a total of eight different treatment groups: using none of studied 
prescriptions, using statins only, using RAS blocking agents only, using other 
anti-hypertensive agents only, as well as using any combination of these agents. 
 
To test the robustness of our study results, we also developed a restricted measurement of 
medication use pattern, which is intended to capture “true” overlap as distinct from 
medication switches. To be qualified for receiving polypharmacy, the overlap days of 
receiving each component of the specified combination therapy should be greater than 3 
months within the 6 months observation window. Meanwhile, the start date and the end date 
of each prescribed medication were determined by medication persistence with an allowed 
90-day medication fill gap.  
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Covariate measures 
Demographic information on age, gender and race was obtained from the Medicare 5% 
sample files. Age was measured as both a continuous variable and a categorical variable with 
four levels. Race was captured as a categorical variables as white, black, Asian, others and 
unknown. Part D coverage was determined by subjects’ enrollment status at baseline. Patients 
who had at least one calendar month in 2008 with Part D enrollment and receipt of the 
low-income subsidy (LIS) were classified as “Part D with LIS”, otherwise were classified as 
“Part D without LIS”. Among patients receiving LIS, those who were automatically qualified 
for LIS and automatically eligible for benefits were further classified as “with deemed LIS”, 
while the rest were classified as “with non-deemed LIS”. The presence of comorbidities at 
baseline was determined by a previously vailed method: having a qualifying diagnosis/ 
procedure code of ICD-9-CM and HCPCS on at least one inpatient claims or two outpatient 
claims within the 2-year baseline period. Separate indicators of diabetes, common 
cardiovascular conditions and procedures were created following the same method described 
above. An adapted Charlson comorbidity index was calculated serving as a measurement of 
the overall comorbidity burden. We calculated the Deyo CCI with exclusion of diabetes, 
renal and cardiovascular conditions
168
. 
    
4.3.4 Statistical analyses 
We first stratified the study population into two groups based on whether or not using ACEIs/ 
ARBs during the first 6 months after CKD diagnosis. Then we conducted descriptive 
analyses of demographic factors, cardiovascular conditions and procedures, as well as 
medication use related factors. The difference of patients’ baseline characteristics between 
ACEIs/ARBs users and non-ACEIs/ARBs users were examined using  
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chi-square tests and two-tailed t-tests for categorical variables and continuous variables 
separately. The Cox proportional hazard model was utilized to examine the association 
between different treatment strategies and progression to ESRD, as well as overall survival. 
The multivariate logistic model was applied to explore the predictors of receiving 
ACEIs/ARBs. Moreover, sensitivity analyses were conducted to handle the potential 
measurement errors and uncertainty due to the definition of medication use. The more 
restricted measurement of medication use pattern was developed and used in the Cox 
proportional hazard models.  
 
4.4 Results 
Our study population comprised a total of 66,315 aged Part D enrollees with hypertension 
who had been newly diagnosed with CKD. Approximately half of our study samples received 
pharmacological therapies including ACEIs/ARBs within the first 6 months after CKD 
diagnosis. Table 4-1 and 4-2 showed the descriptive statistics for individual demographic 
characteristics and cardiovascular-related characteristics by patients’ status of ACEIs/ARBs 
use. All eligible patients were followed for a period of 4.5 years, on average, while patients 
who used ACEIs/ABRs demonstrated a significantly longer follow-up period (5.0 years vs. 
3.9 years), a lower death rate (41% vs. 66%), and a higher rate of progression to ESRD (1.1% 
vs.0.9) compared to those who did not receive ACEIs/ARBs. The average age of 
ACEIs/ARBs users was 2 years younger than non-ACEIs/ARBs users, at 78.3 years old vs. 
80.3 years old. Particularly, compared with non-ACEIs/ARBs users, significantly fewer 
ACEIs/ARBs users aged 80 and over (40% vs. 52%), and significantly more ACEIs/ARBs 
users aged below 70 (13% vs. 10%). The majority of our study subjects were white and 
nearly 38% of them were male. Non-ACEIs/ARBs users demonstrated a noticeably heavier 
overall comorbidity burden, as their Charlson index was 1.3 times higher than ACEIs/ARBs 
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users (1.3 vs. 1.0). However, more ACEIs/ ARBs users than non-ACEIs/ARBs users had 
been diagnosed with diabetes at baseline. In term of prescription drug coverage, more 
patients who received ACIEs/ARBs were covered by Part D without any subsidy (35% vs. 
38%), and fewer of them covered by non-deemed LIS (33% vs. 36%), compared to 
non-ACEIs/ARBs users. With regards to cardiovascular-related characteristics, significantly 
more ACEIs/ARBs users than non-ACEIs/ARBs users had presence of atherosclerotic heart 
disease (ASHD, 45.2% vs. 44.5%), acute myocardial infarction (AMI, 9.6% vs 9.0%), and 
had received procedures of percutaneous coronary interventions (PCI, 3.3% vs. 2.5%). 
Nevertheless, a noticeable smaller percent of ACEIs/ARBs users had onset of congestive 
heart failure (CHF, 26.8% vs 28.5%), cerebrovascular accident/transient ischemic attack 
(CVA-TIA, 27.1% vs.29.6%), peripheral arterial disease (PAD, 31.7 vs.35.2%), and atrial 
fibrillation (AFIB, 18.1% vs. 21.1%). 
 
Table 4-3 described the patterns of cardiovascular agents use in hypertensive patients with 
incident CKD. Patients with receipt of ACEIs/ARBs have a higher level of drug burden, as 
the mean number of prescribed cardiovascular agents among them was more than 3 times 
greater than their counterparts without receipt of ACEIs/ARBs (2.5 vs 0.8). The percent of 
using any other anti-hypertensive agents in ACEIs/ARBs users was about 1.7 times greater 
than non-ACEIs/ARBs users, more specifically, 1.6, 1.9 and 2.4 times greater in term of 
receiving beta-blockers, calcium channel blockers and diuretics. Similarly, percent of using 
statins in ACEIs/ARBs users was nearly two-fold greater than non-ACEIs/ARBs users. 
Overall, about one quarter of our study subjects received none of studied cardiovascular 
agents during the first 6 months after being diagnosed with CKD, while approximately half of 
them received combination therapies which included at least two of the following three 
distinct therapeutic groups: RAS blocking agents, other anti-hypertensive agents, and statins. 
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Among those who received monotherapy, a majority of them received one drug of other 
anti-hypertensive agents to regulate their blood pressure.   
 
Table 4-4 and 4-5 presented the results of the Cox proportional hazard models, which 
assessed the relationship between different pharmacologic therapies and progression to 
ESRD, as well as all-cause mortality. Compared to patients receiving combination therapy of 
statins and any other anti-hypertensive agents, patients who received an additional drug of 
RAS blocking agents had a 0.31 lower risk of developing ESRD (HR=0.69, p=0.0115) and a 
0.12 lower risk of death (HR=0.88, p<0.0001). In addition, the risk of CKD progression and 
death was reduced by 0.53 and 0.85 when compared combination therapies of other 
anti-hypertensive agents plus statins to combination therapies of ACEIs/ARBs plus statins 
(HR=0.53, p=0.0112; HR=0.85, p<0.0001). When compared with monotherapy, therapies 
including any other anti-hypertensive agents plus statin performed better than monotherapies 
of other anti-hypertensive agents in both delaying disease progression and death (HR=1.63, 
p=0.0015; HR=1.31, p<0.0001), while no significant difference were observed when 
compared with monotherapy of statins (HR=0.67, p=0.1742; HR=1.05, p=0.1696). Moreover, 
compared to combination therapies with any other hypertensive agents plus statins, 
monotherapies of ACEIs/ARBs were associated with a lower risk of onset of ESRD but a 
higher risk of being died (HR=0.57, p=0.0399; HR=1.14, p<0.0001). 
 
Table 4-6 showed factors that significantly associated with use of ACEIs/ARBs during the 
first 6 months after CKD diagnosis. On one hand, patients who were older, male, having 
higher Charlson comorbidity index, receiving deemed LIS, having occurrence of CVA-TIA, 
PAD and AFIB were less likely to receive pharmacological therapies with ACEIs/ARBs 
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when they were diagnosed with CKD. On the other hand, patients who were nonwhite, 
having diabetes and ASHD, as well as receiving PCI were more likely to receive 
ACEIs/ARBs on time.  
 
Results of sensitivity analyses indicated that the risk factors of progression to ESRD 
remained stable when we extended the censored date from last CKD visits to the end of our 
study. We also re-estimated our models using the restricted measure of therapeutically 
patterns which incorporated the concept of medication persistence and added a requirement 
of having at least 90 days of overlap for each individual drug under the specified combination 
therapy. When employing the restricted measurement of treatment patterns, as we expected, 
more patients were classified as received none of investigated cardiovascular agents 
(increased from 25% to 31%), and fewer patients were classified as receiving all of the three 
drug groups (from 46% to 12%). With regards to the changes in the results of survival models 
(shown in table 4-7 and table 4-8), therapies consisted of drugs from all three therapeutic 
groups persistently showed better survival outcome of progression to ESRD and death than 
the comparison group, combination therapies of other anti-hypertensive agents and statins 
(HR=0.58, p=0.0015; HR=0.78, p<0.0001). Monotherapies of other anti-hypertension agents 
constantly performed worse than the comparison group in delaying disease progression and 
reducing mortality (HR=1.93, p<0.0001; HR=1.54, <0.0001). However, performance of 
monotherapy of statins on mortality became worse when compared with the comparison 
group (HR=1.6, p<0.0001). Meanwhile, monotherapies of RAS inhibitors and combination 
therapies of RAS inhibitors plus statins did not show a significant survival benefit on ESRD 
anymore (HR=1.2, p=0.4388; HR=0.9, p=0.5991). In term of overall survival, monotherapies 
of RAS inhibitors continuously showed an increased risk of death compared to the 
comparison group (HR=1.7, p<0.0001), and combination therapies of RAS inhibitors plus 
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The lack of knowledge about utilization patterns of cardiovascular agents and the effect of 
different anti-hypertensive therapies among hypertensive CKD patients may limit our ability 
to reduce the pill burden and improve treatment outcome in this population. Thus, this study 
assessed different anti-hypertensive therapies of the six most commonly used cardiovascular 
agents among patients with hypertension and CKD. Moreover, compared with previous 
studies, our study had strengths as a large study cohort extracted from nationally 
representative claim data and relatively long study duration. These strengths enabled the 
assessment of differences in direct outcome such as progression to ESRD and all-cause 
mortality.  
 
Overall, this study found 78% of hypertensive CKD patients were on at least one type of 
cardiovascular agents when they were newly diagnosed with CKD. Consistent with previous 
studies, heavy pill burden was observed in our hypertensive CKD cohort as well
88
. More than 
two-third of hypertensive CKD patients who received cardiovascular agents were observed 
on combination therapies: receiving at least two drugs of the following three therapeutic 
groups—RAS inhibitors (ACEIs/ARBs), statins, and other anti-hypertensive agents 
(beta-blockers, diuretics, and calcium channel blockers). However our study found a lower 
utilization rate in all of investigated drug classes compared to the utilization rate of 
cardiovascular agents reported in the USRDS report
1
. This may attributable to the relatively 
older population and a shorter medication assessment window (the first 6 months after first 
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diagnosis of CKD). Overall, only half of our study subjects were on guideline-recommended 
ACEIs/ARBs after being diagnosed with CKD. It was noteworthy that this utilization rate 
remained low in patients with onset of diabetes (56%), despite the fact that clinical evidence 
found ACEIs/ARBs have additional renoprotective benefits for CKD patients
95,96
. Our 
findings revealed that there was a potential improvement for ACEIs/ARBs use in CKD 
patients. 
 
We further assessed the association between different pharmacological therapies and CKD 
outcomes, which were not evaluated by previous studies because of short observation period 
(1-2 years) and lack of claim data
91,92
. In the present study, comparison group was set as 
combination therapy of statins and other hypertensive agents that were not substituted for 
ACEIs/ARBs. Our results found that patients who received ACEIs/ARBs as add-on therapies 
were significantly less likely to progression to ESRD and had a lower risk of death, compared 
with the comparison group. Moreover, with the fixed number of prescribed medications, 
replacing the other anti-hypertensive agents with ACEIs/ARB in the comparison group may 
reduce the risk of developing ESRD and death. However, replacing statins with ACEIs/ARBs 
in the comparison treatment did not result in better CKD outcome. When compared to 
monotherapies with the comparison treatment, we found adding statins to the monotherapy of 
other anti-hypertensive agents yielded a better CKD outcome. Overall, our results illustrated 
pharmacologic therapies including ACEIs/ARBs and statins demonstrated substantial benefits 
to elderly patients with hypertension and CKD than those without ACEIs/ARBs and statins. 
Findings of this observational study provide real-world evidence for the guidelines from 
APC: selecting anti-hypertensive regimens including statins for patients with mild to 
moderate CKD and including ACEIs/ARBs for those with hypertension. Moreover, our 
findings indicated that the priority of ACEIs/ARBs and statins may be higher than other 
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hypertensive agents. And this information is meaningful from a clinical perspective, since 
providing an anti-hypertensive regimen with minimized number of drugs have significant 
benefits in term of overall pill burden, complexity of administration, medication adherence, 
efficacy, side-effects and adverse effects
169–171
.    
 
Receiving ACEIs/ARBs when diagnosed with CKD may related to multiple factors 
including: younger ages, female sex, nonwhite race, less comorbidity burden, without Part D 
low income subsidy, presence of diabetes and ASHD, receiving PCI, as well as without onset 
of CVA-TIA, PAD and AFIB. Kalyani et al explored the predictors of receiving 
anti-hypertensive treatment in CKD patients and found patients who were older, male, white, 
aware of hypertension and diabetes were more likely to use anti-hypertensive agents. The 
inconsistent association in demographic factors may because of distinct study populations 
and types of measurements. We also found patients who were automatically enrolled in Part 
D LIS program were less likely to receive recommended ACEIs/ARBs, even though they had 
the lowest premiums and copayment, and no coverage gap in prescription drug coverage. 
These patients are mainly dual-eligible patients (Medicare and Medicaid). The significantly 
suboptimal utilization rate of ACEIs/ARBs may indicate the existence of barriers to accessing 
recommended prescriptions beyond cost in this vulnerable population.  
 
The present study was limited in several ways. First, the retrospective cohort study design 
cannot establish a causal inference between utilization patters of cardiovascular agents and 
CKD related outcomes. Second, the Medicare claim data lack laboratory values, thus we were 
not able to assess the severity of renal dysfunctions and whether blood pressure was under 
controlled at the time they first diagnosed with CKD. These two factors are associated with 
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the selection of cardiovascular agents as well as number of drugs
172,173
. Third, the precision of 
medication use measures was limited by the characteristics of pharmacy claims data. In this 
study, we assumed that Medicare Part D was the only source of medications, which may not 
be the true in all circumstances. For example, Medicare beneficiaries may use their 
commercial prescription drug coverage to get their ACEIs/ARBs filled, which would not be 
reflected in Medicare claims data. Meanwhile, how to determine combinational therapies is 
challenging, especially considering changes in treatment strategies over time (switching, 
adding on and discontinuation). In this study, we implemented two methods to capture 
utilization patterns: 1) having any billed pharmacy claims; 2) incorporating the concept of 
medication persistence and adding requirement of over-lap more than 3 month in the 6 month 
observation window. As expected, the second method identified more non-cardiovascular 
agents users and monotherapy users, while identified less combinational therapy users. It is 
worth to note that the results of our sensitivity analyses indicated that therapies adding 
ACEIs/ARBs and statins demonstrated a steady substantial benefits compared to therapies 
without ACEIs/ARBs in delaying CKD progression and improving overall survival, with 
adjustment of demographic, medical history, and health plan characteristics. Lastly, the 
generalizability of our study is limited by our study design. In this study, eligible subjects are 
hypertensive patients with newly diagnosed CKD who were covered by Medicare stand-alone 
Part D plans. Medicare beneficiaries who received prescription coverage from the Medicare 
Advantage plan were excluded in this study. Moreover, results of our study may suffer 
selection bias due to the restricted selection criteria. For instance, to capture all pharmacy 
claims, only beneficiaries who continually enrolled in stand-alone Part D plans throughout 
the study period were selected, which results in a slightly older population with higher 
percentage of female, non-white, diabetes and cardiovascular conditions.   
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4.6 Conclusion 
Patterns of cardiovascular medication use are varied among elderly hypertensive patients who 
are newly diagnosed with CKD. Use of guideline-recommended ACEIs / ARBs is suboptimal 
among this population. Whether or not a patient receives therapies including ACEIs/ARBs is 
associated with patients’ own demographic characteristics, co-existing conditions, as well as 
health plan benefits. Moreover, the present study indicates the significance of adding ACEIs 
/ARBs and statins to the anti-hypertensive regimens for hypertensive CKD patients. Findings 
of our study provide important information regarding the choice of medication. 
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Table 4-1 Descriptive statistics of individual demographic characteristics among elderly 
patients with hypertension and incident chronic kidney disease (CKD) by status of 






Baseline characteristics Mean(SD)/% Mean(SD)/% Mean(SD)/% 
Age (years) 78.3 (7.1) 80.3 (7.5) 79.4 (7.4) 
       <70 13.4 9.6 11.5 
     70-75 23.8 18.0 20.9 
     75-80 23.3 20.7 22.0 
        >80 39.5 51.7 45.7 
Charlson comorbidity Index 1.0 (1.6) 1.3 (1.7) 1.2 (1.7) 
Male 37.8 38.8 38.3 
Race    
          White 87.2 88.0 87.6 
          Black  9.4 9.0 9.2 
          Asians 1.6 1.5 1.6 
          Others 1.7 1.3 1.5 
          Unknown 0.1 0.1 0.1 





       Part D without LIS 65.0 62.2 63.6 
       Part D with 
non-deemed LIS 
2.2 2.0 2.1 
       Part D with deemed 
LIS 
32.8 35.8 34.3 
Diabetes mellitus (DM) 42.6 33.2 37.9 
Follow-up characteristics    
Follow-up period (years) 5.0 (1.5) 3.9 (2.0) 4.5 (1.8) 
Died 40.96 65.6 53.35 
end-stage renal disease 
(ESRD) 
1.1 0.9 1.0 
# ACEIs/ARBs use was defined as having at least one pharmacy claim of ACEIs/ARBs during a six-month 
period after the date of first diagnosis of CKD 
* Continuously enrolled in Medicare A&B from 2006/1/1 and continuously enrolled in Medicare Part D from 
2007 to end of 2013/date of death were required. A two-year baseline period was applied (2006-2007) to 
evaluate baseline characteristics, and a one-year baseline period (2007) was used to examine medication use 
history. 
$ Adapted Charlson comorbidity index was calculated by excluding diabetes, kidney diseases and 
cardiovascular diseases 
  84 
 
Table 4-2 Descriptive statistics of individual cardiovascular-related characteristics among 
elderly patients with hypertension and incident chronic kidney disease (CKD) by status of 








user (n=33,342) All(n=66,315) 
Cardiovascular Comorbidities 
   ASHD 45.3 44.3 44.8 
AMI 9.6 9.0 9.3 
CHF 26.7 28.7 27.7 
CVA-TIA 27.3 29.6 28.5 
PAD 31.6 35.6 33.6 
AFIB 18.1 21.5 19.8 
SCA/VA 4.7 4.6 4.6 
Other Cardiovascular diseases 41.8 41.7 41.7 
Cardiovascular Procedures 
   PCI 3.2 2.4 2.8 
CABG 0.9 0.7 0.8 
ICD/CRT-D 0.6 0.5 0.5 
#ACEIs/ARBs use was defined as having at least one pharmacy claim of ACEIs/ARBs during a 
six-month period after the date of first diagnosis of CKD 
* Continuously enrolled in Medicare A&B from 2006/1/1 and continuously enrolled in Medicare Part D 
from 2007 to end of 2013/date of death were required. A two-year baseline period was applied 
(2006-2007) to evaluate baseline characteristics, and a one-year baseline period (2007) was used to 
examine medication use history. 
$ Abbreviations: ASHD, atherosclerotic heart disease; AMI, acute myocardial infarction; CHF, 
congestive heart failure; CVA/TIA, cerebrovascular accident/transient ischemic attack; PAD, peripheral 
arterial disease; AFIB, atrial fibrillation; SCA/VA, sudden cardiac arrest and ventricular 
arrhythmias; PCI, percutaneous coronary interventions; CABG, coronary artery bypass grafting; 
ICD/CRT-D, implantable cardioverter defibrillators/cardiac resynchronization therapy with defibrillator 
devices. 
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Table 4-3 Descriptive statistics of individual medication-related characteristics among elderly patients with hypertension and incident Chronic Kidney Disease 
(CKD) by status of ACEIs/ARBs use (n=66,315)
Variable ACEIs/ARBs user 
(n=32,973) )# * 
non-ACEIs/ARBs user 
(n=33,342) All(n=66,315) 
 Mean(SD)/% Mean(SD)/% Mean(SD)/% 
N of Cardiovascular agents 2.5 (1.2) 0.8 (1.0) 1.6 (1.4) 
Other anti-hypertension agents user $ 80.8 48.1 64.3 
Calcium channel blockers user 31.13 16.26 23.65 
Beta-blockers user 53.23 33.05 43.08 
Diuretics user 40.98 17.14 28.99 
Statins user 54.34 27.93 41.06 
Therapeutic strategies    
None NA 44.63 22.44 
Statins only NA 7.31 3.67 
Other Anti-hypertension agents only NA 27.45 13.8 
ACEIs/ARBs only 10.48 NA 5.21 
Other Anti-hypertension agents+Statins NA 20.62 10.37 
ACEIs/ARBs+Statins 8.76 NA 4.36 
ACEIs/ARBs +other anti-hypertension agents 35.18 NA 17.49 
ACEIs/ARBs +other anti-hypertension 
agents+Statins 
45.58 NA 22.66 
# Medication use was defined as having at least one pharmacy claim within each pharmacologic therapy during a six-month period after the date 
of first diagnosis of CKD 
* Continuously enrolled in Medicare A&B from 2006/1/1 and continuously enrolled in Medicare Part D from 2007 to end of 2013/date of death 
were required. A two-year baseline period was applied (2006-2007) to evaluate baseline characteristics, and a one-year baseline period was used 
to examine medication use history. 
& ACEIS/ARBs window is defined as time distance between first observed date of refilling ACEIs/ARBs and first observed date of CKD 
diagnosis. 
$ Other anti-hypertension agents user defined as having any pharmacy claim of calcium channel blockers, beta-blockers or diuretics. 
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Table 4-4 The association between different pharmacologic therapies and developing end-stage renal disease 
(ESRD) among elderly patients with hypertension and incident chronic kidney disease (CKD) , using Cox 
proportional hazards (PH) model (n=66,315) 
Variables&*$ HR 95% CI 
 Therapeutic strategies #    
 None 1.57 1.07 2.31 * 
Statin only 0.67 0.38 1.19 
 Other Anti-hypertension agents only 1.63 1.21 2.20 ** 
ACEIs/ARBs only 0.57 0.34 0.98 * 
Statins+ other Anti-hypertension agents ref ref ref  
Statins +ACEIs/ARBs 0.53 0.32 0.87 * 
ACEIs/ARBs+ other Anti-hypertension agents 0.93 0.70 1.23  
Statins+ ACEIs/ARBs + other Anti-hypertension 
agents 
0.69 0.52 0.92 
* 
N of drug classes received 1.17 1.06 1.29 ** 
Age (years) 0.95 0.94 0.96 *** 
Charlson comorbidity index  0.94 0.89 0.99 * 
Male  1.33 1.14 1.57 *** 
Race (ref.White)    
           Black  1.70 1.36 2.11 *** 
          Asians 1.62 0.98 2.69 
           Others 1.33 0.79 2.22 
           Unknown 2.34 0.33 16.68 
 Prescription coverage at baseline (Part D without 
LIS) 
   
        Part D with non-deemed LIS 0.76 0.40 1.42 
        Part D with deemed LIS 1.20 1.01 1.43 * 
Diabetes mellitus (DM) 1.70 1.45 2.00 *** 
ASHD 0.88 0.73 1.06 
 AMI 1.07 0.81 1.43 
 CHF 1.30 1.07 1.58 ** 
CVA-TIA 0.87 0.72 1.04 
 PAD 1.05 0.88 1.25 
 AFIB 0.98 0.79 1.23 
 SCA/VA 0.77 0.51 1.18 
 Other Cardiovascular diseases 1.04 0.87 1.24 
 PCI 0.73 0.44 1.22 
 CABG 0.93 0.41 2.09 
 ICD/CRT-D 0.74 0.23 2.38 
 # Medication use was defined as having at least one pharmacy claim within each 
pharmacologic therapy during a six-month period after the date of first diagnosis of CKD. 
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 * Continuously enrolled in Medicare A&B from 2006/1/1 and continuously enrolled in 
Medicare Part D from 2007 to end of 2013/date of death were required. A two-year 
baseline period was applied (2006-2007) to evaluate baseline characteristics, and a 
one-year baseline period was used to examine medication use history. 
$ patients were censored at the date of death or last CKD visits  
Abbreviations: ASHD, atherosclerotic heart disease; AMI, acute myocardial infarction; 
CHF, congestive heart failure; CVA/TIA, cerebrovascular accident/transient ischemic 
attack; PAD, peripheral arterial disease; AFIB, atrial fibrillation; SCA/VA, sudden 
cardiac arrest and ventricular arrhythmias; PCI, percutaneous coronary interventions; 
CABG, coronary artery bypass grafting; ICD/CRT-D, implantable cardioverter 
defibrillators/cardiac resynchronization therapy with defibrillator devices. 
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Table 4-5 The association between different pharmacologic therapies and all-cause mortality among elderly 
patients with hypertension and incident chronic kidney disease (CKD), using Cox proportional hazards (PH) 
model (n=66,315) 
Variables* HR 95% CI 
 Therapeutic strategies #$    
 None 3.64 3.45 3.83 *** 
Statin only 1.05 0.98 1.13 
 Other Anti-hypertension agents only 1.31 1.25 1.38 *** 
ACEIs/ARBs only 1.14 1.07 1.21 *** 
Statins+ other Anti-hypertension agents     
Statins +ACEIs/ARBs 0.85 0.79 0.91 *** 
ACEIs/ARBs+ other Anti-hypertension agents 1.08 1.03 1.13 *** 
Statins+ ACEIs/ARBs + other Anti-hypertension 
agents 
0.88 0.84 0.93 
*** 
N of drug classes received 0.94 0.92 0.95 *** 
Age (years) 1.05 1.05 1.05 *** 
Charlson comorbidity index  1.05 1.04 1.06 *** 
Male  0.98 0.96 1.00 
 Race (White)    
           Black  0.92 0.89 0.96 *** 
          Asians 1.02 0.94 1.10 
           Others 0.91 0.83 1.00 * 
          Unknown 0.83 0.63 1.10 
 Prescription coverage at baseline (Part D without 
LIS) 
   
        Part D with non-deemed LIS 1.25 1.17 1.34 *** 
       Part D with deemed LIS 1.43 1.40 1.47 *** 
Diabetes mellitus (DM) 1.11 1.08 1.13 *** 
ASHD 1.06 1.04 1.09 ** 
AMI 1.09 1.05 1.13 *** 
CHF 1.29 1.26 1.32 *** 
CVA-TIA 1.06 1.03 1.08 *** 
PAD 1.08 1.05 1.10 *** 
AFIB 1.20 1.16 1.23 *** 
SCA/VA 1.05 0.99 1.10 
 Other Cardiovascular diseases 0.96 0.94 0.98 *** 
PCI 0.91 0.85 0.98 ** 
CABG 0.73 0.64 0.84 *** 
ICD/CRT-D 1.13 0.98 1.29 
 # Continuously enrolled in Medicare A&B from 2006/1/1 and continuously enrolled in Medicare 
Part D from 2007 to end of 2013/date of death were required. A two-year baseline period was 
applied (2006-2007) to evaluate baseline characteristics, and a one-year baseline period was used 
to examine medication use history 
* Medication use was defined as having at least one pharmacy claim within each pharmacologic 
therapy during a six-month period after the date of first diagnosis of CKD 
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Abbreviations: ASHD, atherosclerotic heart disease; AMI, acute myocardial infarction; CHF, 
congestive heart failure; CVA/TIA, cerebrovascular accident/transient ischemic attack; PAD, 
peripheral arterial disease; AFIB, atrial fibrillation; SCA/VA, sudden cardiac arrest and 
ventricular arrhythmias; PCI, percutaneous coronary interventions; CABG, coronary artery 
bypass grafting; ICD/CRT-D, implantable cardioverter defibrillators/cardiac resynchronization 
therapy with defibrillator devices. 
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Table 4-6 Predictors of ACEIs/ARBs use among elderly patients with hypertension and incident chronic 
kidney disease (CKD): multivariate logistic regression (n=66,315)
Variables#*$ OR 95% CI  
Age (years) 0.96 0.96 0.97 *** 
Charlson comorbidity index  0.91 0.90 0.92 *** 
Male  0.84 0.81 0.87 *** 
Race (White)     
          Black  1.08 1.02 1.14 ** 
          Asians 1.16 1.02 1.31 * 
          Others 1.23 1.08 1.40 ** 
          Unknown 0.79 0.49 1.26  
Prescription coverage at baseline (Part D without LIS)   
       Part D with non-deemed LIS 1.03 0.92 1.14  
       Part D with deemed LIS 0.84 0.81 0.87 *** 
Diabetes mellitus (DM) 1.42 1.38 1.47 *** 
ASHD 1.10 1.06 1.15 *** 
AMI 1.04 0.98 1.10  
CHF 0.99 0.95 1.03  
CVA-TIA 0.96 0.92 0.99 * 
PAD 0.91 0.88 0.94 *** 
AFIB 0.87 0.83 0.90 *** 
SCA/VA 1.04 0.96 1.13  
Other Cardiovascular diseases 1.09 1.06 1.13 *** 
PCI 1.18 1.07 1.30 ** 
CABG 1.04 0.87 1.24  
ICD/CRT-D 1.08 0.87 1.35  
#ACEIs/ARBs use was defined as having at least one pharmacy claim of ACEIs/ARBs during a six-month 
period after the date of first diagnosis of CKD 
* Continuously enrolled in Medicare A&B from 2006/1/1 and continuously enrolled in Medicare Part D 
from 2007 to end of 2013/date of death were required. A two-year baseline period was applied (2006-2007) 
to evaluate baseline characteristics, and a one-year baseline period was used to examine medication use 
history. 
$ Anti-hypertension agents user defined as having any pharmacy claim of calcium channel blockers, 
beta-blockers or diuretics. 
 Abbreviations: ASHD, atherosclerotic heart disease; AMI, acute myocardial infarction; CHF, congestive 
heart failure; CVA/TIA, cerebrovascular accident/transient ischemic attack; PAD, peripheral arterial 
disease; AFIB, atrial fibrillation; SCA/VA, sudden cardiac arrest and ventricular 
arrhythmias; PCI, percutaneous coronary interventions; CABG, coronary artery bypass grafting; 
ICD/CRT-D, implantable cardioverter defibrillators/cardiac resynchronization therapy with defibrillator 
devices. 
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Table 4-7 Sensitivity analysis: the association between different pharmacologic therapies and 
developing end-stage renal disease (ESRD) among elderly patients with hypertension and 




Table 4-8 Sensitivity analysis: the association between different pharmacologic therapies and 
all-cause mortality among elderly patients with hypertension and incident chronic kidney 
disease (CKD) , using Cox proportional hazards (PH) model (n=66,315).  
Variables&* HR 95% CI 
 Therapeutic strategies     
 None 2.75 1.87 4.05 *** 
Statin only 1.05 0.67 1.64 
 Other Anti-hypertension agents only 1.93 1.42 2.61 *** 
ACEIs/ARBs only 1.17 0.78 1.75  
Statins+ other Anti-hypertension agents Ref Ref Ref  
Statins +ACEIs/ARBs 0.88 0.56 1.40  
ACEIs/ARBs+ other Anti-hypertension 
agents 
1.01 0.74 1.37 
 
Statins+ ACEIs/ARBs + other 
Anti-hypertension agents 
0.58 0.42 0.82 ** 
* Demographics and clinical factors were adjusted.  
Variables* HR 95% CI 
 Therapeutic strategies     
 None 4.92 4.63 5.23 *** 
Statin only 1.59 1.49 1.70 *** 
Other Anti-hypertension agents only 1.54 1.46 1.63 *** 
ACEIs/ARBs only 1.67 1.57 1.77 *** 
Statins+ other Anti-hypertension agents Ref Ref Ref  
Statins +ACEIs/ARBs 0.93 0.86 1.01  
ACEIs/ARBs+ other Anti-hypertension 
agents 
1.04 0.98 1.10 
 
Statins+ ACEIs/ARBs + other 
Anti-hypertension agents 
0.78 0.74 0.83 
*** 
* Demographics and clinical factors were adjusted.   






Chapter 5  
DISSERTATION MANUSCRIPT TWO: Effects of adherence to 
angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers 
inhibitors (ARBs) on the progression of chronic kidney disease (CKD) in Medicare Part 
D enrollee 
 
5.1 Abstract  
OBJECTIVES Limited research has systematically assessed the long-term effects of 
adherence to ACEIs and ARBs in delaying the progression of CKD and death using large 
patient cohorts. This study examined how patients’ ACEIs and ARBs utilization potentially 
related with renal failure and mortality among hypertensive Medicare Part D-enrolled CKD 
patients in the United States.  
METHODS This retrospective cohort study was conducted using Medicare 5% sample claim 
data from USRDS (2006-2013). Elderly Medicare beneficiaries who were diagnosed with 
hypertension and CKD, having a history of using ACEIs/ARBs, and continuously enrolled in 
Medicare Part D were included. Baseline characteristics were examined using a two year 
baseline period. Adherence to ACEIs, ARBs and other blood pressure/ lipid lowering agents 
was measured as time-dependent covariates using Proportion of Days Covered (PDC). The 
time-dependent Cox proportional hazard regression was performed to estimate the 
relationship between medication adherence and progression to end-stage renal disease 
(ESRD) and death.  
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RESULTS A total of 65,574 hypertensive CKD patients were included. Approximately 2.7% 
of them developed ESRD and 54.9% of them died during the follow-up period. Consistently 
being adherent to ACEIs and ARBs was associated with a significant decreased hazard of 
developing ESRD (Hazard Ratio: 0.11 95%CI [0.11–0.12] p<0.0001; 0.11 95% CI [0.10, 
0.12]; p<0.0001) after adjusting for demographic and clinical confounders. Patients with 
good adherence to ACEIs and ARBs throughout study period had a reduced risk of death 
(Hazard Ratio: 0.10 95%CI [0.10–0.11] p<0.0001; 0.10 95% CI [0.09, 0.10]; p<0.0001). 
Increased adherence to calcium channel blockers, beta-blockers, diuretics, and statins was 
associated with lower ESRD and mortality risk.  
CONCLUSIONS Increased adherence to ACEIs and ARBs, as well as other cardiovascular 
agents, for elderly patients with hypertension and CKD is associated with delay in CKD 
progression and lower mortality risk. These findings could have important implications for 
hypertension management in this population. 
 
  
  94 
 
5.2 Introduction 
CKD is becoming a serious public health issue worldwide because of the growing prevalence 
of CKD and the rising burden from CKD and its serious complications
13,174
. In United State, 
the prevalence of recognized CKD in Medicare beneficiaries increased to 15% in 2014. The 
total Medicare expenditures on CKD reached $52.8 billion in 2014—about 21% of total 
Medicare expenditures 
1
. Additionally, healthcare expenditures on CKD are increased with 
disease progression. CKD patients who progressed to renal failure, also called ESRD, need to 
receive costly kidney replacement therapy, either regular dialysis or kidney transplantation, to 
stay alive. As reported by the USRDS ADR, the average per person per year Medicare 
spending for ESRD patients was 3.3 times greater than CKD patients, at $75,214, compared 
to $22,745 in 2014. Patients with advanced CKD were more likely to experience adverse 
cardiovascular outcomes
22
. In fact, a majority of CKD patients died prior the occurrence of 
ESRD
56,175
. Thus, delaying the progression of CKD and reducing CKD related mortality have 
significant meaning for reducing financial burden on the healthcare system, as well as 
improving individual utility and social welfare.  
 
Oral medications, particularly anti-hypertension agents, play a significant role in CKD 
treatment. Findings from nationally representative data illustrated that nearly 74% of elderly 
CKD patients in the United States had hypertension
1
. In addition, uncontrolled blood pressure 
is the second leading cause of kidney failure (diabetes is the lead cause) in the United 
States
39
. Previous studies found patients with uncontrolled blood pressure had a more rapid 
rate of CKD progression
176,177
. Although anti-hypertension agents and statins were widely 
used in CKD patients, as these medications occupied 3 of 5 most commonly used oral 
medications in elderly CKD patients, the prevalence of uncontrolled blood pressure remained 









ACEIs and ARBs are recommended to CKD patients by clinical practice guidelines, 
particular for patients whose underlying cause of CKD was diabetes, as well as hypertensive 
patients with mild kidney dysfunctions
42,94
. Findings derived from clinical research provided 
evidence that ACEIs and ARBs had renoprotective effects for CKD patients in addition to 
lowering blood pressure
6,95,96,178
. However, there was lack of real world evidence from 
observational studies to support the long-term use of these two drug classes. Previous 
observational studies had assessed the effects of adherence with prescribed anti-hypertension 
treatment in CKD patients, but they were limited by small sample size and self-reported 
measurements of medication taking behaviors
120
. Most importantly, these studies did not 
have a sufficiently long observation periods to examine the long-term survival benefit of 
being adherent to anti-hypertension treatment, such as delaying progression to ESRD and 
lowering risk of mortality. In this study, we proposed to assess the association between 
ACEIs/ARBs adherence and CKD outcomes in hypertensive CKD patients using a 
retrospective cohort design with long-term follow-up. Additionally, current research literature 
found CKD patients generally had a heavy pill burn and a majority of them received multiple 
anti-hypertension agents to regulate their blood pressure
4,88,91,92
. We therefore developed 
time-dependent measurements of medication adherence for not only ACEIs and ARBs, but 
also the other four drug classes that had been widely used in CKD patients: statins, diuretics, 
beta-blockers, and calcium channel blockers. The time-varying measurement of medication 
adherence helped us to precisely capture the discontinuation and change (switching or adding 
on) that might occur in CKD treatments.  




5.3.1 Study design and data source 
This observational study developed a retrospective cohort of elderly hypertensive CKD 
patients in the United States, using data on the 5% Medicare cohort from the USRDS 
database (2006-2013). The 5% sample of Medicare claims are linked to the USRDS ESRD 
database, which contain information on initiation of ESRD extracted from the Medical 
Evidence form (CMS2728) and information on all-cause death obtained from the ESRD 
Death Notification form (CMS 2746) and the Master Beneficiary Summary File.  
 
This study design comprised three main periods. A selection period starting from January 1, 
2006 to December 31, 2012 was assigned to select hypertensive patients who had a diagnosis 
of CKD. All study subjects were then followed from the index date, January 1, 2008, until the 
date of death or the end of the study, December 31, 2013. A 2-year and 1-year baseline period 
prior to the index date were employed to assess comorbidity history and medication use 
history separately.   
 
5.3.2 Study population 
Patients were included if they had a diagnosis of CKD during the selection period and had be 
diagnosed with hypertension prior to the index date. We employed a previously validated 
method: having at least one inpatient claim or two outpatient claims to identify patients with 
hypertensive CKD. In order to capture all Medicare claims for our study subjects, we further 
restricted the study cohort to elderly subjects who continuously enrolled in Medicare Part 
A&B and covered by stand-alone Part D plans. To ensure our study subjects had a 
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sufficiently long follow-up period, exclusion in the cohort required the date of first observed 
CKD related claim was later than January 1, 2013, developing ESRD before the index date 
and having non CKD related claim in the follow-up period. Lastly, we excluded patients 
without any pharmacy claim of ACEIs/ARBs at baseline. Having a history of using 
ACEIs/ARBs might indicate that ACEIs/ARBs were applicable to these patients. 
 
5.3.3 Measures 
Survival outcome measures 
ESRD free time was set as the time from the index date to the date of first ESRD service 
reported by the CMS 2728 form. Patients without presence of ESRD by the end of our study 
were censored at the date of death or the date of the last CKD related visit. Overall survival 
time referred to the time between the index date and the date of death from all-cause.   
 
Medication adherence 
We developed time-varying repeated measures to assess patients’ adherence to their 
prescribed ACEIs and ARBs. PDC was established as a proffered method to evaluate 
medication adherence
179
. Thus, a three-month PDC was calculated quarterly for each drug 
class from the index date until the date of death or the end of the study. For each specified 
drug class, we first aggregated total days of supply over a three-month window, and then 
subtracted the overlap days and divided by 90 days. We used PDC threshold of 80% to 
distinguished patients who had good adherence and those who had poor adherence. A 
time-dependent dummy variable of medication adherence was further developed, where 1 
indicated PDC above 80%. A one-year fixed PDC in the baseline period and an overall PDC 
in the follow-up period were assessed by the same algorithmic structure.  




The following covariates were adjusted when we examined the association between 
medication adherence and CKD related outcomes including demographic variables (age, 
gender, race), Part D coverage, and comorbid conditions. Age was calculated at the index 
date. In term of Part D coverage, patients were first stratified into with and without LIS 
groups based on whether or not had at least one month of low income subsidy at baseline. We 
then separated patients with deemed LIS from patients with non-deemed LIS. Different with 
those without LIS, Part D enrollees with LIS were not limited by the gap in prescription drug 
coverage, also known as “donut hole”. And deemed LIS beneficiaries typically have the 
lowest premiums and copayments compared to the other two groups
151
. Comorbid conditions 
at baseline were evaluated using the same algorithmic structure as described in study design. 
Separate indictors were generated for conditions that closely related with CKD, like diabetes, 
cardiovascular conditions and procedures. Meanwhile, adapted Charlson comorbidity index 
was calculated to measure the overall comorbidity burden. Moreover, medication use of other 
commonly used cardiovascular agents like beta-blockers, calcium channel blockers, diuretics 
and statins were evaluated using PDC. 
    
5.3.4 Statistical analyses 
Descriptive analyses of demographics, medical history, and medication use related 
characteristics were conducted using means for continuous variables and percentages of 
categorical variables. The Multivariate Cox proportional hazards regression analyses with 
medication adherence as time-varying covariates were performed to assess the association 
between adherence to ACEIs/ARBs and progression to ESRD and all-cause mortality.  




We studied a total of 65,574 elderly Medicare beneficiaries with hypertensive and CKD who 
had taken at least one medication of ACEIs/ARBs in the baseline period. The study subjects 
were followed on average of 4.3 years (table 5-1). Nearly half (54.9%) of them died by the 
end of this study, while only 2.7% of them had presence of ESRD. More than half of patients 
were aged above 75 with a mean age of 79.2 years; 39.3% were male; and 86.4% were white, 
10.1% were black and 1.8% were Asian-American. In addition, about half of patient had been 
diagnosed with diabetes (47.5%) and the mean Charlson comorbidity score was 1.4 for this 
population. Table 5-2 described patients’ cardiovascular related conditions and procedures at 
baseline and follow-up period. Approximately half of patients had diagnosis of ASHD at 
baseline (52.8%), and about one-third of them had onset of CHF, CVA-TIA and PAD 
(37.8%, 32.9%, and 40.8% respectively). The percentage of patients received PCI was three 
times greater than those received coronary artery bypass grafting (CABG), an alternative 
intervention of PCI (4.1% versus 1.4%). An increased prevalent was observed in all 
cardiovascular conditions and procedures from baseline to follow-up.  
 
Table 5-3 presented utilization of investigated drug classes in our study cohort. With regard 
to utilization rate of each drug class at baseline, about two-third of our study subjects had 
used at least one medication of ACEIs and this prevalence was 40% for ARBs. The other four 
drug classes were widely used in this population as well, as about half of our population had 
ever used statins, beta-blockers, and diuretics, and one-third of them had ever used calcium 
channel blockers at baseline. Additionally, the utilization rate of the investigated drug classes 
were all increased from baseline to follow-up, varied from 8% for ARBs to 60% for calcium 
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channel blockers. In term of medication adherence at baseline, measured as the proportion of 
days covered by the specified drug class in the year of 2007, 63.1% and 61.8% of our study 
subjects were adherent to their prescribed ACEIs and ARBs respectively (PDC above 80%). 
Meanwhile, more patients were qualified for being adherent to statins and diuretics (59.6% 
and 61.3%) than those qualified for being adherent to beta-blockers and calcium channel 
blockers (50.4% and 56.6%). When we assessed the medication adherence in long run, 
adherence rate decreased sharply in all of the six studied drug classes.  
 
Table 5-4 reported the association between medication adherence and progression with 
adjustment of demographic and clinical history covariates. Hypertensive CKD patients with 
consistently good adherence of ACEIs had an 89% lower risk of developing ESRD 
(HR=0.11, p<0.0001) compared to those with consistently poor adherence. Consistently 
adherent to ARBs was also associated with a significantly decreased risk of ESRD (HR=0.11, 
p<0.0001). Risk factors of ESRD included older age, white race, greater comorbidity burden, 
receiving any type of Part D low-income-subsidy, onset of diabetes and cardiovascular 
conditions. It was worth to note that patients who received PCI and CABG had a lower risk 
of ESRD (HR=0.90, p=0.0001 and HR=0.75, p<0.0001, respectively), while patients who 
received cardiac resynchronisation therapy like implantable cardioverter defibrillators 
(ICD)/cardiac resynchronization therapy with defibrillator devices (CRT-D) were more likely 
to develop ESRD (HR=1.16, p=0.0024). As expected, being adherence to other 
cardiovascular agents besides ACEIs/ARBs was associated with a substantial decreased risk 
of ESRD as well.  
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Results of time-dependent Cox proportional hazard regression of all-cause mortality were 
showed in table 5-5. Being adherent to ACEIs and ARBs throughout the follow-up period 
were associated a 90% decreased in risk of death (both HR=0.10, p<0.0001). The same risk 
factors and protective factors of death were identified as in the model of ESRD. Patients who 
were older, white, receiving subsidy for their Part D coverage, having onset of diabetes and 
cardiovascular conditions were more likely to die in the study period. Additionally, receiving 
cardiovascular intervention PCI and CABG were significantly related with a lower risk of 
mortality (HR=0.91, p=0.0003, and HR=0.75, p<0.0001), but not ICD/CRT-D (HR=1.16, 
p=0.0025). Meanwhile, continuously being good adherent to statins and other 
anti-hypertension agents were associated with significantly lowering risk of death. 
 
5.5 Discussion 
To the best of our knowledge, this study is the first observational study to assess the 
long-time benefits of adherence with ACEIs and ARBs in elderly patients with hypertension 
and CKD. A strength of this study is that hypertensive CKD patients were extracted from a 
nationally representative database, and they were followed up to 6 years to observe CKD 
outcomes. Moreover, by employing the time-varying measures of medication adherence, we 
were able to take both changes (either switching or adding on) and discontinuation of 
regimens into account when examined the relationship between medication use and treatment 
outcome.  
 
As observed in previous cohort studies, CKD patients were more likely to die before 
progression to ESRD
22,180
. The mortality rate was higher in our study population, which may 
because we had an older cohort with an average age of 79.2 years and high prevalence of 
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cardiovascular conditions. As expected, utilization rate of investigated cardiovascular agents 
were increased from baseline to follow-up, and calcium channel blocker demonstrated the 
highest increasing rate (60%), followed by beta-blockers (48%), diuretics (28%) and statins 
(26%). These changes may due to the long observation time in follow-up period and the 
changes in pharmacological therapies. Anti-hypertension treatment regimen is individualized 
based on demographics, onset of comorbid conditions, therapeutic goal, efficacy, tolerability 
and cost
181
. For example, physicians may need to add a new drug when patients cannot 
achieve the target blood pressure with the current anti-hypertension treatment regimen. In 
another case, patients may initiate ACEIs/ARBs after being diagnosed with diabetes.  
 
In term of medication adherence, our study demonstrated a slightly lower adherence rate 
(50%-60%) compared to previous research (65%-70%) because of the different 
measurements and study population characteristics
122
. In addition, we found adherence rate 
decreased to 27%-46% in the follow-up period. A study by Chang et al followed a cohort of 
patients who were discharged from hospital for myocardial infarction. Researchers found 
patients’ adherence to prescribed ACEIs/ARBs, beta-blockers and statins were all decreased 
over the three-year study period. And patients with worse kidney function at baseline had a 
lower long-term medication adherence
123
. Another study of 140 CKD patients by Magaho et 
al found patients’ adherence to medication varied over time
121
. Medication adherence was 
assessed in person at baseline and by phone interview at 12-month follow-up. Patients were 
considered as adherence if they were able to correctly report all medications that they were 
prescribed and take their medications on time without skipping doses. Researchers found the 
adherence rate increased from 17.4% at baseline to 26.8% at follow-up. Moreover, about 
50% of adherent patients became non-adherent and 22% of non-adherent patients turned to be 
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adherent at follow-up. Overall, the changes in regimens and medication adherence emphasize 
the significance of developing time-varying measurements for medication adherence.  
 
Results of our survival analyses showed that hypertensive CKD patients with consistently 
good adherence to ACEIs and ARBs had a substantial decreased risk of developing ESRD 
and mortality, after adjusting for demographic, clinical and medication use confounders. In 
order words, regardless patients’ utilization of other cardiovascular agents, consistently being 
adherent to ACEIs/ARBs had independent protective effects on delaying renal dysfunctions 
and extending the overall survival. Our findings were consistent with evidence derived from 
randomized controlled trials
94
. A study by Yasuda evaluated the effects of adding ARBs to 
conventional therapy (without ARBs) on CKD progression and found patients who received 
therapy including ARBs had a 42.5% decreased risk of renal event
178
. We also found onset of 
cardiovascular conditions at baseline was associated with increased risk of ESRD and 
mortality. This may because cardiac dysfunction may worsen kidney function through several 
mechanisms, such as haemodynamic abnormalities, neurohormonal activation, and 
inflammatory activation
53
.      
 
There are some limitations in this study. First, external validity was threatened by our study 
design, that is, aged Medicare beneficiaries with CKD and hypertension who were covered 
by stand-alone Part D plans and having a history of ACEIs/ARBs use were selected in this 
study. Meanwhile, restrict inclusion criteria in this study may result in selection bias. By 
requiring of continuously enrolled in Medicare Part D throughout the study period, we 
obtained a study cohort that was slightly older, having more women, non-white, and having a 
heavier burden of illness. Second, the precision of medication use measures was limited by 
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the characteristics of pharmacy claims data. Patients with multiple prescription drug coverage 
may get ACEIs/ARBs through the program other than Part D. That resulted in underestimates 
of time-varying PDC in this study. Meanwhile, by using pharmacy claims data, we assume 
the dispensed drug was actually taken by the patient, which results in overestimates of our 
medication use. Overall, imprecise measures of medication adherence may bias our results to 
any direction. Third, patients with better medication adherence may indicate they visit 
primary physicians/ nephrologists more frequently, which could in turn allow physicians have 
more chances to detect their renal events earlier compared with those who visit physicians 
fewer times per year. In this case, the effect of ACEIs and ARBs were overestimated. This 
study may also suffer from omitted variable bias. Confounder variables like hospitalization 
and control of blood pressure were not adjusted in this study. For further analyses, we would 
improve our model by adding time-varying measurement of hospitalization. Meanwhile, we 
would assess the long-term benefits of using ACEIs/ARBs on cardiovascular events. Further 
researchers were also recommended to assess the long-term effects of ACEIs/ARBs on CKD 
progression if laboratory measures were available, such as halving of estimated GFR or 
doubling of serum creatinine.  
 
5.6 Conclusion 
In summary, medication adherence to ACEIs and ARBs was suboptimal in elderly patients 
with hypertension and CKD. Moreover, the adherence rates were decreased over time.  Our 
study found increasing adherence to ACEIs or ARBs, as well as other cardiovascular agents, 
for patients diagnosed with both CKD and hypertension could substantially delaying their 
occurrence of ESRD and mortality. The findings of our study provided important information 
on physicians’ prescribing strategies aimed at preventing CKD progression and improving 
treatment outcomes among aged hypertensive patients with CKD.  
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Table 5-1 Descriptive statistics of individual demographic characteristics among elderly 
patients with hypertension and chronic kidney disease (CKD) (n=65,574) 
 
  
Baseline characteristics* Mean (SD)/% 
Age (years) 79.2 (7.3) 
Age (years)  
       <70 11.9 
     70-75 21.2 
     75-80 22.5 
        >80 44.5 
Male 39.3 
Race  
          White 86.4 
          Black  10.1 
          Asians 1.8 
          Others 1.6 
          Unknown 0.1 
Prescription coverage at baseline  
       Part D without LIS 61.3 
       Part D with non-deemed LIS 2.2 
       Part D with deemed LIS 36.5 
Diabetes mellitus (DM) 47.5 
Charlson comorbidity index$ 1.4 (1.8) 
Follow-up characteristics  
Follow-up period (years) 4.3 (2.0) 
Died 54.9 
End-stage renal disease (ESRD) 2.7 
* Continuously enrolled in Medicare A&B from 2006/1/1 and continuously enrolled 
in Medicare Part D across the follow-up period (2008-2013)/date of death were 
required. A two-year baseline period was applied (2006-2007) to evaluate medical 
history, and a one-year baseline period (2007) was used to examine medication use 
history. CKD patients with date of last CKD claim before 01/01/2008 and CKD 
patients with date of first CKD claim after 01/01/2013 are excluded. CKD patients 
with ESRD diagnosis before 01/01/2008 were excluded. Patients without any use of 
ACEIs/ARBs in baseline period were excluded. 
$ Adapted Charlson comorbidity index was calculated by excluding diabetes, kidney 
diseases and cardiovascular diseases 
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Table 5-2 Descriptive statistics of individual cardiovascular-related characteristics among 








  ASHD 52.8 72.3 
AMI 13.7 31.1 
CHF 37.8 64.6 
CVA-TIA 32.9 56.5 
PAD 40.8 73.1 
AFIB 23.7 45.6 
SCA/VA 6.5 19.7 
Other Cardiovascular diseases 49.1 74.9 
Cardiovascular Procedures  
 PCI 4.1 9.5 
CABG 1.4 3.7 
ICD/CRT-D 1.1 2.5 
* Continuously enrolled in Medicare A&B from 2006/1/1 and continuously enrolled 
in Medicare Part D across the follow-up period (2008-2013)/date of death were 
required.  A two-year baseline period was applied (2006-2007) to evaluate medical 
history, and a one-year baseline period (2007) was used to examine medication use 
history. CKD patients with date of last CKD claim before 01/01/2008 and CKD 
patients with date of first CKD claim after 01/01/2013 were excluded. CKD patients 
with ESRD diagnosis before 01/01/2008 were excluded.   
$ Abbreviations: ASHD, atherosclerotic heart disease; AMI, acute myocardial 
infarction; CHF, congestive heart failure; CVA/TIA, cerebrovascular 
accident/transient ischemic attack; PAD, peripheral arterial disease; AFIB, atrial 
fibrillation; SCA/VA, sudden cardiac arrest and ventricular 
arrhythmias; PCI, percutaneous coronary interventions; CABG, coronary artery 
bypass grafting; ICD/CRT-D, implantable cardioverter defibrillators/cardiac 
resynchronization therapy with defibrillator devices. 
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Table 5-3 Descriptive statistics of individual medication-related characteristics among elderly 
patients with hypertension and chronic kidney disease (CKD) (n=65,574) 






  ACEIs  67.0 68.1 
ARBs 40.5 43.9 
Statins  53.1 66.9 
Calcium channel blockers  30.9 49.4 
Beta-blockers 46.3 68.7 
Diuretics 45.4 57.9 
Medication Adherence (PDC above 80%) $ 
  ACEIs  63.1 36.8 
ARBs 61.8 36.7 
Statins  59.6 42.1 
Calcium channel blockers  61.3 36.9 
Beta-blockers 50.4 45.8 
Diuretics 56.6 26.8 
* Continuously enrolled in Medicare A&B from 2006/1/1 and continuously enrolled in 
Medicare Part D across the follow-up period (2008-2013)/date of death were required. A 
two-year baseline period was applied (2006-2007) to evaluate medical history, and a one-year 
baseline period (2007) was used to examine medication use history. CKD patients with date 
of last CKD claim before 01/01/2008 and CKD patients with date of first CKD claim after 
01/01/2013 were excluded. CKD patients with ESRD diagnosis before 01/01/2008 were 
excluded.   
# Medication use was defined as having any pharmacy claim within each drug class  
$ PDC was calculated as proportion of days covered by the specific drug class. PDC above 
80% was classified as having good adherence 
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Table 5-4 The association between medication adherence and developing end-stage renal 
disease (ESRD) among elderly patients with hypertension and chronic kidney disease (CKD) 







 Age (years) 1.04 1.04 1.04 *** 
Charlson comorbidity index$ 1.04 1.04 1.05 *** 
Gender 
   
      Female  ref ref ref 
      Male 0.95 0.93 0.97 *** 
Race  
   
      White ref ref ref 
      Black  0.92 0.89 0.95 *** 
     Asians 1 0.92 1.07 
      Others 0.85 0.78 0.92 *** 
     Unknown 1 0.78 1.28 
 Part D coverage 
   
   without LIS ref ref ref 
   with non-deemed LIS 1.32 1.24 1.42 *** 
  with deemed LIS 1.45 1.42 1.48 *** 
Diabetes mellitus (DM) 1.24 1.21 1.26 *** 
Baseline Cardiovascular diseases/procedures$ 
   
 ASHD 1.12 1.10 1.15 *** 
AMI 1.14 1.10 1.17 *** 
CHF 1.40 1.36 1.43 *** 
CVA-TIA 1.02 0.99 1.04 
 PAD 1.13 1.10 1.15 *** 
AFIB 1.18 1.15 1.21 *** 
SCA/VA 1.09 1.04 1.13 *** 
Other Cardiovascular diseases 0.99 0.97 1.01 
 PCI 0.93 0.88 0.98 *** 
CABG 0.76 0.69 0.83 *** 
ICD/CRT-D 1.19 1.08 1.31 ** 
Time-dependent Medication Adherence 
(PDC above 80%)#    
 ACEIs  0.17 0.17 0.18 *** 
ARBs  0.16 0.16 0.17 *** 
Statins  0.27 0.26 0.28 *** 
Calcium channel blockers  0.39 0.38 0.40 *** 
Beta-blockers 0.36 0.35 0.37 *** 
Diuretics  0.41 0.40 0.43 *** 
  109 
 
* Continuously enrolled in Medicare A&B from 2006/1/1 and continuously 
enrolled in Medicare Part D across the follow-up period (2008-2013)/date of 
death were required. A two-year baseline period was applied (2006-2007) to 
evaluate medical history, and a one-year baseline period (2007) was used to 
examine medication use history. CKD patients with date of last CKD claim 
before 01/01/2008 and CKD patients with date of first CKD claim after 
01/01/2013 were excluded. CKD patients with ESRD diagnosis before 
01/01/2008 were excluded.   
 $ Abbreviations: ASHD, atherosclerotic heart disease; AMI, acute myocardial 
infarction; CHF, congestive heart failure; CVA/TIA, cerebrovascular 
accident/transient ischemic attack; PAD, peripheral arterial disease; AFIB, 
atrial fibrillation; SCA/VA, sudden cardiac arrest and ventricular arrhythmias; 
PCI, percutaneous coronary interventions; CABG, coronary artery bypass 
grafting; ICD/CRT-D, implantable cardioverter defibrillators/cardiac 
resynchronization therapy with defibrillator devices 
 
# Medication adherence for each drug class was measured quarterly, and a 
dummy variable was developed, where 1 indicated PDC above 80% 
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Table 5-5 The association between medication adherence and all-cause mortality among 
elderly patients with hypertension and chronic kidney disease (CKD), using time-dependent 







 Age (years) 1.05 1.04 1.05 *** 
Baseline Charlson comorbidity index 1.04 1.04 1.05 *** 
Gender 
   
           Female ref ref ref 
           Male 0.94 0.92 0.96 *** 
Race  
    
          White ref ref ref 
 
          Black  0.88 0.85 0.91 *** 
          Asians 0.97 0.90 1.05 
 
          Others 0.81 0.75 0.89 *** 
          Unknown 0.96 0.75 1.24 
 
Part D coverage 
    
       without LIS ref ref ref 
 
       with non-deemed LIS 1.33 1.25 1.43 *** 
       with deemed LIS 1.46 1.43 1.50 *** 
Diabetes mellitus (DM) 1.22 1.19 1.24 *** 
Baseline Cardiovascular diseases/procedures$ 
    
ASHD 1.13 1.10 1.16 *** 
AMI 1.14 1.10 1.17 *** 
CHF 1.38 1.34 1.41 *** 
CVA-TIA 1.02 1.00 1.05 
 
PAD 1.12 1.10 1.15 *** 
AFIB 1.19 1.16 1.22 *** 
SCA/VA 1.10 1.05 1.14 *** 
Other Cardiovascular diseases 0.99 0.96 1.01 
 
PCI 0.94 0.89 0.99 * 
CABG 0.75 0.68 0.83 *** 
ICD/CRT-D 1.18 1.07 1.30 *** 
Time-dependent Medication Adherence (PDC 
above 80%)#     
ACEIs  0.17 0.17 0.18 *** 
ARBs  0.15 0.15 0.16 *** 
Statins  0.25 0.24 0.25 *** 
Calcium channel blockers  0.33 0.32 0.35 *** 
Beta-blockers 0.33 0.32 0.34 *** 
Diuretics  0.39 0.38 0.41 *** 










* Continuously enrolled in Medicare A&B from 2006/1/1 and continuously 
enrolled in Medicare Part D across the follow-up period (2008-2013)/date of 
death were required.  A two-year baseline period was applied (2006-2007) 
to evaluate medical history, and a one-year baseline period (2007) was used 
to examine medication use history. CKD patients with date of last CKD 
claim before 01/01/2008 and CKD patients with date of first CKD claim after 
01/01/2013 are excluded. CKD patients with ESRD diagnosis before 
01/01/2008 are excluded.   
 $ Abbreviations: ASHD, atherosclerotic heart disease; AMI, acute 
myocardial infarction; CHF, congestive heart failure; CVA/TIA, 
cerebrovascular accident/transient ischemic attack; PAD, peripheral arterial 
disease; AFIB, atrial fibrillation; SCA/VA, sudden cardiac arrest and 
ventricular arrhythmias; PCI, percutaneous coronary interventions; CABG, 
coronary artery bypass grafting; ICD/CRT-D, implantable cardioverter 
defibrillators/cardiac resynchronization therapy with defibrillator devices. 
 # Medication adherence for each drug class was measured quarterly, and a 
dummy variable was developed, where 1 indicated PDC above 80% 
 










Chapter 6  
DISSERTATION MANUSCRIPT THREE: Environmental and individual predictors of 
medication adherence among elderly patients with hypertension and chronic kidney 
disease (CKD): a geospatial approach 
 
6.1 Abstract 
OBJECTIVES: Previous research in the elderly has shown medication cost, regimen 
complexity, health literacy, and cognitive function to be associated with medication adherence. 
Few studies have assessed geographical variation in medication adherence across different 
regions. This study aimed to explore local variation in medication adherence and examine 
environmental and individual influences on adherence to angiotensin-converting enzyme 
inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) among elderly hypertensive 
CKD patients in the United States. 
METHODS: This retrospective cohort study utilized a linked dataset from Medicare 5% 
sample claim data (2006-2013), American Community Survey 5-Year Data (2005-2009) 
and the Health Resources and Services Administration (HRSA) Primary Care Service Area 
(PCSA) data (2007). We included hypertensive CKD patients who were aged 67 and above, 
continuously enrolled in Medicare Part D and had at least one ACEIs/ARBs pharmacy claim. 
Patients’ one-year adherence to ACEIs/ARBs was measured using Proportion of Days Covered 
(PDC), and then aggregated as a mean PDC at county level. Contextual factors including rate 
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of general physician (per 10,000), proportion of population residing in MUAs and deprivation 
score were derived for each county. The geographically weighted regression (GWR) and the 
linear mixed-effects models were applied to investigate the relationship between 
environmental, individual risk factors and medication adherence. 
RESULTS: A total of 70,201 eligible patients with hypertension and chronic kidney disease 
residing in 2,981 counties of the United States using ACEIs/ARBs were included in the final 
sample. The mean ACEIs/ARBs PDC by county was 0.76±0.12 SDs. Significant spatial 
autocorrelation was observed in average ACEIs/ARBs PDC, as the West North Central and 
New England region had higher average adherence rate compared with the East South Central 
and West South Central regions. The GWR model demonstrated significant improvement 
relative to the global regression model. Proportion of population residing in MUAs and 
deprivation score were related with lower average PDC. Results of the linear mixed-effect 
model highlighted several individual statistically significant (p<0.05) risk factors for 
non-adherence including higher comorbidity severity score, and having multiple 
cardiovascular diseases. Patients, who were female, white, enrolled in Part D Low-income 
Subsidy program, having diabetes and atrial fibrillation were associated with better adherence. 
CONCLUSIONS: Medication adherence is geographically differentiated across the United 
States. Both contextual and individual factors such as proportion of population residing in 
MUAs, county deprivation score, and coverage of Part D Low-income Subsidy program are 
factors that are related with medication adherence. Such factors may be helpful in the design of 
local interventions focused on improving patient outcomes, from a population perspective.    
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6.2 Introduction 
ACEIs and ARBs are recommended by the practice guideline as preferred anti-hypertension 
agents for CKD patients because of their additional renoprotective benefits
42,94
. Compliance 
to anti-hypertensive treatment is crucial for patients with hypertensive CKD, as poor 
medication adherence may result in uncontrolled blood pressure, and further accelerate the 
rate of CKD progression and increase risk of hospitalization, cardiovascular conditions and 
death
4,88,120,163
. A previous research using nationally representatively data showed 
approximately only one-third of CKD patients in the United States had their blood pressured 
under controlled
86
. Despite the importance of anti-hypertensive agents, adherence to 
anti-hypertensive agents remains suboptimal in this population. Previous studies of 
medication compliance found approximately 65% - 83% of CKD patients had good 
adherence to their prescribed anti-hypertensive agents, while studies using self-report 
measures of adherence generally demonstrated a better adherence rate than those using 




Reasons of having poor adherence to anti-hypertensive treatment in CKD patients may be 
different from study to study because of the distinct characteristics of investigated 
medications and populations. For example, individuals’ social and demographic factors like 
younger age, male, lower level of income and education were associated with increased risk 
of poor adherence in some studies but not in others
88,120,121,131
.Regarding to patients’ health 
status, patients with depression, having more hospitalizations, and unable to self-administrate 
their medications were more likely to have poor medication compliance
4,88,121
. Inconsistent 
relationship between mediation adherence and renal function were observed in previous 
research
4,123,131
. Moreover, interview based and survey based studies found that forgetfulness 
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was the most common reason of nonadherence reported by CKD patients
88,120,132
. Compliance 
to anti-hypertension treatments in CKD patients were also influenced by other subjective 
factors, like patients’ perceived need of mediations, perceived efficacy of medication, 
concerns of side effects, as well as physician-patient communications
132,133
. With regard to 
characteristics of treatment, side effect, complexity of regimens and the overall pill burden 




Although a number of studies have explored predictors of poor adherence to medications, few 
of them have examined how medication adherence varied across different regions, in 
addition, how neighborhood-level factors were related with individuals’ medication taking 
behaviors. One recently published medication adherence study by Erickson et al found there 
was a geographical clustering in adherence to statins in the state of Michigan
182
. Similarly, 
another study by Hoang et al observed a spatial clustering in medication adherence when they 
followed a total of 1081 patients residing in the southeast of Michigan State who were 
discharged with acute coronary syndrome conditions
183
. When compared medication 
adherence across the United States, a study by Couto found adherence rate were highest in 
New England and the West North Central region, and followed by the East North Central and 
the Middle Atlantic region
184
. While the whole south area, including the West south central, 
the East South Central, and the South Atlantic region had relatively poor adherence. 
Moreover, similar geographical variation was observed in both Medicare beneficiaries and 
commercial insurance beneficiaries, and the variation was stable across different therapeutic 
drug classes (antidiabetics, antihypertensives and antilipidemics). However, these studies did 
not investigate local-characteristics that might cause the geographical difference in 
medication adherence.  
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According to the Andersen’s behavioral model of health services use, patients’ utilization of 
health care are influenced by not only patients’ own characteristics but also contextual 
factors, such as structures of the health system and neighborhood socioeconomics
185,186
. 
Identifying contextual risk factors of medication adherence is helpful to design 
population-based strategies and have greater impact on health promotion. Therefore, the aim 
of this study was to explore local variation in medication adherence of ACEIs/ARBs, and 
examine contextual and individual influences on medication adherence. We hypothesized that 
medication taking behaviors, in this study, adherence to prescribed ACEIs/ARBs, were 
associated with both patients’ individual characteristics and the characteristics of the 
neighborhood they lived in. Moreover, we expected that the adherence rate of ACEIs/ARBs 
were varied across regions in the United State. We also expected the relationship between 
contextual factors and medication adherence varied across the United States. In this study, we 




6.3.1 Study design and data source 
We conducted a retrospective cohort study of Medicare Part D beneficiaries with 
hypertension and CKD in the United States between 2006 and 2013. This study deign 
comprised three main periods: a selection period to identify eligible hypertensive CKD 
patients (from 01/01/2006 to 12/31/2012); a 2-year baseline period to assess patient’s history 
of comorbid conditions and procedures (from 01/01/2006 to 12/31/2007), and a follow-up 
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period to assess patients’ medication compliance from the beginning of 2008 to the end of 
our study, 12/31/2013.  
 
This study used Medicare 5% sample files from the USRDS databases, which contained 
individual claims obtained from the CMS Medicare 5% Sample SAFs, ESRD related 
information extracted from the ESRD Medical Evidence form (CMS 2728), and death related 
information extracted from the ESRD Death Notification form (CMS 2746) as well as the 
Master Beneficiary Summary File. To assess the relationship between contextual factors and 
medication taking behaviors, Medicare claims were further merged with external data 
resources by state code and county code to obtain contextual information. Information from 
the U.S. Census Bureau American community Survey (ACS) 5-Year Estimates data 
(2009-2013) and the Health Resources and Services Administration (HRSA) Primary Care 
Service Area (PCSA) data (2007) were extracted for contextual characteristics and primary 
care resources at county level. This unique linked dataset also included spatial information of 
population center, extracted from the Map of Centers of Population from the U.S. Census 
Bureau (2008)
148
. Information contained in the final dataset for statistical analyses in this 
study was completely de-identified. 
 
6.3.2 Study population 
We selected all elderly Medicare beneficiaries who had hypertension in the 2-year baseline 
period and been diagnosed with CKD in the selection period. To capture a complete history 
of medication use, we then restricted our study subjects to Medicare fee-for-service 
beneficiaries with continuous prescription drug coverage. Moreover, to assess the one-year 
medication compliance of ACEIs/ARBs, we further excluded hypertensive CKD patients 
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who did not have any ACEIs/ARBs claim in the follow-up period, those whose first 
ACEIs/ARBs claim was after 12/31/2012, as well as those who died within one year period 
from their first ACEIs/ARBs claim in the follow-up period.   
  
6.3.3 Measures 
Medication related outcome measures 
One-year ACEIs/ARBs adherence was measured by PDC, which was defined as the 
percentage of days covered by ACEIs/ARBs in a fixed one year refill interval, starting from 
the first date of dispensing ACEIs/ARBs. A threshold of 80% PDC was applied to define 
good medication adherence.  
 
Individual factors 
Demographic information like age, gender and race was extracted from the Medicare 5% 
files. Age was calculated at the baseline, and race was classified as white, black, Asian, 
others and unknown. Part D coverage was classified into three categories based on their Part 
D enrollment status in 2008, which included Part D with deemed Low-income Subsidy (LIS), 
Part D with non-deemed LIS, as well as Part D without LIS. Patients who are dual eligible to 
Medicare and Medicaid can automatically enroll in LIS (deemed LIS), while the rest eligible 
LIS beneficiaries whose income level below 150% of the Federal Poverty Level need apply 
to receive subsidy (non-deemed LIS). All LIS enrollees do not have a prescription gap, also 
known as “donut hole”, while deemed LIS qualified a 100% subsidy for monthly premium 
and a lower fixed amount of copy compared to those with non-deemed LIS. Comorbid 
conditions were assessed in the 2-year baseline period using Medicare claims and following 
the previously validated algorithm: having at least one inpatient claims or at least two 
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outpatient claims. We generated separate indicators for conditions associated with kidney 
dysfunctions, include diabetes, cardiovascular conditions and cardiovascular procedures. We 
further calculated an adapted Deyo Charlson comorbidity index (CCI) with exclusion of 
diabetes, renal and cardiovascular conditions
168
. A higher value of CCI indicated a heavier 





Characteristics of contextual factors were assessed at county level. The counties’ 
socioeconomic status was measured by the Townsend deprivation index, a composite score 
derived from four census statistics: percentage of household without car ownership and home 
ownership, percentage of household overcrowding (more than 1 person per room), and 
unemployment rate among people aged 16 and over
155
. A higher Townsend index indicates a 
higher average level of deprivation. In addition, available primary care resources for each 
county were measured by the rate of general physicians per 10,000 persons and the 
percentage of population residing in MUAs. Percentage of residents covered by Medicare 
was also assessed as a measurement of predisposing characteristics in the county. 
 
6.3.4 Statistical analyses 
To conduct descriptive analyses of baseline individual characteristics, study subjects were 
categorized into two groups based on their medication adherence: a PDC of at least 80% vs. a 
PDC below 80%. Patients with PDC above 80% were generally considered as being adherent 
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to prescribed ACEIs/ARBs. We presented the means and standard deviation for continuously 
variable, and percentages for categorical variables. Group differences in these factors were 
examined using two-tailed t-tests for continuous variable and chi-square tests for categorical 
variables. Descriptive statistics of contextual characteristics at county level were reported as 
well, where patients’ one-year PDC and one-year persistence were aggregated to county 
level.  
 
GWR was utilized to investigate the relationship between contextual factors and medication 
adherence at county level. We first examined the spatial distribution of medication across 
counties in the United States. We then developed a multivariate linear regression model, also 
called global model, to establish a properly specified model for GWR. The redundancy of our 
explanatory variables was assessed using VIF value, with a cut off at 2. Next, we ran the 
GWR model and checked the increase in goodness-of-fit through R
2
, AICc and Bayesian 
Information Criterion (BIC). We also compared the statistical performance between the 
global model and the GWR model through the GWR ANOVA test. Lastly, we conducted the 
geographical variability test for each explanation variables, which indicated whether the local 
estimates of the specified variable demonstrated significant spatial variability. The results of 
GWR model were displayed as maps of local parameter estimates. It was noteworthy that the 
statistics reported in the GWR model was local t value. We used the da Silva and 
Fotheringham correction to calculate the adjusted p value at different significant level
187
, and 




The mixed effect model was performed to assess the association between individual factors, 
contextual factors, and medication adherence, controlling the random effects of counties. The 
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statistical significant level was set of p<0.05. We used SAS 9.3 for data management, and 
statistical analysis. The GWR software was used specifically for GWR models.  
 
6.4 Results 
Our study cohort consisted of 70,201 aged Medicare beneficiaries with hypertension and 
CKD who used ACEIs/ARBs during our study period. These patients resided in a total of 
2,981 counties in the United States, with an average of 24 persons per county. Approximately 
61% of them had one-year PDC of at least 80% (mean=0.9, SD=0.1) while the rest of them 
had poor adherence (mean=0.5, SD=0.2). 
 
Table 6-1 and 6-2 reported the descriptive statistics of individual characteristics between 
groups. There was no difference in the distribution of age and having diabetes between 
patients with good adherence or poor adherence to ACEIs/ARBs. Nevertheless, fewer male 
and more whites were observed in the good adherence group (male: 38.9% vs. 41.3%; white: 
87.9% vs.85.1%). In addition, slightly fewer beneficiaries in the good adherence group were 
deemed LIS beneficiaries (33.3% vs.34.2%), compared to the poor adherence group. In term 
of comorbid conditions, patients with poor adherence demonstrated a higher CCI scores 
compared to those being adherence to ACEIs/ARBs (1.4 vs. 1.2). When assessed patients’ 
history of cardiovascular related conditions and procedures, patients classified into the poor 
adherence group showed a significantly higher percentage in almost all of investigated 
conditions and procedures except CABG (shown in table 6-2).  
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Table 6-3 summarized the descriptive statistics of environmental characteristics in county 
level. The average PDC of ACEIs/ARBs in a one-year fixed interval was 0.76. The average 
number of general physician per 10,000 patients was 7. On average, about 14% of total 
population living in the studied counties had Medicare coverage and approximately 56% of 
people residing in MUAs. The mean value of the deprivation score among our investigated 
counties was -0.01, where a higher positive score indicate greater deprivation.  
 
Adherence rate of ACEIs/ARBs in county level were geographically clustered, and the map 
of medication adherence displayed a geographic variation across the United States (figure 
6-1). Results of GWR model were summarized in table 6-4. Overall, negative associations 
between deprivation score, more people residing in MUAs and medication adherence were 
observed across the United State, while positive association between number of available 
physicians per population, percentage of older residents and medication adherence were 
observed. We also drew maps of the estimated relationship between medication adherence 
and predictors, which reflect these geographic differences (figure 6-2 - 6-5). Figure 6-2 
revealed the West mountain region, the West South Central region and the Northeast region 
had a significantly strong to moderate negative association between deprivation score and 
rate of medication adherence. Figure 6-3 displayed the varied association between adherence 
rate and proportion of population residing in MUAs across the United States. A significantly 
strong negative association was observed in the Northeast region, the Midwest region and the 
West region. Figure 6-4 and 6-5 indicated both percentage of older residents and number of 
available physicians per population were positively associated with medication adherence, 
and these associations were only significant in the Great Lake region and the New England 
region, By comparing the goodness of fit statistics, we concluded the GWR model fits our 
data better than the OLS model. 
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Results from the mixed effect model indicated that predictors of increased medication 
adherence include: female, receiving LIS either deemed or non-deemed, having diagnosis of 
diabetes, having AFIB as well as residing in a county with more available general physician 
and residing in counties with the oldest population. Meanwhile, heavy comorbidity burden, 
having cardiovascular conditions, living in the deprived area and region lack of medical 
resources were associated with poor adherence to ACEIs/ARBs. 
 
6.5 Discussion 
This study is, to our knowledge, the first national representative study to examine the spatial 
variation in adherence to ACEIs/ARBs among CKD patients, and investigate the spatial 
association between contextual factors and medication adherence across the United States. 
Approximately 61% of our study subjects were adherent to their prescribed ACEIs/ARBs, 
defined as having a PDC at least 80%, which is lower than the adherence rate demonstrated 
in previous studies using claims data or pill counts (from 65% to 70%). The difference may 
be due to the older age and the great comorbidity burdens in our population.  
 
The average proportion of days covered by ACEIs/ARBs was 76% after aggregating 
individuals’ adherence to county level. Consistent with previous studies, we found there was 
spatial clustering in adherence to ACEIs/ARBs in our hypertensive CKD cohort
182,183
. 
Moreover, we observed comparable geographic variation observed in Cuto’s study
184
. In our 
study, the Northeast region and the Midwest region demonstrated better adherence compared 
to the South region.  
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Our findings of GWR models indicated adherence to ACEIs/ARBs were related with the 
characteristics of the place that patients lived in. Previous studies had revealed that 
accessibility to healthcare were related with neighborhood socioeconomic status, distance and 
travel time to facilities, and availability of healthcare resources
189–192
. Consistent with 
previous findings, we found a negative association between medication adherence and living 
in regions with high deprivation level and lack of primary care resources across the United 
States. Additionally, by displaying the estimated local relationship in maps, we found the 
magnitude and significance of the relationship were varied across regions. For example, 
deprivation score was significantly related with declined medication adherence in the 
Northeast region, the West South Central region and the Wet mountain region. Proportion of 
population residing in MUSs reflects the availability of primary care resources. Different 
with deprivation score, lack of primary care resources were significantly associated with 
decreased adherence in all regions except the South region, despite the fact that the South 
region had a more severe shortage of healthcare resource. Results of our study indicate that in 
the West region, the Midwest region, and the Northeast region, interventions for enhancing 
medication adherence may consider to target on CKD patients living in the place lack of 
primary care resources. While in the West Mountain region, the West South Central region 
and the Northeast region, interventions for medication adherence are recommend to target on 
patients residing in deprivation counties. Moreover, it is worth to note that neither deprivation 
score nor lack of primary care resources explained the poor medication adherence in the East 
South Central and the South Atlantic. Other contextual factors that are not captured in this 
study may drive the geographical difference in medication adherence, like treatment 
strategies and healthcare quality
80–82
. A study of high risk medication use found Part D 
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enrollees who lived in the Southern United Sates were at higher risk of receiving regimens 




Besides the contextual factors, our study found patients’ adherence to their prescribed 
medication were also associated with their demographic characteristics, medical conditions, 
and health plan coverage. In this study, we did not establish a significant relationship between 
age and medication adherence. This may be attributable to the relatively older age of our 
population and less variation (SD=7.1 mean=78.6). A review paper by DiMatteo evaluated a 
total of 568 adherence studies from 1949 to 1988 and found inconsistent relationship between 
age, gender and treatment adherence
130
. Results of our study also found patients with heavy 
comorbidity burden had a declined adherence to their prescribed medication, and this may 
because they have the greater pill burden and more complex regimens
121,134
. Moreover, as 
what previous studies found, onset of diabetes was associated better adherence to 
ACEIs/ARBs. This may because ACIEs/ARBs are first-line therapy for patients with diabetic 
CKD
42
. Additionally, presence of AFIB was associated with better adherence to 
ACEIs/ARBs, which may attributable to the protective effect of these RAS inhibiting agents 
on the recurrence of AFIB
193
. With regard to status of Part D coverage, receiving the low 
income subsidy from Part D was associated with a better adherence. Beneficiaries with LIS 
may have a lower risk of cost-related medication nonadherence because they are not only 
receiving subsidy for premium and copayment but also not limited by the coverage gap. A 
study of patients with kidney failure found patients reduced their medication use when they 
fell into the coverage gap
194
.   
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There are several limitations in this study. First, as a retrospective cohort study it cannot draw 
causal inference but only provide associative information. Second, internal validity may be 
threated due to the characteristics of administrative claim data, selection bias and omitted 
variable bias. Although our study subjects are all Part D enrollees, we may still not able to 
fully capture all pharmacy claims, especially among those who have multiple prescription 
drug coverages. This may result in underestimation of medication adherence. Additionally, 
patients with hypertension may have a higher risk of experiencing cardiovascular events, 
such as hospitalization because of coronary disease, heart failure, stroke or peripheral arterial 
disease. Therefore, further studies are recommend to exclude days of hospitalization in the 
denominator when calculating medication adherence. Moreover, administrative claims data 
do not sufficiently reveal actual medication adherence. It is possible that the refills dispensed 
by pharmacies are not taken by patients, and lead to overestimating of medication 
consumption. The findings from this study should be interpreted with caution, especially 
when generalize these results to practice. Although we extracted a large cohort of 
ACEIs/ARBs users with hypertension and CKD from a nationally representative dataset, 
sicker patients who died within one year period after filling ACEIs/ARBs were excluded in 
our study. Meanwhile, patients were required to continuously enroll in Part D. These 
inclusion and exclusion criteria may cause selection bias. Additionally, because of the 
security concern, counties with less than ten CKD patients were not included in our spatial 
analysis, which cause rural areas may be under represented in this study. Third, this study 
was lack of self-report measures, like patients’ perceived need of medications, perceived 
benefits of medications, side effects and effective physician-patient communications. These 
subjective factors are related with patients’ medication taking behaviors. Future research is 
warranted to conduct qualitative studies to understand local barriers to appropriate 
medication use and medication adherence. Meanwhile, researchers can perform spatial 
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analyses with both individual characteristics and contextual characteristics in small local 
regions. Then, researchers and healthcare providers could design population based strategies 
in the local area to promote medication compliance in CKD patients, from perspective of 
population.  
6.6 Conclusion 
Medication adherence to ACEIs/ARBs is varied across the United States, where Northeast 
region and Midwest region illustrate better medication adherence than South region. Different 
risk factors and modifiable factors at both individual level and contextual level have been 
detected in this study. Additionally, our study displays the geographic variation of the 
relationship between environmental characteristics and medication adherence, which help us 
understand the place effects behind these relationships. This information is valuable in policy 
implication in local area, especially when researchers and practitioners implement local 
interventions to improve medication use among hypertensive CKD patients in the United 
States. 
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Table 6-1 Descriptive Statistics of individual demographic characteristics among elderly 
patients with hypertension and chronic kidney disease (CKD) by status of ACEIs/ARRs 
adherence (n=70,201) 
Variable# 






Baseline characteristics Mean (SD)/% Mean/% Mean/% 
Age (years) 78.6 (7.1) 78.6 (7.1) 78.6 (7.1) 
Age (years)    
       <70 12.7 12.7 12.7 
     70-75 22.7 22.7 22.7 
     75-80 23.2 23.3 23.3 
        >80 41.4 41.4 41.4 
Male 38.9 41.3 39.9 
Race    
          White 87.9 85.1 86.8 
          Black  8.8 11.3 9.8 
          Asians 1.7 1.6 1.7 
          Others 1.5 1.8 1.6 
          Unknown 0.1 0.1 0.1 
Prescription coverage at 
baseline 
   
       Part D without LIS 64.3 63.8 64.1 
       Part D with 
non-deemed LIS 
2.4 2.1 2.3 
       Part D with deemed 
LIS 
33.3 34.2 33.7 
Diabetes mellitus (DM) 45.3 45.8 45.5 
Charlson comorbidity index $ 1.2 (1.7) 1.4 (1.8) 1.3 (1.7) 
* Continuously enrolled in Medicare A&B from 2006/1/1 and continuously enrolled in 
Medicare Part D from 2007 to end of 2013/date of death were required. A two-year 
baseline period was applied (2006-2007) to evaluate baseline characteristics, and a 
one-year baseline period (2007) was used to examine medication use history. Patients 
without any claim of ACEIs/ARBs were excluded. 
# Significant difference was observed in all variables except age (P<0.05)  
$ Adapted Charlson comorbidity index was calculated by excluding diabetes, kidney 
diseases and cardiovascular diseases 
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Table 6-2 Descriptive Statistics of cardiovascular-related characteristics among elderly 
patients with hypertension and chronic kidney disease (CKD) by status of ACEIs/ARRs 
adherence (n=70,201)  
Variable # 
PDC above 80% 
(n=42,733)* 





   ASHD 48.52 53.71 50.55 
AMI 11.44 13.68 12.32 
CHF 30.88 35.91 32.85 
CVA-TIA 29.67 33.26 31.08 
PAD 36.82 40.51 38.26 
AFIB 20.63 21.79 21.08 
SCA/VA 5.47 6.45 5.85 
Other Cardiovascular diseases 44.95 49.2 46.61 
Cardiovascular Procedures 
   PCI 3.61 4.46 3.94 
CABG 1.32 1.4 1.35 
ICD/CRT-D 0.78 1.01 0.87 
* Continuously enrolled in Medicare A&B from 2006/1/1 and continuously enrolled in Medicare Part D 
from 2007 to end of 2013/date of death were required. A two-year baseline period was applied 
(2006-2007) to evaluate baseline characteristics, and a one-year baseline period (2007) was used to 
examine medication use history. Patients without any claim of ACEIs/ARBs were excluded, 
# Significant difference was observed in all variables except CABG (P<0.05) 
$ Abbreviations: ASHD, atherosclerotic heart disease; AMI, acute myocardial infarction; CHF, congestive 
heart failure; CVA/TIA, cerebrovascular accident/transient ischemic attack; PAD, peripheral arterial 
disease; AFIB, atrial fibrillation; SCA/VA, sudden cardiac arrest and ventricular 
arrhythmias; PCI, percutaneous coronary interventions; CABG, coronary artery bypass grafting; 
ICD/CRT-D, implantable cardioverter defibrillators/cardiac resynchronization therapy with defibrillator 
devices. 
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Table 6-3 Descriptive Statistics of environmental characteristics in county level (n=2981) 
 
Table 6-4 The association between environmental characteristics and average ACEIs/ARBs 





Variable* Mean SD 
ACEIs/ARBs adherence (PDC) 0.76 0.12 
Numbers of patients per county  23.50 57.36 
Number of General physicians per 
10,000 persons 6.96 4.33 
Percent of Medicare Beneficiaries in 
Total Population 0.14 0.04 
Proportion of People Residing in 
Medically Underserved Areas 0.56 0.45 
Deprivation score# -0.01 2.79 
*A total of 70,201 elderly patients with hypertension and chronic kidney disease 
resided in 2,981 counties.  
# Deprivation score was measured by Townsend index, which incorporating 
unemployment rate, percentage of households without care ownership, home 











Number of General 
physicians per 
10,000 persons 
0.0008 0.0006 0.0000 0.0003 0.0006 0.0013 0.0026 
Percent of Medicare 
Beneficiaries in 
Total Population 
0.1738 0.0911 0.0126 0.0932 0.1608 0.2415 0.3609 




-0.0178 0.0075 -0.0278 -0.0252 -0.0189 -0.0116 -0.0007 
Deprivation score# -0.0028 0.0008 -0.0057 -0.0032 -0.0028 -0.0023 -0.0013 
*Counties with less than ten CKD patients were excluded.  
# Deprivation score was measured by Townsend index, which incorporated unemployment rate, percentage 
of households without care ownership, home ownership and overcrowding. 
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Table 6-5 The association between individual, environmental characteristics and 
ACEIs/ARBs adherence at individual level using Mixed model (n=70,201) 
Variable Estimate Standard Error Pr > |t|  
Age (years) 0.000 0.000 0.924  
Charlson comorbidity index  -0.005 0.001 <.0001 *** 
Female  0.010 0.002 <.0001 *** 
Race (White) 
   
 
          Black  -0.034 0.004 <.0001 *** 
          Asians 0.001 0.008 0.8788  
          Others -0.019 0.008 0.0186 * 
          Unknown -0.044 0.031 0.1462  
Prescription coverage at baseline (Part 
D without LIS) 
   
 
       Part D with non-deemed LIS 0.018 0.007 0.0066 ** 
       Part D with deemed LIS 0.012 0.002 <.0001 *** 
Diabetes mellitus (DM) 0.011 0.002 <.0001 *** 
ASHD -0.010 0.002 <.0001 *** 
AMI -0.008 0.003 0.0135 * 
CHF -0.016 0.003 <.0001 *** 
CVA-TIA -0.009 0.002 <.0001 *** 
PAD -0.007 0.002 0.0013 ** 
AFIB 0.006 0.003 0.0352 * 
SCA/VA -0.002 0.005 0.7011  
Other Cardiovascular diseases -0.010 0.002 <.0001 *** 
PCI -0.010 0.005 0.065  
CABG 0.010 0.009 0.2743  
ICD/CRT-D -0.002 0.011 0.8431  
Number of General physicians per 
10,000 persons 
0.001 0.000 0.0035 ** 
Percent of Medicare Beneficiaries in 
Total Population 
0.081 0.033 0.0123 * 
Proportion of People Residing in 
Medically Underserved Areas 
-0.013 0.003 <.0001 *** 
Deprivation score# -0.001 0.000 0.0002 *** 
# Deprivation score was measured by Townsend index, which incorporating 
unemployment rate, percentage of households without care ownership, home 
ownership and overcrowding. 
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Figure 6-1 Distribution of 1 year ACEIs/ARBs adherence
 
*Counties with less than ten CKD patients were excluded 
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*Counties with less than ten CKD patients were excluded 
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Figure 6-3 Proportion of population residing in MUAs (distribution, β & p-value)
 
*Counties with less than ten CKD patients were excluded 
Distribution 
p-value Estimated β 
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*Counties with less than ten CKD patients were excluded. 
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*Counties with less than ten CKD patients were excluded 
  137 
 
Chapter 7  
OVERALL CONCLUSION 
Over 15% of Americans have CKD, and approximately 74% of them have coexisting 
hypertension. Although uncontrolled blood pressure is a previously established risk factor of 
CKD progression, only 28% of CKD patients have made their blood pressure 
under-controlled
1
. The objectives of this dissertation were to assess the relationship between 
access to cardiovascular medications, medication use behaviors, and CKD outcomes among 
elderly patients with hypertension and CKD in the United States. This study is innovative in 
sense of providing a geographic approach to explore factors that associate with medication 
adherence. In addition, this study is significant in term of systematically assessing the 
long-term benefits of being adherent to prescribed cardiovascular agents in improving 
outcomes for hypertensive CKD patients. To achieve our study goals, we used a large 
combined dataset which contained Medicare claims, census data, primary care resources data 
and spatial information.  
 
This dissertation work is comprised of three study aims, and findings from each of the three 
study aims contribute to the overall objective of the study. First, the study presented in 
chapter four evaluated cardiovascular agents use patterns in elderly patients with 
hypertensive CKD, and further investigated the association between different pharmacologic 
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therapies and CKD outcomes. Then, the second study in chapter five examined the long-term 
benefits of adherence to prescribed cardiovascular agents in CKD outcomes among elderly 
patients with CKD and hypertension. Finally, the last study in chapter six examined 
geographic variation in medication adherence across the United State at first, and then 
explored individual and contextual factors that were associated with medication compliance 
among old adults with CKD and hypertension.  
 
7.1 Major findings 
In chapter four, we first evaluated incident CKD patients’ medication use pattern using a 
six-month period after the date of first diagnosis of CKD. A total of six most commonly used 
cardiovascular agents were investigated: ACEIs, ARBs, calcium channel blockers, 
beta-blockers, diuretics and statins. Consistent with previous studies, a heavy pill burden was 
observed in our study cohort as well, as more than half of hypertensive CKD patients were on 
combination therapies
88
. However, there was still about 22% of patients were not receiving 
any of investigated medications, and only half of patients received guideline-recommended 
ACEIs/ARBs. Our findings reveal that there is a need to promote cardiovascular agents use, 
particularly use of ACEIs/ARBs, in hypertensive CKD patients. Second, we assessed the 
association between different pharmacologic therapies and CKD outcomes, and we found 
patients receiving therapies including ACEIs/ARBs and statins demonstrated better treatment 
outcomes. Lastly, we explored factors that were associated with using ACEIs/ARBs and 
found patients who enrolled Part D low-income subsidy program were less likely to receive 
recommended ACEIs/ARBs. These patients are typically facing the lowest premiums and 
copayment, and having no coverage gap. Our findings may indicate the existence of barriers 
to accessing guideline-recommended prescriptions beyond cost in this vulnerable population.  
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In chapter five, we established an approach to systematically evaluate long-term benefits of 
adherence to cardiovascular agents for elderly patients with hypertension and CKD. We 
performed the Cox proportional hazards regression analyses with medication adherence as 
time-varying covariates to assess the association between adherence to cardiovascular agents 
and CKD progression, as well as all-cause mortality. Our findings showed consistently good 
adherence to ACEIs/ARBs, as well as other cardiovascular agents, was associated with 
substantial decreased risk of developing ESRD and mortality. It was worthy to note that 
medication adherence rate of investigated drug classes was suboptimal at baseline, ranged 
from 50% to 60%. Overall, our findings indicate there is a need for improving medication 
compliance, particularly regarding the long-term medication adherence. 
 
In chapter six, we found there was geographical variation in adherence to ACEIs/ARBs 
among hypertensive CKD patients who used ACEIs/ARBs, as patients residing in the West 
North Central and New England region demonstrated a relatively better adherence than those 
residing in the East South Central and West South Central regions. Then, we implied an 
innovative approach to explore how contextual factors were associated with adherence at 
county level using geographically weighted regression model. By using this spatial analysis, 
we were able to incorporate the spatial autocorrelation when model medication adherence as 
a function of potential predictors, and provide visualized results. Our study results found 
residing in MUAs and place with high deprivation score were associated with poor 
adherence, while living in counties with more old adults and having more available 
physicians were associated with increased adherence. Besides contextual factors, individual 
factors like prescription drug coverage and comorbidities were also related with poor 
adherence. Receiving Part D LIS was associated with increased medication adherence, as Part 
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D LIS beneficiaries have no coverage gap and in turn may less like to experience cost-related 
medication nonadherence. 
 
7.2 Study implications and future research  
This dissertation research raises several implications for the care of CKD patients. First, this 
study emphasized the importance of utilization and use behaviors of cardiovascular agents in 
CKD treatments. Our study found both utilization rate and medication compliance of 
cardiovascular agents, especially guideline-recommended ACEIs/ARBs, were suboptimal in 
elderly patients with CKD and hypertension. Interventions are needed to improve utilization 
rate of both ACEIs/ARBs and other cardiovascular agents, particularly regarding the 
long-term adherence. There is evidence to suggest that interventions with clinical pharmacy 
activities have benefits for CKD patients
195–197
. These interventions performed by 
pharmacists generally include medication review, identification of drug-related problems, 
providing therapeutic recommendations, laboratory monitoring, as well as patient counselling 
and education, while few of them have components that target on promoting medication 
compliance
198,199
. Moreover, there is lack of high-quality research to evaluate the 
effectiveness of clinical pharmacy services on CKD outcomes. Further studies are warranted 
to develop interventions to promote medication compliance, and add indicators of medication 
compliance as criteria for evaluating medication management interventions for CKD patients. 
Second, findings from this study may help healthcare providers make informed treatment 
decisions. For example, according to our findings, adding ACEIs/ARBs and statins to 
anti-hypertensive therapy is recommended for patients with hypertension and CKD. Finally, 
our study revealed the geographic variation of the relationship between contextual factors and 
medication adherence. This information is critical for policy makers to allocate health care 
resources, and in turn improve medication taking behaviors and therapeutic treatment 
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outcomes. Moreover, individual and contextual predictors of medication adherence found in 
our study are helpful for researchers and healthcare providers to identify CKD patients at 
high risk of medication nonadherence.  
 
On the basis of current literature, including this study, several directions may be warranted 
for future research. First, apply the spatial analysis in a local region to identify communities 
where medication compliance is suboptimal. Meanwhile, conduct qualitative studies to 
understand local barriers to appropriate medication use and medication adherence, and then 
design population based strategies in local area to promote medication compliance in CKD 
patients, from perspective of population. Lastly, additional studies are needed to explore the 
geographical variation in processes of care in CKD patients across the United States. 
 
7.3 Study limitations  
This dissertation work has some limitations. First, the retrospective cohort study design 
cannot draw causal inferences. Second, Medicare 5% claims files are lack of data for 
beneficiaries who enroll in Medicare Advantage plan. Thus, our study cohort was limited to 
Part D enrollees who were not covered by Medicare Advantage plan. In addition, the 
restricted selection criteria may result in selection bias. For example, to capture all pharmacy 
claims, we excluded patients who were not continuously enrolled in Part D over the study 
period, which results in a study cohort with slightly older age, having a higher percentage of 
female, non-white, diabetes and cardiovascular conditions. Third, this study may suffer from 
omitted variable bias. For instance, hospitalization was not adjusted when we examined the 
association between medication adherence and CKD outcomes, which may bias our results to 
unknown directions (Chapter 5). Our next step is to add a time-varying covariate of 
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hospitalization to the survival model. Moreover, there is no laboratory data in Medicare 5% 
claims files. For this reason, we were lack of direct measurement of blood pressure and 
kidney function. We also not able to assess subjective factors, like patients’ awareness of , 
patients’ perceived need of medication, perceived efficacy of medication, concerns of side 
effects, as well as physician-patient communications. These qualitative variables are 
previously established determinates of medication adherence in qualitative studies
132,133
. 
Fourth, pharmacy claims do not sufficiently reveal actual medication taking behaviors. 
Patients may not take their prescribed medications following recommendations. Moreover, 
we are not able to fully capture all pharmacy claims, if patients obtain medications from 
outside resources other than Medicare Part D. Finally, a certain number of counties were 
excluded in spatial analysis because of the security concern (Chapter 6). This may bias our 
results as rural areas may be under represented in the study.   
 
7.4 Overall conclusion  
The use of cardiovascular agents is the corner stone for the treatment of hypertensive CKD. 
Although there are significant benefits from medication use on delaying the progression of 
CKD and reducing mortality risk, the utilization rate of these medications and their long-term 
adherence, especially guideline-recommended ACEIs and ARBs, are suboptimal among 
elderly adults with hypertension and CKD. In addition, geographical variation exists in 
medication adherence in the United Sates, and patients’ medication adherence is associated 
with both individual and contextual characteristics. Developing local interventions to 
promote medication compliance for patients with CKD and hypertension are thus warranted. 
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